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Abstract 
SHABANA AKHTAR 
Molecular mechanisms of myricetin bulk and nano forms mediating 
genoprotective and genotoxic effects in lymphocytes from pre-cancerous 
and myeloma patients 
Key words: myricetin; bulk and nano forms; genotoxic; genoprotective; human 
lymphocytes; pre-cancerous blood disorders; myeloma patients; healthy 
individuals; PhIP and H2O2 
Cancer is one of the leading causes of death across the globe which needs 
appropriate and cost-effective treatment. Several recent studies have 
suggested that dietary intake of various flavonoids such as myricetin have a 
protective effect against different types of cancers and cardiovascular diseases. 
The present study was conducted to investigate the genoprotective and 
genotoxic effects of myricetin nano and bulk forms on the lymphocytes from 
pre-cancerous and multiple myeloma cancer patients compared to those from 
healthy individuals. Also, to investigate the protective potential of myricetin bulk 
and nano against the oxidative stress produced in vitro by 2- amino-1-methyl-6 
phenylimidazo [4, 5-b] pyridine and reactive oxygen species- induced DNA 
damage using the Comet assay, micronucleus assay, cellular reactive oxygen 
species and glutathione detection assay, Western blotting, real-time polymerase 
chain reaction and immunofluorescence. Lymphocytes from the patient groups 
showed significantly higher levels of basal DNA damage compared to the 
lymphocytes from healthy individuals which was observed throughout the in 
vitro treatment. 
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Myricetin in both forms has not induced any significant DNA damage in all of the 
investigative groups at selective lower concentrations; in fact, the results 
demonstrate a reduction in DNA damage upon treating with myricetin nano in 
lymphocytes from pre-cancerous patients demonstrated by significant reduction 
in micronuclei formation in mononucleated cells. DNA repair capacity of 
myricetin bulk and nano was determined by co-treating the drugs with hydrogen 
peroxide. Myricetin significantly reduced the oxidative stress related damage 
caused by hydrogen peroxide, where myricetin nano seemed to be more 
effective employing the Comet assay. In the presence of myricetin bulk and 
nano, the damaging effects of 2- amino-1-methyl-6 phenylimidazo [4,5-b] 
pyridine were considerably decreased, where myricetin nano was more 
effective.  This could be because nanoparticles have a larger surface area 
which could improve their reactivity and also the reduction in size of the 
particles could improve the anti-cancer properties of this compound.  
Myricetin has shown genoprotective and anti-oxidant effects by demonstrating 
the potential to reduce DNA damage caused by over-production of reactive 
oxygen species and oxidative stress. It has also shown anti-cancer potential in 
the lymphocytes from multiple myeloma patients by regulating the apoptosis 
related proteins, dependent on oxidative stress. Therefore, this study suggests 
that myricetin supplementation in our regular diet with enhanced bioavailability 
could have potential health beneficial effects and possibly protect against 
various diseases including cancer. 
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1.1 General Introduction 
 
Cancer is considered to be an important cause of death across the world. It 
accounted for 8.2 million deaths in 2012 and according to the World Health 
Organisation (WHO, 2016); the number of cases is due to increase from 14 to 
22 million within two decades. Being second leading cause of death globally, 
cancer is responsible for 1 in 6 deaths (WHO, 2018). Cancer is defined as a 
rapid transformation of normal cells into malignant tumours as a multistage 
process, interacting with a person’s genetic factors and environmental factors 
(Doll and Peto, 1981; WHO, 2018). Early detection and treatment of cancer can 
notably make the difference in prognosis of the disease, thereby reducing the 
damage and financial burden. Biological markers play a crucial role in early 
diagnosis of cancer.  
Most of the human genome is comprised of deoxyribonucleic acid (DNA) 
sequences that do not code for proteins. Protein coding sequences only make 
up 1.5% of the genome. There are two types of nucleotide sequences within a 
gene: exons (coding) and introns (non-coding) (Alberts et al., 2002). The 
mutations in exons alone affect the amino acid protein composing sequences. 
Cancers start from a single somatic cell then a series of genetic changes occur 
in the cells of the emerging neoplasm which lead to alterations in gene function 
and phenotype therefore causing tumour development (Ponder, 2001; NCI, 
2018).  
Various studies have been conducted in the past few decades in order to 
understand the cell cycle processes and those, involved in transforming a 
normal cell to a cancerous cell. A manifestation of various important alterations 
gives rise to most of the cancer cells’ genotypes that together dictate cancer 
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progression. In order for cancer to develop, a cell must acquire several 
capabilities: independence of external growth signals, insensitivity to anti-growth 
signals, evade apoptosis, immortality, be able to trigger angiogenesis and 
become metastatic. However, several types and subtypes of cancer have made 
it difficult to determine a specific tumour’s aetiology and origin.  
The focus of our current study is the pre-cancerous state and blood cancer, 
especially, multiple myeloma (MM). Following is a brief description of various 
blood cancer types.  
1.2 Blood Cancer and its types 
 
Blood cancer is a canopy term used for the cancers that are associated with the 
blood, lymphatic system and bone marrow. Sadly, a large number of people are 
affected by blood cancer daily, worldwide. The three main types of blood 
cancers are leukemia, lymphoma and myeloma. 
 Leukemia 
 
Leukemia is the cancer of leukocytes where an abnormal number of immature 
cells is produced which are gathered up in bone marrow forming masses and 
disrupts the production of other important cell types. These abnormal white 
blood cells are rapidly produced in large numbers and enter the main blood 
stream so that these leukaemia cells crowd out the normal blood cell number, 
leading to serious problems e.g. anaemia. 
Depending on the degree of progression, it is divided into two types: acute, 
develops and progresses quickly needing urgent treatment (Appelbaum, 2006) 
whereas chronic, develops gradually over months and years. Depending on 
which cell type is affected, it can be further categorised into lymphocytic or 
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myelogenous leukaemia. The former is leukaemia of white blood cells and the 
later affects other cell types including erythrocytes and platelets (Kantarjian and 
O'Brien, 2011).  The standard staging system for leukaemia has not yet been 
developed but symptoms can be monitored and prevented using certain 
treatments.  
1.2.1.1 Acute myeloid leukemia (AML) 
 
This is a cancer of myeloid cells which occurs in bone marrow. Normally, 
myeloid cells develop into different cell types i.e. RBCs, platelets and WBCs, 
whereas in AML growth stops at a very young and developing stage forming 
immature myeloblasts in an uncontrolled manner. Meanwhile these immature 
cells multiply quickly stopping normal growth of blood cells. AML is rare in the 
UK and it is more common in people over 70 years of age. 
1.2.1.2 Chronic myeloid leukemia (CML) 
 
This is very rare cancer, of a particular myeloid cell called a granulocyte, 
causing overproduction of these cells in bone marrow and affects normal growth 
of other blood cells. 
1.2.1.3 Acute lymphoblastic leukemia (ALL) 
 
ALL is a cancer involving lymphocytes from the WBCs. At the immature 
developmental stage of lymphocyte the cell is said to be a lymphoblast then it 
develops into a fully functional lymphocyte. In ALL, cells stop their growth at this 
immature stage and multiply quickly affecting the proper working of lymphocytes 
in the immune system. Clusters of lymphoblasts clog up in bone marrow 
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distressing other blood constituents. It is rare in adults but a very common 
leukemia in children in the UK (Kantarjian and O'Brien, 2011). 
1.2.1.4 Chronic lymphoblastic leukemia (CLL) 
 
CLL affects the function of lymphocytes and causes over production of 
lymphoblasts over a period of time and slowly fills up the bone marrow with 
these undeveloped lymphocytes reducing the number of other blood cells 
essential for bodily functions. It may also cause big, swollen lymph nodes. It is 
common in elderly people. 
 Lymphoma 
 
Lymphoma is caused by excessive production of lymphocyte affecting our 
lymphatic system which plays an important role in balancing the immune 
responses and provides protection against infection and disease. It can develop 
in the blood, spleen, lymph nodes, bone marrow and other organs. There are 
two main types of lymphoma: 
Hodgkin lymphoma (HL): In this type of lymphoma, cancer originates from 
lymphocytes and it can develop at any age but most commonly occurs in young 
adults. 
Non Hodgkin lymphoma (NHL): Most lymphomas are NHL. It is the sixth most 
common cancer in UK, affecting typically people over 70 years of age 
(https://www.anthonynolan.org/patients-and-families/blood-cancers-and-blood-
disorders/what-blood-cancer/lymphoma). 
 Myeloma 
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Plasma cells are a type of B-lymphocytes WBCs forming an important part of 
our blood, found in bone marrow and produce antibodies to help fighting against 
infection. Plasma cells normally produce antibodies composed of two types of 
proteins; light chains and heavy chains, two of each assembled in Y shape. Five 
main types of antibodies or immunoglobulins (Igs) are produced by our plasma 
cells known as IgG, IgA, IgM, IgD or IgE. In myeloma, clogging up of abnormal 
plasma cells in bone marrow stops those from producing an important part of 
our immune system instead producing excessive abnormal antibodies called 
paraprotein or monoclonal gammopathy or M protein in blood and bones which 
is not able to fight infection and its presence is an initial and important sign of 
myeloma.  Therefore, MM, commonly called myeloma is cancer of these plasma 
cells. It is a neoplastic disorder involving plasma cells that is categorized by 
colonialization and proliferation of malignant plasma cells in the bone marrow 
(Palumbo and Anderson, 2011). It can occur anywhere in the body where there 
is bone marrow present including the spine, ribcage and pelvis, which is why it 
is often called MM.  
People over 70 years of normally get myeloma and it does not occur in children. 
There are two types of myeloma; asymptomatic, showing no symptoms or 
tissue damage and symptomatic, expressing symptoms and tissue damage.  
There are no known causes of this neoplasm but it is always preceded by a 
premalignant state called monoclonal gammopathy of undetermined 
significance (MGUS) (Landgren et al., 2009; Weiss et al., 2009). MGUS is a 
condition where small number of plasma cells starts producing paraprotein but 
does not have myeloma at this stage. People who suffer from MGUS are at 
higher risk of getting myeloma. It is quite a common disorder in UK. Around 1 in 
100 people with MGUS develop myeloma each year. The precise risk of 
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myeloma development depends on several factors including the concentration 
and type of monoclonal protein, plasmacytosis of bone marrow, ratio of serum 
free light chains and percentage of phenotypically clonal plasma cells 
(Rajkumar et al., 2014). There is no permanent cure for myeloma and it always 
relapses. However, chemotherapy using combination of drugs, corticosteroids 
and targeted therapies are normally used to treat the symptoms, slow down the 
proliferation, increase the survival rate and to improve the quality of life of 
patient (Rajkumar, 2011; Rajkumar et al., 2014).  Likewise, diet, enriched with 
fruits and vegetables has been shown to alter the risk of developing MGUS as 
well as advancement to MM (Thordardottir et al., 2016; Thordardottir et al., 
2018). 
1.3 Biomarkers of cancer 
 
According to the Institute of Medicine (IOM) a biomarker can be described as a 
property that can justly measure various biological samples and that can be 
assessed as an exposure marker of regular or pathogenic biological 
mechanisms or pharmacologic responses to a certain intervention (Corella and 
Ordovas 2015). 
The most commonly used biological samples include blood, plasma, serum, 
faeces, saliva, nails, urine and different tissue samples. Biomarkers of exposure 
and disease status can be determined from these samplings. Biomarkers can 
be used for diagnostic reasons, to determine disease status, to suggest 
prognosis of disease and to help with the effective treatment of any disease. 
Biomarkers are also used for designing and formulation of diagnostic 
classifications (Ceusters and Smith 2015). 
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1.4 Dietary nutrients and disease prevention 
 
Dietary requirements for prevention of DNA damage and that of deficiency 
diseases are different. The diet may affect the basic level of DNA damage rates 
and may have radiation protective effects. Several in vitro and in vivo studies 
showed that concentrations of dietary constituents (folate and vitamin B12) (e.g. 
150pmol/l vs 300pmol/l respectively) recommended against anaemia and other 
deficiency diseases, are not sufficient for prevention of DNA damage  (Fenech, 
2009).  It has been proven that these minor differences in dietary concentrations 
are as proficient at causing DNA damage as high as mutagens or other cancer-
causing agents. A series of papers by Michael Fenech promoted this concept 
that recommendations for dietary concentrations should be made considering 
DNA damage as a large factor. Because this could be a most important cause 
of multiple disorders as genome damage is implicated (in cancer, infertility, 
ageing etc.) (Fenech, 2001). 
Research has found calcium and vitamin D are chemo preventative aids against 
colon cancer in humans, by understanding their mechanism of action in 
reducing the risks related to disease and establishing treatable risk biomarkers, 
for colon cancer. Studies based on fossils and human-gatherings etc. has 
proposed that our modern dietary intake of calcium and vitamin D is very low as 
compared to then (1500-2000 mg/day) which could increase risk of chronic 
diseases especially colon cancer. That intake was even greater than the 
present recommendation which is between 1000-1200mg/day among different 
gender and age groups. This is certainly due to today’s life style, clothes and 
less ultraviolet light exposure. Vitamin D was primarily considered in 
maintaining bone and calcium homeostasis but now the vitamin D receptor 
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(VDR), CYP24 (catalyses 1a, 25-[OH]2-vitamin D) and CYP27B1 (catalyses 25-
OH-vitamin D). These are abundantly expressed in the colon and other tissues, 
where vitamin D has autocrine/paracrine functions. It regulates over 200 genes, 
highly involved in colorectal tumorigenesis ( McCullough et al., 2009). 
Similarly flavonoids, semi-essential food components, secure great importance 
in our modern research by exhibiting incredible health beneficial effects against 
various chronic diseases. However, estimating their amount in our diet is a first 
step towards listing their protective effects. Studies have shown their daily 
intake estimation between 20mg-1g in Western countries (Chun, 2007). These 
results could vary due to different confounding factors associated with these 
studies including differences in antioxidant compounds, their strengths, doses 
and the characteristics of the subjects involved, etc. An epidemiological study 
showed an inverse correlation between the coronary heart disease in elderly 
males and the intake of flavonoids (Hertog et al., 1993). The pharmacological 
and biological attributes of flavonoids are comprehensively studied. In addition 
to their free radical scavenging property, they are capable of various biological 
actions including vasodilation, anti-inflammatory, anti-carcinogenic, anti-viral 
and bacterial, immune-stimulatory as well as inhibiting glutathione reductase 
(Elliott et al., 1992). 
1.5 The flavonoids and their role in human nutrition 
 
Research shows that utilization of a low fat diet with enhanced fruits and 
vegetables, particularly enriched with phenolic compounds may help to reduce 
the risk of many life threatening diseases. Phenolic compounds are present in 
many fruits, vegetables and nuts etc. These compounds have been utilized by 
humans since their existence on this earth. There are thousands of phenolic 
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compounds found and are described. These compounds are produced by 
plants as secondary metabolites important in various responses including 
development, fertilization and fighting against pathogens. These plant pigments 
are found in all types of foods of plant origin (Kyselova, 2011). The main dietary 
sources of polyphenols are fruit and beverages (tea, coffee, wine, fruit juices, 
beer and chocolate) and to a lesser amount vegetables, cereals and dry 
legumes (Augustin and Williamson, 2000).   Flavonoids are a major group of 
phenolic compounds which are contributed by edible plants to the human diet 
but the precise nature of these compounds is not known. They are classified as 
low-molecular-weight polyphenolic compounds that are ubiquitously present in 
fruit and vegetables, bearing a diphenylpropane (C6C3C6)  skeleton, and 
categorised according to their chemical structure, into flavonols, flavones, 
flavanones, isoflavones, anthocyanidins and chalcones (Kurzawa, 2012). Each 
group is different from the other on the basis of the number and arrangement of 
hydroxyl groups and to the degree and extent to which these groups undergo 
glycosylation. Those with dihydroxylation in positions 3’ and 4’ on B ring mostly 
occur in flavones and flavonols. The ideal glycosylation site on the flavonoids is 
in position 3’ and seldom in position 7’. The most common sugar residue is 
glucose but others could be galactose, xylose and rhamnose (Rice-evans et al., 
1995). Most of the flavonols and flavones demonstrate two key absorption 
patterns in the visible region/ultraviolet; B ring absorption characterised by Band 
I in the 320-385nm range and Band II in the 250-285nm range indicating the A 
ring absorption. Increase in the number of hydroxyl groups increase absorption 
band position (Mabry et al., 1970). The presence of the hydroxyl group at 
position 3 (3-OH) on the B ring of flavonols distinguishes them from flavones. 
This means Band I of flavonols is always at a longer wavelength by 20-30nm 
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than in the corresponding flavones. Flavanones possess saturated heterocyclic 
C ring (without a double bond), lacking consequent conjugation between rings A 
and B as compared to flavonols and flavones, contributing to their lower 
antioxidant activity (Mabry et al., 1970). Hence the C ring unsaturation is 
important for electron delocalisation across the molecule and to stable aryloxyl 
radicals.  
Fruit and vegetable intake could help to reduce atherosclerosis, hypertension, 
thrombosis, inflammatory processes related to cardio-vascular diseases and 
many other health issues.  The protective effects are largely contributed by the 
antioxidants derived from antioxidant nutrients vitamin C, E and β carotene. 
Also minor carotenoids and plant phenolic compounds such as flavonoids may 
also have a significant role by acting as antioxidant or a mediator of other 
involved mechanisms. Plant phenolics are capable of performing various 
actions acting as a reducing agent, oxygen scavenger and oxidising antioxidant 
by donating a hydrogen ion. Their antioxidant activity is conferred by the 
hydroxyl groups attached ring structures and predicted by their chemical 
property of having phenolic hydrogens, available as hydrogen donating radical 
scavengers (Halliwell, 1990). Also by their radical’s lower reduction potential as 
compared to those of superoxide and alkyl peroxyl which means flavonoids 
could disable these species and prevent the consequences of their harmful 
reactions (Jovanovic et al., 1992).  Research has shown the possible health 
benefit of a flavonoid enriched diet that it could modulate expression of various 
genes directly linked to disease risk. Similarly the potential of flavonoids to 
defend against circulatory disease has been summarized by many substantial 
studies. Research has also shown the ability of anthocyanins as useful agents 
in triggering apoptosis in leukaemia cells by inducing oxidative stress (Guarrera 
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et al., 2007). Various features of these compounds are parallel to those of 
anticancer drugs comprising attachment and cleavage of DNA and the 
production of ROS in the presence of transition metals ions (Arif et al., 2015). 
Studies have shown that the consumption of flavonoids can lower the mortality 
rate caused by coronary heart disease (CHD) (Kaur et al., 2007). 
Due to various reasons including structural differences, lack of analytical 
methods, variations in particular food contents, it is extremely difficult to 
estimate the daily intake of polyphenols but most authors refer to data published 
many years ago (Ku..hnau, 1976) where a total daily intake of phenols was 
reported as 1g.  
Little is known about the bioavailability, metabolism and absorption of flavonoids 
and it is likely that various groups have different pharmacokinetic characteristics 
(Figure 1.1a,b). Biological characteristics of these compounds depend on their 
bioavailability. The antioxidant capacity of the plasma increases by the indirect 
evidence of their absorption through the gut barrier. And more direct evidence 
of their absorption has been obtained by measuring the concentration in plasma 
and urine after ingestion of polyphenol rich food. Chemical structure is the main 
determinant of levels of intestinal absorption and the nature of metabolites 
circulating in the plasma. Studies showed that the amounts of excreted 
polyphenol in urine vary from one phenolic compound to another. The absence 
of polyphenols in urine implies that either they have not been absorbed by the 
gut barrier, digested and discharged in the bile, processed by communal 
microflora or absorbed by our own tissues (Hollman et al., 1995). A study 
proved that catechin is absorbed by the human gut and the plasma level of its 
major urinary metabolite, a sulphate of 3-O methyl catechin, reached a peak 
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within two hours of administration (Das, 1971). Most flavonoids rarely reach 
1µМ concentration in our plasma when the amount of polyphenols does not 
exceed what is normally consumed in our diet as our diet varies.  This 
concentration is usually achieved within 1-2 hours of ingestion except for the 
ones which are partially degraded by the clonal microflora. After elimination of a 
half-life period (i.e. 1-2 hours normally) plasma concentration drops rapidly. 
Thus, for the maintenance of plasma concentrations of flavonoids regular intake 
is required.  
Certain classes of flavonoids such as flavonols and flavones etc. are normally 
glycosylated. The sugar can be substituted at any position on the compound 
and could be further replaced by an acid group e.g. malonic. The removal (by 
enzymes e.g. cosidases) of hydrophilic moiety (sugars) is typically required for 
passive diffusion through the intestinal wall, as a first step of metabolism. In the 
acidic conditions of the stomach, non-enzymatic deglycosylation does not occur 
(Gee et al., 1998). 
It was proposed by De Eds in 1959 that flavonoids are readily absorbed and 
converted to a range of hydroxyaromatic acids which are quickly excreted in the 
urine. This suggests scission of larger flavonoids molecules into lower weight 
forms, in gastrointestinal tract before absorption. The metabolic transformation 
of flavonoids involves methylation of hydroxyl group, hydrogenation of side 
chains,  dehyroxylation in the para-position and β-oxidation forming conjugates 
(Rice-Evans et al., 1995) determined by their chemical structure. Another 
potential factor affecting the uptake could be the interaction of flavonoids with 
protein species as flavonoids are multi-dentate ligands which have ability to 
bind simultaneously at different points on protein surface (Hagerman and Butler, 
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1981). Studies confirmed that various flavonoids readily autoxidise in chemical 
systems including myricetin, quercetin, delphinidin and querceitagetin drawing 
conclusion that adjacent tri or para di-hydroxyl groups bearing flavonoids, show 
significant rate of autoxidation producing superoxide and hydrogen peroxide 
(Hodnick et al., 1994). Studies confirm that some flavonoids exhibit pro-oxidant 
properties (in higher concentrations) in the presence of metal ions and stimulate 
hydroxyl radical production and DNA damage in vitro. The metal chelating 
potential of some flavonoids, depend on their precise structure and adjacency of 
their hydroxyl groups. Thus, there may be a possibility of them chelating metal 
ions and preventing metal catalysed development of initiating radical species 
(Aruoma et al., 1993). Higher concentrations of myricetin and gossypetin 
showed involvement in alteration of LDL through covalent modification of 
apoB100 protein. These studies used relatively higher concentrations of the 
flavonoids (i.e. 100µМ), which are unlikely to be achieved in vivo systems 
(Rankin et al., 1993). 
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Figure 1.1a Absorption of flavonoids in human, based on in vitro and in vivo studies, a 
hypothesis (Panche, 2016) 
 
 
 
 
 
 
Figure 1.1b Potential routes of ingested flavonoids (Panche, 2016) 
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 Flavonoids as antioxidant agents 
 
Flavonoids are described as antioxidants (most abundant reducing agents in 
our diet), directly as free radical scavengers and indirectly by modulating intra-
cellular pro and antioxidant enzymes but these compounds have the potential of 
performing dual actions and protect our body’s tissues against oxidative 
damage. Thus depending on cell type, the applied stimulus and disease state, 
unpredictable results are possible when flavonoids interact with intracellular 
signalling pathways (Justino, 2010). For example they may provide protection 
against oxidative stress related diseases such as cancers and cardiovascular. 
The biological properties (bioavailability, interactions with cellular receptors and 
enzymes, antioxidant potential and others) of flavonoids depend on their 
chemical structure.  
Flavonoids are regarded as antioxidants due to the ease at which an H atom 
can be abstracted from their molecule by a radical (e.g. ROS), producing a 
flavonoid radical which is more stable and less reactive than the original 
attacking radical. For a flavonoid to be an antioxidant, it has to fulfil two basic 
conditions: first, it can negatively affect the free radical-mediated oxidation or 
autoxidation when present in relative concentration to the substrate to be 
oxidised; second, the resultant radical should be stable through intramolecular 
hydrogen bonding by additional oxidation (Shahidi, 1992). Maximum radical 
scavenging effectiveness requires a C ring with a 3-OH group attached to 2-3 
double bond and adjacent to 4-carbonyl (unsaturation). The di-hydroxyl groups 
adjacent to each other on B ring strongly influence the antioxidant activity of a 
flavonol whereas these groups at different positions are not that useful. 
Antioxidant activity does not enhance by adding more than two hydroxyl groups 
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in aqueous phase radicals. However, mono hydroxyl substituent containing a B 
ring is not an effective hydrogen donor and does reduce the activity (Pokorny, 
1987). An extra hydroxyl group at position 5’ on B ring (i.e. on myricetin) does 
enhance the properties of flavonols in lipid systems (Pratt, 1990). Many studies 
have established that the position and extent of hydroxylation is a key to the 
antioxidant property of flavonoids (Furuno et al., 2002). The main determinants 
of radical scavenging potential are hence, summarized as; adjacent 
dihydroxylation on B ring (conferring higher stability to the radical form), a free 
hydroxyl group at position 5 and/or 3 of ring A and B, respectively, the carbonyl 
group at position 4 and 2-3 double bond in C ring (for electron delocalization 
from B ring) (Van Acker  et al., 1996; Chobot  and Hadacek, 2011). 
Large numbers of studies have been piloted to investigate the beneficial effects 
of flavonoids. The ability to scavenge reactive oxygen species (ROS) shows the 
chemo preventative properties of flavonoids; however their pro-oxidant action 
could be a crucial process  for their apoptosis-inducing and anticancer 
properties as ROS have the ability to mediate fragmentation of apoptotic 
deoxyribonucleic acid (DNA) (Anderson  et al., 1998; Wasson et al., 2008). 
 Myricetin and its protective effects against various diseases 
 
Myricetin belongs to a class of flavonoids, flavonols: bearing B-ring 
hydroxylation in the 3' and 4' positions. Myricetin has an extra hydroxyl group 
attached at position 5’ in B ring in contrast with other flavonols. It also has a 
hydroxyl group attached to position 3 with a double bond from positions 2-3 on 
C ring and at position 5 and 7 on A ring, as well as a carbonyl group at position 
4. The unique structure (Figure 1.2) of myricetin determines its strong 
antioxidant property and other biological functions. The hydroxyl groups 
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adjacent to each other on B ring are responsible for conferring higher stability to 
the formed radical whereas the unsaturated C ring with carbonyl group at 
position 3 is crucial for electron localisation from the B ring. All these factors 
contribute to the maximum radical scavenging potential of myricetin (Pratt, 
1990; Chobot and Hadacek, 2011).  
 
Figure 1.2 Structure of myricetin (Büchter et al., 2013) 
The presence of a reactive oxygen species (ROS) i.e. •OH, •O2− and H2O2 can 
cause oxidative stress to the biological molecules. Although, ROS are normally 
produced as by-products of cellular metabolism activities, their higher levels are 
potentially damaging to the cells, DNA, lipids and proteins could steadily lead to 
the development of various diseases. Myricetin presents various oxidative 
properties. It acts as an antioxidant by directly scavenging the free radical 
species (ROS), by chelating the intracellular metal ions (which eventually 
produce ROS) or by inducing intra-cellular antioxidant enzymes (Ross and 
Kasum, 2002). Myricetin can increase the positive effect of other antioxidants 
and is able to induce glutathione-S-tranferase (GSH) enzyme which protects 
cells against free radicals and peroxides. 
Studies demonstrate that myricetin has the potential to act as a pro-oxidant due 
to its ability to autoxidise, depending on the substrate and environment, also 
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due to its tendency, to accelerate the production of hydroxyl radicals by reacting 
with ferrous or ferric (bound to EDTA) and H2O2.  The ability of myricetin to act 
as an inhibitory agent against glutathione reductase (GR) also demonstrates its 
pro-oxidative characteristic (Ong and Khoo, 1997; Semwal et al., 2016). 
Studies have shown that myricetin is very beneficial flavonoid antioxidant which 
has the ability to protect cells from hydrogen peroxide (H2O2) –induced damage, 
apoptosis and exhibits cyto-protective effects. It reduces adverse effects of 
H2O2 by decreasing the fragmentation of DNA, inhibiting the release of 
mitochondrial cytochrome C, increasing Bcl-2 up regulation and enhancing Bax 
down regulation. Myricetin is effective against both mitochondrial dependent 
and caspase dependent induced oxidative stress through regulation of different 
signalling pathways (Kang et al., 2010). Studies (in vitro) have proved that 
myricetin can directly lessen DNA damage caused by H2O2 in human 
lymphocytes, inhibits strands breakage and protects against oxidative base 
damage (Duthie et al., 1997). Myricetin triggered apoptosis in cisplatin (a cancer 
treatment drug used for the induction of apoptosis) resistant ovarian cancer cell 
lines, OVCAR-3 and A2780/CP70 through intrinsic (regulated by P53) and 
extrinsic pathways (Huang, 2015). 
1.6 Food derived mutagens and carcinogens 
 
A large number of human cancers, about 70-80%, are associated with lifestyle 
factors, of which 35-45% accounts for diet. Dietary factors which correlate 
strongly with cancer include low fibre, use of well-cooked food, high fat 
consumption, nitrite intake, less vitamin C usage, mycotoxins and alcohol (Doll 
and Peto 1981; Parkin et al., 2011). Heterocyclic amines (HCAs) comprise a 
group of compounds formed when meat is cooked and are considered to be 
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powerful bacterial genotoxins. HCAs are produced by cooking proteinaceous 
food, at very high temperature, allowing the reaction of creatinine, free amino 
acids and monosaccharides (Schut and Snyderwine, 1999; Sugimura et al., 
2004). More than 20 carcinogenic/mutagenic HCAs have been isolated (Nagao 
et al., 1997; Wakabayashi et al., 1992). The main subclasses of HCAs found in 
the human diet include aminoimidazoazaarenes (AIA), 2-amino-3-
methylimidazo[4,5-f]quinoline (IQ), 2-amino-3,4-dimethylimidazo[4,5-
f]quinolone(MeIQ),2-amino 3,8dimethylimidazo[4,5-f]quinoxaline (MeIQx), 2-
amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline (DiMeIQx) and 2-amino-1-
methyl-6-phenylimidazo[4,5-b]pyridine(PhIP) (Schut and Snyderwine, 1999; 
Turesky and Marchand, 2011).  Studies have shown these to be rodent 
carcinogens as well (Sugimura and Sato 1983; Sugimura et al., 2004). 
Activation of HCA to genotoxic compounds only implicates N-hydroxylation of 
exocyclic amines role whereas C-oxidation is just a purification reaction. 
Research shows that humans are exposed to HCAs through diet which are 
bioavailable and converted to genotoxic derivatives by CYP1A2 and can bind to 
DNA causing mutations but their association with diet related tumours 
development is not fully understood. Although a number of host drug-
metabolizing enzymes have the ability to activate and detoxify HCA including 
CYP1A2, N-acetyltransferase, sulphotransferase, prolyl tRNA synthetase, 
phosphorylase and COX isomers (Wolz et al., 2000). The involvement of HCA 
in the etiology of human cancer is well evident, which has triggered several 
positive efforts to determine various exogenous and endogenous factors that 
transform health risks caused by HCA. The production of oxidative damage, in 
addition to the DNA adducts plays a significant part in the carcinogenic activity 
of food mutagens (Najefzadeh, 2009) 
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 PhIP, a potential carcinogen 
 
Diet is an important avoidable cause of cancer (WHO). Consumption of well-
done cooked meat is associated with an increased risk of breast and other 
cancers. This association between meat preparation time and an elevated 
cancer risk is most likely due to an abundant formation of HCA. The most 
common HCA in the human diet is 2- amino-1-methyl-6 phenylimidazo [4,5-b] 
pyridine (PhIP) and it is also considered to be the most abundant HCA 
responsible for triggering different tumours in rats (Felton, 2004). 
The oxidation of PhIP by cytochrome P450 (CYP1A2) forms an N-hydroxy 
derivative, which sustains successive sulphation or acetylation to produce a 
nitrenium ion free radical that covalently binds to guanine residues at the C8 
position (Turesky, 2007). The consequent adduct is the main inducer of 
GC→TA transversions and toxic frameshift alterations of a guanine within a G-
rich repetitive sequence (Gooderham, 2002). The formation of these mutations 
is the basis for the genotoxic effects of PhIP comprising DNA damage, 
chromosomal aberrations, chromatid exchange and micronuclei (Otsuka, 1996). 
A failure to correct these genomic faults can lead to cancer, especially when 
they occur in proto-oncogenes and tumour suppressor genes. Research shows 
oxidative stress as a possible causing factor of DNA damage caused by HCAs 
(Maeda et al., 1999; Murata et al., 1999; Gooderham, 2002). 
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1.7 Nanotechnology 
 
Nanotechnology has been very important and useful in biomedical applications. 
This is a technique where designed nanostructures are assembled. Nano 
materials have been successfully used for different processes including protein 
characterization, bio sensing, drug delivery also for enzymes and biometric 
assemblies (Sun et al., 2014) 
Nanotechnology is the systematic study of a specific system at the nano level 
(1-100nm). The US National Nanotech Initiative defines nanomedicine as those 
drugs with particle size between 1-100nm (Boisseau and Loubaton 2011). 
However most of the literature accepts that nanomedicine can be anything up to 
500nm or even a 1micron (Martin 2006). The European Technology Platform on 
Nanomedicine describes nanomedicine as follows: ‘Nanomedicine is defined as 
the application of nanotechnology to health. It exploits the improved and often 
novel physical, chemical, and biological properties of materials at the 
nanometric scale. Nanomedicine has potential impact on the prevention, early 
and reliable diagnosis and treatment of disease’ (Boisseau and Loubaton 2011). 
It is worth noting that their definition eliminates the scale of the nanoparticles 
classified under nano medicine. In all cases submicron particles have been 
shown to exhibit a higher dissolution rate than those above 3 microns. Although 
particles with less than 100nm have a higher tendency to cross some biological 
membranes, it is worth noting that larger nanoparticles are likely to shrink in 
size when diluted in body fluid before reaching the size of action. 
The maximum average bond lengths range at which molecules can manipulate 
at the molecular level in the pico metre range is 74 pico metres for H-H bond 
and 200 for C-I bond. But nanotechnology provides further opportunities for 
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material science research, medicine, biology and several other disciplines 
through manipulation of single atoms and molecules in a certain manner which 
fits into a specific application (Nie et al., 2007). Nanotechnology reduces the 
limitations and difficulties of many other techniques such as proteomics 
technology and help to retrieve fresh information from biological systems that 
were not otherwise possible with conventional methods. Several fundamental 
cellular structures comprising proteins, lipid polymer and carbohydrates have 
similar sizes to numerous nanostructures (Vo-Dinh, 2005). This similarity 
between nanostructures and biological molecules is very significant in design 
and manufacture of modern nano-assemblies that have crucial biotechnological 
and medical applications (Yang et al., 2015). 
 History of nanotechnology 
 
Nanoparticles were introduced in the 9th century by artisans who used them for 
glittering effects or lustre on the surface of pottery. These NPs were produced 
by reacting copper and silver oxides with vinegar, salts, clay and ochre on fixed 
pottery and heated to 6000C. Copper and silver migrated to the outer surface 
when the glaze would have been softening by the heat. Reformation of ions to 
metal form was prevented by maintaining low pressure which helped NPs to 
obtain optic effects. The lustre technique was developed by the Muslim world 
when Muslim men were not allowed to wear gold hence they achieved similar 
effects on ornaments without using gold. The first scientific definition of NPs 
was proposed in 1857 by Michael Faraday. The very initial thought about 
nanotechnology was delivered by an American physicist, Richard Feynman at 
the American Physical Society on December 1959. He defined nanotechnology 
as a process by which smaller atoms and molecules can be developed by 
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deploying larger ones (Taniguchi, 1974). Later on the term was described by 
Professor Norio Taniguchi in 1974 as a procedure of separation, consolidation 
and deformation of compounds using single atoms or molecules. In the 
beginning of 1980s, nanotechnology started development and with it came the 
discovery of the scanning tunnelling microscope (STM). This progress led to the 
Innovation of fullerenes and carbon nanotubes in 1985. Then in 2000, the 
United States National Nanotechnology Initiative was founded to organize 
Federal nanotechnology research and improvement (Guzman et al., 2006; 
Tinkle, 2010). 
Nanotechnology is currently being utilised to tackle global water challenges to 
make water safe and purified (Mauter et al., 2018), in agricultural field to 
enhance livestock and crop productivity (Jasrotia et al., 2018), in 
cosmeceuticals (Kaul et al., 2018), in medicine field for effective drug delivery to 
treatment various diseases including cancer (Hu et al., 2018) and in storage of 
solar energy (Mohamed et al., 2018). 
 Properties of nanoparticles 
 
NPs are in between the form of the bulk material and atomic structure of a 
compound. Bulk materials show persistent physio-chemical characteristics 
irrespective of their size, whereas NPs depict completely diverse properties 
(Hutter and Maysinger, 2010). NPs are agglomerated as they are held together 
by different kinetic forces including Van der Waals, electrostatic forces and 
sintered bonds. The solubility of particles is greatly affected by these forces 
between agglomerates, under various conditions (Allouni et al., 2009). As the 
size decreases to nanometre, the surface area to volume ratio increases. This 
enhances the diffusion capacity and reactivity, particularly at high temperatures. 
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Reduction in size lowers the melting temperature of the particles and changes 
various other catalytic properties as well (Buffat, 1976). 
 Applications of nanotechnology 
 
Nanomedicine is a vast industry which utilizes the medical applications of 
nanotechnology.  The nanosize particles of the drug maximise its bioavailability 
to the site of need, for a continued period of time. Thus the biggest application 
of nanomedicine is drug delivery. However there is a need to understand the 
toxicity of NPs to tackle current problems (Amiji, 2010).  
NPs are very beneficial in cancer diagnosis, for example, in MRI imaging more 
detailed and higher contrast images can be produced of the cancer site due to 
size tuneable light emission (Kubik et al., 2005). Due to ineffective lymphatic 
drainage, NPs favourably accumulate at the tumour site because of their 
reduced size. This could be useful to consider NPs in future cancer treatments 
for targeting specific tumours and replacing the existing therapies (Leary et al., 
2006). Scientists are considering the development of a multifunctional 
nanoparticle which could directly target tumour cells (Brown et al., 2010).  
Other possible future medical uses of NPs include photo-dynamic therapy 
(Yamakoshi et al., 1999), surgery (Matteini et al., 2010) and cell repair etc. 
(Moghimi et al., 2005). However, commercially NPs are used in consumer 
products such as sunscreens, cosmetics, foodstuffs, outside furniture polishes, 
surface glaze and paint etc. (Parlini, 2008). Other applications of NPs include 
household use, nano-filtration, optics and in the textile industry (Bai et al., 
2010). 
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 Toxicity of nanoparticles 
 
Although, NPs quickly agglomerate in the environment there still is the possibility of 
environmental and clinical risks due to their unpredictable activities particularly large 
surface area which makes them more reactive and easily diffusible through membrane 
barriers, allowing interaction with biological systems (Bharali and Mousa, 2010). 
NPs can enter our tissues through different routes i.e. breathing (Oberdorster, 
2001), the digestive system (Jung et al., 2000) and perhaps through the skin 
(Kreilgaard, 2002). 
Hence, in the modern era rapid and excessive use of engineered nano-particles 
in research and various fields requires emphasis on toxicological matters 
related to NPs exposure. NPs have the potential to cause DNA damage, and 
there is a strong association of DNA damage with mutations and then 
carcinogenesis, which is critical. Different mechanisms of NPs causing DNA 
damage could be due to the production of oxidative stress, direct interaction 
with DNA by disturbing spindle fibre plus other components or by inducing 
genome instability through epigenetic mechanisms. Some damage inducing 
properties of NPs include their size, agglomeration state, release of toxic metal 
ions and their capability to produce ROS. Hence detection of genotoxicity, 
induced by NPs is very important and crucial for reducing their effects. 
(Karlsson et al., 2015). 
1.8 Genotoxicity produced by ROS induced Oxidative stress 
 
Genotoxicity is described as a characteristic of chemical substances that 
causes harm to the DNA, destroys DNA structure, damages genetic material 
and segregation leading to mutations, which may cause serious consequences 
in the absence of effective repair mechanism, initiating mutagenesis which 
further leads to tumorigenesis (Magdolenova et al., 2012). Genotoxicity and 
27 
 
mutagenicity are often confused, since all genotoxic agents are not mutagen but 
all mutagens are genotoxic. Hence mutagenicity is a step further away from 
genotoxicity. Mutagens may cause DNA damage directly or indirectly. Cells 
naturally use their defence mechanism (i.e. enzymatic and non-enzymatic 
system) to fight against genotoxic substances and ROS. Antioxidant enzymes in 
the cell and antioxidant nanoparticles work together as a first line of defence 
against ROS and maintain their concentration at levels compatible with cell 
integrity (Schins, 2002). All direct genotoxic agents certainly cause DNA 
damage but the damage induced at lower levels can be potentially repaired by 
DNA repair processes (Jenkins et al., 2010). 
ROS are oxygen containing ions and molecules which are normally produced 
as by-products of biological processes such as cellular metabolism. They play a 
vital role in inducing apoptosis under various physiological and pathological 
conditions. However, high ROS levels are damaging to cells, they cause 
oxidative stress leading to cellular malfunctioning and death. 
It has been documented that the cellular production of ROS increases under 
oxidative stress in various conditions. If expression of genotoxic mutations is not 
prevented either by repair mechanisms or by apoptosis, damage may not be 
fixed continuing degenerative processes leading to mutagenesis and cancer 
(Moody and Hassan 1982). DNA by definition is the prime target of 
mutagenesis. Hence mutations in DNA may lead to initiation and development 
of cancer, as compromised integrity of genetic material has been known to 
cause tumorigenesis. Different genotoxic agents cause DNA damage by their 
respective mechanism of action. Some transition metals while in high-valent 
oxidation states interact with DNA to incur lesions leading to cancer while some 
28 
 
substances such as pyrrolizidine alkaloids (PAs) cause damage by producing 
DNA adducts, breaks, micronuclei, aberrations, cross linking and gene mutation 
etc. in vivo and in vitro. PAs are mutagenic and are responsible for causing 
cancer especially in the liver (Chen et al., 2010). 
Genotoxic effects, if they do not immediately lead to death, can cause cancer. 
Severity of DNA damage is not the same among populations as among 
individuals differ in their ability to detoxify genotoxic agents. This leads to 
differences in occurrence of cancer among people. This ability comes from 
inherited polymorphisms of certain genes, important in activation of the 
chemical or due to variations in the efficiency of repair mechanisms of 
individuals (Bolognesi, 2003). Metabolism of some chemical substances leads 
to the generation of ROS, which is a possible system of genotoxicity.  
1.9 DNA damage and repair mechanisms 
 
Our body is composed of trillions of cells and every cell sustains thousands of 
lesions per day caused by various sources such as sunlight, chemicals, cellular 
metabolism and radiations etc. (Browner et al., 2004). Thus our cellular DNA 
constantly receives these insults which trigger DNA damage and gradually lead 
to DNA adducts (DNA segments bound to any carcinogen), interrupt gene 
expression, compromise genome integrity, mutations and structural alteration to 
the DNA. This damage could be either intrinsic (replication error, hydrolytic or 
ROS) or extrinsic (radiations, alkylation compounds, base analogues, 
intercalating agents).  The mismatch repair system (MRS) is responsible for 
ensuring the accuracy of replication. Post-replication defects can only be 
corrected if the MRS recognises mismatch pair, determine the incorrect base, 
excises it and repairs the DNA. Most frequent hydrolytic damage includes 
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deamination when during replication, cytosine is converted to uracil and 
adenine is introduced (instead of guanine) at the opposite position. The most 
severe hydrolytic attack is when the purine base is totally removed from the 
DNA backbone (Branzei and Foiani, 2008).  ROS (oxidising agents) present an 
important source of DNA damage, are not only produced by ionising radiations 
but also from cellular metabolism (Roy and Sil, 2012). Oxidation of guanine 
leads to 7, 8-dihydro-8-oxoguanine or ‘oxoG’, which readily pairs with adenine 
or cytosine. The type of mis-pairing promoted by oxoG would lead to a 
G:C→T:A transversion. Alkylation (by mutagens) transfers methyl or ethyl 
groups to either the base itself or to phosphate groups on the DNA backbone 
(Whitaker et al., 2017). Base analogues are almost identical in structure to 
genuine bases but are highly mutagenic (e.g. 5-bromouracil). Intercalating 
agents are compounds that are able to slide into the DNA backbone adjacent to 
purine or pyrimidine bases (e.g. ethidium bromide) 
Our DNA is a very precious component; hence, our cells have evolved a variety 
of repair mechanisms for protecting it from assaults, to maintain our genome 
integrity and stability (Dexheimer, 2013). The cells initiate the DNA repair 
response which recognises, detects and mediates repair mechanisms by 
activating different pathways such as apoptosis, cell-cycle arrest or DNA repair. 
Accumulated DNA damage and impaired damage response could lead to the 
development of many conditions and diseases including cancer. 
DNA damage could be repaired by the following mechanisms: 
 Base Excision Repair (BER) 
 
Damaged bases are generally repaired via the 3 R’s: Recognition, Removal and 
Replacement. In the case of BER an enzyme termed a glycosylase recognises 
30 
 
the damaged base, ‘snips’ it out of the DNA backbone and the resulting gap is 
filled in. Although excision repair is the most common mechanism for repairing 
damaged bases, a simpler mechanism also exists such as direct reversal 
‘undoes’ the damage done to the base. For example, for direct reversal of 
alkylation events, an alkyl group is detected and removed by a DNA 
methyltransferase or glycosylase (Watson et al., 2004). Usually used for repair 
of single strand breaks (SSBs).  
 Nucleotide excision repair (NER) 
 
NER does not recognise specific damaged bases rather it detects errors in the 
shape of the DNA helix. All the damage is repaired using the undamaged 
complementary strand of DNA (Wilson et al., 1997). 
 Homologous recombinant (HR) 
 
Homologous recombination is very important process. In addition to repairing 
double strand breaks (DSBs) caused by Ionising radiation, homologous 
recombination is essential during meiosis. HR requires an identical sequence to 
be used as a template for the damaged chromosome repair through a sister 
chromatid which would be available in G2 (Watanabe et al., 2009). 
 Non-homologous end-joining (NHEJ) 
 
Non-homologous end-joining (NHEJ) is a major DNA DSB repair system that a 
human cell can employ to repair DSBs. All proteins participating in this pathway 
possess significant mechanistic flexibility which allows NHEJ to produce various 
outcomes initiating from same ends (Srivastava and Raghavan, 2015). DNA 
Ligase IV together with cofactor XRCC4 act together to directly join the two 
broken DNA ends (Wilson et al., 1997; Gerodimos et al., 2017).  
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1.10  The cell cycle controls and cancer genetics 
 
Cellular growth and division is a fundamental characteristic of all living 
organisms. The cell cycle starts from two daughter cells originated from a single 
parental cell and finishes when the daughter cells divide. The cycle consists of 
following phases: M phase; short span phase when nuclear division (mitosis) 
occurs followed by cytoplasmic division (cytokinesis), G1 phase; (longest) 
cellular growth phase where some cells differentiate further and some never 
escape from this phase rather enter G0 (resting phase), S phase; accounts for 
DNA synthesis, genome replication and checkpoints prone to DNA damage, G2 
phase; rapid growth prior to M-phase with G2-M checkpoints (figure 1.3). The 
entire cell cycle machinery is regulated by and dependent on cyclin-dependent 
kinases (CdKs) either activation or inhibition (Hamel and Hanley-Hyde, 1997) 
and triggered by the action of growth factors. Cdks in G1 activate and stimulate 
a protein called retinoblastomas (Rb) to release a transcription factor (E2F) that 
then switches on the necessary genes to drive the cell into S-phase. Defects in 
Rb regulation are a common cause of cancer. Checkpoint mechanisms ensure 
the accomplishment of the previous phase before entering the next one.  
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Figure 1.3 Cell cycle and its checkpoints (Schnerch et al., 2012) 
Normally cell growth is a highly regulated process but when it is derailed, it 
leads to the production of uncontrolled cellular growth referred to as a tumour or 
neoplasm. These could be either benign (restricted to one point) or metastatic 
(spread around the body). Cancer cells are clonal which may be produced due 
to exposure to chemical substances which in turn cause DNA damage or due to 
chromosomal aberrations. Transformation (normal cell to tumour) occurs when 
a cell acquires a mutation and evades cell cycle check points i.e. G1/S-phase 
(replication), G2/M-phase (DNA damage check by P53 or PRb) and mitotic 
spindle (spindle formation) (Hanahan and Weinberg, 2000; Hanahan and 
Weinberg, 2011). Malignant cells are generally defective at all these 
checkpoints. There are three main types of cancer genes; tumour suppressor 
genes, oncogenes and DNA repair genes. Tumour suppressor genes are also 
called anti-oncogenes; their function in normal cells is to regulate cellular 
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proliferation. Mutations in these genes lead to cancer development and loss of 
function (Lodish et al., 2000b).  Oncogenes (cancer causing genes) activate 
cellular proliferation leading to differentiation and unregulated cellular growth 
(Ponder, 2001). They develop from proto-oncogenes which are responsible for 
regulation of normal cell growth processes. The normal function of DNA repair 
genes is to correct errors which occur when cells duplicate before cell division, 
whereas mutation in these genes results in failure of the repair system allowing 
successive mutations to accumulate. 
 P53 role in cell cycle regulation 
 
P53 is a crucial gene, encoding 393 amino-acid proteins, arranged into various 
domains and plays a substantial role in cell cycle regulation. The fundamental 
domain (aa102-292) of P53 has been presented, responsible for sequence-
specific DNA binding action to the protein (Wang et al., 1993). This particular 
domain encompasses the four reserved areas of the gene and the most 
important mutation hot-spots found in cancer-derived mutants (Pavletich et al., 
1993). P53 also contains C-terminus and N terminal domain which concentrate 
on the majority of various post-transcriptional alteration sites that maintain 
regulation of its function (Appella and Anderson, 2001). P53 can incorporate 
various signalling pathways which are triggered by different stimuli including 
DNA damage, oncogene initiation or hypoxia. In such circumstances P53 
stimulates different metabolic responses which ultimately lead to senescence, 
cell-cycle arrest, apoptosis, separation, DNA repair and inhibition of 
angiogenesis. The G1-S checkpoint on the cell cycle inhibits the replication of 
cells with damaged DNA and P53 plays a prominent role at this transition and 
arrests cellular growth there. It has been proposed that cell growth arrest (G1 
arrest) is mediated by transcriptional regulation of p21 (inhibitor of CDKs 
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2,3,4,6), GADD45, Cdc25C and 14-3-3s dependant on P53 (Hermeking et al., 
1997). Studies also show that Cdc25A initiates the delay in P53 dependent 
growth arrest at G1 which gives sufficient time for the cell to repair the damaged 
DNA (Nyberg et al., 2002). DNA repair can be triggered by P53 through the 
induction of p21, GADD45 and p48 protein expression (Hwang et al., 1999) and 
helps maintain genome integrity. Bax is amongst those P53 target genes which 
are involved in P53-induced apoptosis and are up-regulated (Shaw, 1996) but 
there are a few genes, down-regulated by P53 including Bcl 2 (anti-apoptotic 
gene) and cyclin A (a key protein in progression through S phase). The main 
responses of P53, cell-cycle arrest and apoptosis are usually based on stimulus 
and cell type. This is not fully understood that when and which pathway is 
activated by P53 first, though it is proposed that it could be dependent on 
affinity. Detecting low levels of DNA damage, it is possible that P53 upregulates 
high affinity genes and initiates cellular arrest. In contrast when stress levels 
cross the repair capacity then apoptotic genes might be activated (Inga et al., 
2002). P53 also demonstrates transcriptional-independent activity in 
mitochondrial apoptosis (Mihara et al., 2003), though most of the studies have 
focused on its transcriptional related role. The role of P53 in S-phase 
checkpoints is proposed to stop the cells with incomplete DNA replication, from 
entering mitosis (Taylor et al., 1999). P53 plays a role in the maintenance of 
growth arrest at G2-M phase where various P53 targets also play a part (Shaw, 
1996).  
 Mutant P53 (TP53) and cancer 
 
P53 in its wild-form (WTP53) is the key tumour suppressor which provides 
protection against cancer. Missense mutation (substituting a single amino acid 
in P53 protein), commonly clustered in the DNA binding domain in mutant P53 
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(TP53) (P53 encoded gene)   is the most common genetic damage observed in 
all tumour types and loss of wild-type function is a key process towards the 
cancer development (Olivier et al., 2010). As P53 is dominant negative, one 
mutated copy can corrupt the tetramer of whole protein. Loss of function results 
in the complete absence of P53 expression or production of mutant proteins 
which are unstable and truncated. Like all other tumour suppressors, the normal 
function of P53 has to be completely inactivated for a tumour to develop; hence, 
it needs two genetic lesions of the gene to occur, one on each allele in each 
cell, i.e. dominant negative. The resultant TP53 might depict diverse biological 
and biochemical characteristics, not present in its wild-type and could contribute 
towards the tumour developmental stages (Muller and Vousden, 2014). These 
properties and activities are often referred to as gain of function (GOF) 
manifesting dominant-negative impact over WTP53. A gradual rise in genome 
instability is a major hallmark of tumour progression demonstrated from 
increased mutations levels to deviations in chromosomal number and 
arrangement. TP53 can increase genome instability by disrupting the normal 
spindle formation checkpoint mechanism resulting in clusters of cells with 
polyploidy genomes (Gualberto et al., 1998). It can also affect the DNA repair 
by weakening the BER (Offer et al., 1999). A study has demonstrated that 
depletion of TP53 decreases tumourgenicity (both in vitro and in vivo), 
anticancer drug resistance, and proliferation in a range of cancer cell lines. It 
also weakens the aggressiveness of cancers (Bossi et al., 2006). This gives an 
appealing explanation of the effects of TP53 on cancer progression. TP53 has 
the ability to make the cell susceptible to a raised resistance against various 
pro-apoptotic signals (Lotem and Sachs, 1995). Its anti-apoptosis action may 
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not only speed up the cancer development but also reduce the response to 
cancer therapies.  
The anti-proliferative effects of the transforming growth factor β (TGF-β) on 
epithelial cells are supposed to be facilitated by WTP53 at the early stage of 
cancer (Cordenonsi et al., 2003). Hence, TP53 existence at this stage could 
override the inhibitory effect of TGF-β and if it influences after the proliferation 
stage, it could worsen the condition. Thus overexpressed TP53 could 
accelerate the tumour cells proliferation.  Efficient GOF activity of TP53 
depends on its higher levels in the affected cells and stability gained through 
cancer progression. As WTP53 is short lived and degraded mainly by Mdm2, 
evasion from Mdm2-mediated degradation is a key factor stabilizing TP53 (Oren 
and Rotter, 2010). TP53 is the most occurring mutated gene in all human 
cancer. 
 Mechanism of apoptosis and related genes 
 
Apoptosis is programmed cell death. It occurs in multicellular organisms and is 
a crucial process to maintain genome stability. Excess of it causes atrophy 
whereas defective apoptosis gives rise to uncontrolled growth and various 
conditions including cancer. Induction of apoptosis in cancer cells may present 
a promising strategy against drug resistance as it was reported that decreased 
vulnerability of tumours to apoptosis was closely associated with drug 
resistance (Hall et al., 2008). It is activated by the protein caspases and derived 
through two pathways intrinsic (mitochondrial) and extrinsic (receptor-
mediated). An intrinsic pathway is regulated by the Bcl-2 family proteins (pro; 
Bax, Bad and anti; Bcl-2, Bcl-xl etc.) which controls the mitochondrial 
membrane permeability and discharge of pro-apoptotic factors (Brunelle and 
Letai, 2009) whereas extrinsic pathways are regulated by tumour necrosis 
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factor-related apoptosis-inducing ligand (TRAIL) comprising Apo2L/TRAIL and 
associated receptors. The balance between pro and anti-apoptotic proteins, 
which is regulated by P53, decides whether a cell will undergo apoptosis or not. 
Loss of P53 correlates with high levels of anti and low levels of pro-apoptotic 
proteins (Kim et al 2014). 
 Role of Gamma-H2AX (γ-H2AX) in recognition and signalling of 
DNA double-strand breaks (DSBs) 
 
Since the study of the DNA damage which leads to serious illnesses like 
cancer, is essential for understanding the underlying processes, the emergence 
of a rapid and sensitive method and biomarkers, needed to quantify the 
damage, has great potential to not only monitor the tumour response but also 
the effect of certain treatment on normal cells predicting any acute or long term 
consequences. 
DSBs are the most damaging cellular lesions which, if left unrepaired could 
bring severe consequences for cellular homeostasis. It is believed that 
formation of a single DSB may be enough to disrupt the genome and cause 
cancer or cell death (Jackson, 2002). Hence, a system to locate and quantify 
these breaks is highly desirable.  For this purpose, the natural protein function 
of the cell involved in repair processes could be used to locate DSBs under 
fluorescence microscopy.  
Various factors are involved in DSB induction. Our cells are designed to activate 
a highly systematic mechanism called DNA damage response (DDR) in reaction 
to any kind of DNA damage, which detects and repairs it. The induction of DSBs 
triggers a process where a large number of chromatin protein, H2AX (a subtype 
of H2A), is phosphorylated forming γ -H2AX at the site of the break on location, 
serine 139 of H2AX, giving rise to a distinct γ-H2AX focus per DSB. This 
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phosphorylation plays a crucial role in DDR for gathering DNA repair proteins at 
damaged chromatin sites, also for the initiation of important checkpoint proteins 
which stops the cell cycle progression (Podhorecka, 2010). Histone H2AX is a 
substrate of various phosphoinositide 3-kinase-related protein kinases (PIKKs) 
such as ataxia telangiectasia mutated (ATM), ATM-Rad3-related (ATR) and 
DNA-dependent protein kinase (DNA-PK) dependent on the origin of the DNA 
damage and timing, but ATM is considered as the main physiological mediator 
of H2AX phosphorylation in response to DSB formation. ATM is initiated by its 
auto-phosphorylation at Serine 1981 location, which separates the inactive ATM 
dimers into single protein molecules with improved kinase activity (Bakkenist 
and Kastan, 2003). 
Visualisation and quantification of DNA DSBs can be achieved by fluorescent 
staining of nuclei for γ-H2AX foci, using specific antibodies. There is a direct 
correspondence between DSBs and γ-H2AX foci (Sedelnikova et al., 2002). 
As lymphocytes can be easily taken from a donor’s peripheral vein, use of γ-
H2AX staining to detect DSBs in these cells is considered as an established 
method (Löbrich et al., 2005), as explained further in section 1.11.1.3. 
Gamma-H2AX is a sensitive and primary indicator of DSBs in vitro and in vivo. 
It has proved beneficial for sensing low-levels of DNA damage. The use of γ-
H2AX in cancer therapy is currently being investigated. As studies have shown 
that the H2AX gene location, 11q23, is commonly transformed in tumour cells 
which may bring a 3-fold rise in γ-H2AX development. As a marker for DNA 
damage, H2AX will be greater in transformed tumour cells due to mutated and 
unregulated cell cycles (Kuo and Yang, 2008). 
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1.11 Methods for the study of genotoxic effects 
 
Genotoxicity assays are methods commonly used to mark substances that are 
able to react with nucleic acids at very low concentrations. This interaction 
between DNA and toxic agents could result in chromosomal aberrations and 
mutations in DNA structure. This has the ability to affect the accuracy of the 
message, leading to reversible changes in the cell. Such DNA impairment could 
result in harmful consequences e.g. establishment of a disease, altered 
heritable features, decreased reproductive capacity and increased mortality 
(Cavas et al., 2014). There are a number of methods for assessing DNA 
damage that have been used to determine agents with genotoxic ability. The 
biological effects resulting from DNA damage include micronuclei, chromosomal 
structural changes and mutations. The single cell gel electrophoresis (SCGE) or 
the Comet assay is a useful and reliable approach for calculating this damage 
and has been extensively used in various studies conducted in our laboratory 
(Anderson et al., 1996; Anderson et al., 1997; Anderson et al., 1998a; Anderson 
et al., 1998b; Anderson et al., 1999; Anderson et al., 2003; Anderson, 2005). 
 The Comet Assay 
 
1.11.1.1 Development and principles of the Comet assay 
 
A micro gel electrophoresis technique for assessing DNA damage at single cell      
level was first developed by Ostling and Johanson in 1984. But due to use of 
neutral conditions for the procedure, the general utility of the assay was limited. 
Then Singh et al., (1988) formulated a micro gel electrophoresis method for 
detection of DNA damage in individual cells, under alkaline conditions (pH ˃13). 
This design of assay massively enhanced sensitivity for determining genotoxic 
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substances because most of the genotoxic agents activate a greater magnitude 
of SSB than DSB. A pH ˃13 is expected to maximize the expression of alkali 
labile sites (ALS) as SSBs. Since presentation of this assay at pH˃13, its 
applications and uses have greatly increased. It has been used in various 
research areas including human and environmental biomonitoring, genetic 
toxicology and DNA repair processes. 
The attributes of the Comet assay include its rapidness, simplicity, low cost and 
high sensitivity. Its advantages also include assessing very low levels of 
damage, less quantity of cells needed per sample, conduction of studies using 
relatively smaller amounts of test substances. The Comet assay is a standard 
procedure for calculating DNA genomic damage. On a microscope slide, cells 
fixed in agarose are lysed to liberate DNA forming nucleoids which comprise 
supercoiled rings of DNA connected to a nuclear matrix. Structures similar to 
comets are formed by electrophoresis towards the anode using ph ˃13 (Singh 
et al., 1988). Then alkali is neutralized followed by DNA staining with ethidium 
bromide or SYBR green. Finally observed under a fluorescence microscope 
where higher damage is shown by lengthy intense tails and less damage by 
relatively shorter tails. The word comet identifies the DNA migration pattern of 
individual cell, developed by this assay.  
1.11.1.2 The Comet assay in genotoxicology 
 
Studies have proved that complex associations of different antioxidants and 
various modifying agents with ROS related DNA damage inducing substances 
and their reprotoxic  or genotoxic  effects can be assessed in all types of 
eukaryotic cells including human lymphocytes using the Comet assay. 
According to the systemic review by Sponchiado in 2015 the single cell gel 
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electrophoresis (SCGE) or the Comet assay in vivo and in vitro is the 3rd most 
often used assay for genotoxicity assessment of herbal extracts. In humans it is 
used to determine genetic damage with the aim of accessing human exposure 
to genotoxic agents due to several factors including lifestyle and environment. It 
has been used for DNA repair studies and environmental biomonitoring (Faust 
et al., 2004). Genotoxicity of NPs has been examined by this assay for the last 
decade and it has been confirmed suitable for measuring their toxicity (Karlsson 
et al., 2015) (Magdelenova et al., 2012). The Comet assay is very suitable for 
use with lymphocytes because the DNA damage of somatic cells can potentially 
lead to cancer development (Gopalan et al., 2011).  
1.11.1.3 Lymphocytes, as surrogate cells in genotoxic studies 
 
Vulnerability to cancer depends on several determinants including sensitivity of  
the genome, exposure to genotoxins and probable efficiency of the DNA 
repairing system (Collins 2004). Lymphocytes are considered as an appropriate 
choice to examine genome sensitivity; this is because the sub-populations of 
lymphocytes have long lives and have the ability to retain genetic mutations 
induced by a mutagen for more than 40 years (Anderson et al., 2014).  
As genotoxins cover a major percentage (>90%) of human carcinogens, use of 
lymphocytes is recommended by the World Health Organisation International 
Programme for Chemical Safety (WHO/IPCS), for detecting genotoxicity (WHO, 
2000). Peripheral blood lymphocytes are easy to obtain for sampling and large 
numbers of them circulate around the body in the blood which makes them easy 
target for genotoxins (Albertini et al., 2000). Research suggests that cytokines 
and chemokines involved in tumour development impair lymphocyte 
functionality. Lymphocyte genomic damage is further enhanced when 
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inflammatory mechanisms directly affect cancer development by inducing 
mutations (Ben-Baruch, 2006). Chemokines are involved in regulation of 
various cellular processes in WBCs including lymphocytes via initiation of G-
proteins (Guanine nucleotide binding proteins) and downstream receptor 
kinases and are important regulators of WBCs trafficking. Their participation in 
affecting the activities of other cell types and their expression in cancer 
development processes is well evident. Particular chemokines have been 
shown to be involved in recruitment of WBCs to tumour sites (Singh et al., 
2011). This shows that the ability and function of the leukocytes including 
lymphocytes is somehow connected to cancer development processes. 
Therefore in the current study we used the lymphocytes as model cells from 
pre-cancerous and MM patients to investigate the effects of MYR B and MYR N.  
As lymphocytes form a major cellular part of the adaptive immune response, the 
DNA damage and repair biomarkers could potentially provide information about 
disease status and condition in other cell types. For instance, DSBs are most 
deleterious types of DNA lesions which if left unrepaired could possibly cause 
mutations leading to cancer development and cell death (Jackson, 2002). Their 
detection in lymphocytes could provide a track and extent of DNA damage and 
repair in other cell types. 
The circulation of lymphocytes throughout the body provides them best 
exposure to genotoxic chemicals thus lymphocytes reflect an overall state of the 
organism. Their long half-life, ability to be stimulated once thawed from frozen 
conditions and ability to repair the induced damage make them better surrogate 
cells to be used in human monitoring and genotoxicity studies than other WBCs 
((Bausinger and Speit 2016). 
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 The cytokinesis-block micronucleus (CBMN) assay  
 
1.11.2.1 Improvement and principle 
 
Micronuclei were assigned various names, terminologies and description in the 
past. These structures were constantly found after cells were exposed to 
radiation and it was assumed that micronuclei (MNi) develop from acentric 
fragments which at later phase of mitosis, are extruded from two daughter 
nuclei (Kirsch-Volders et al., 2003). Micronuclei were discovered as a biomarker 
for cytogenetic damage by Evans et al in 1959, when they compared 
effectiveness of gamma rays to that of neutrons in Vicia faba roots. Countryman 
and Heddle in 1976, for the first time described the development of the 
micronucleus assay in human lymphocytes. But major flaws were observed in 
this assay by Michael Fenech in its then current form, due to fact that the 
observed micronucleus frequency was dependent on two things i.e. ratio of 
lymphocytes that gave a response to mitogen stimulation and the number of 
divisions which took place before harvesting during the culture period. He 
predicted that this method would only be fully optimal when a way to identify 
once divided cells was established.  He further found that the short-lived 
binucleated stage in telophase is the only point where once divided cells can be 
identified. The MN frequency could decrease with repeated cell divisions and 
hence comparison between MN frequencies and dividing cell populations could 
not be accessed. For this reason, cytokinesis needed to be blocked to stop cells 
completing cellular division after completing nuclear division. Cytochalasins are 
inhibitors of cytokinesis; they do this by stopping the polymerisation of actin into 
microfilaments which are essential for cytokinesis. Cytochalasin B is the most 
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efficient form that could inhibit cytokinesis in lymphocytes and other mammalian 
cells (Fenech, 2009). 
Micronuclei are formed as a result of lesions at the DNA or chromosomal level 
or at the protein level which are involved in the segregation of chromosomes 
e.g. tubulin. Their formation normally requires meiotic or mitotic division.  
Validity for the in vitro MN test for in vitro genotoxicity had been delayed due to 
limited understanding of mechanisms involved in induction of micronuclei and 
inadequate procedures to calculate cell proliferation and MN induction. But the 
combination of the cytokinesis block assay with immunochemical labelling of 
kinetochores, made it easier to identify major systems involved in MN induction, 
formation of double-stranded breaks (resulting in micronuclei with acentric 
fragments) and a compromised mitotic apparatus (leading to micronuclei with 
entire chromosomes). Specific aspects of the current protocol for the MN assay 
were developed and agreed upon at The Washington ‘2nd International 
Workshop on Genotoxicity Testing’ (25-26 March 1999) on following topics 
comprising option of cells, assessment of micronuclei, slide preparation, use of 
cytochalasin B, toxicity, treatment times and number of doses.  
The Human MicronNucleus (HUMN) project was aimed at establishing the 
application and understanding of the lymphocyte cytokinesis block micronucleus 
assay (CBMN). One of the fundamental aims of this project was to determine 
methodological variables and scoring MN to minimize their confounding effects, 
enabling better accuracy of the assay for determining genotoxic events. 
Therefore the reliability of the assay for comparing DNA damage rates 
increases. Also exposure conditions that induce increase in MN can be 
identified (Fenech et al., 2003). 
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1.11.2.2 Advantages 
 
The MN assay is considered to be highly reliable, quick and a suitable method 
to determine a wide spectrum of DNA damage at basal level especially for 
mutagenicity assessment (Hovhannisyan, 2010). According to a systemic 
review  (Sponchiado et al., 2015), the MN assay was the most frequently used 
method for evaluating genotoxicity of herbal extracts. Scoring has been made 
very simple and there are vast applications of the MN test (in vitro) in various 
cell types which have made it an accessible tool to determine cytogenetic 
damage. At present the CBMN method is the most widely used procedure for 
calculating MN frequency in human lymphocytes, and for determining the fate of 
a once-divided cell after chemical exposure (figure 1.4). CBMN can be used to 
score MN and other DNA biomarkers that are observed in binucleated cells (i.e. 
nucleoplasmic bridges and nuclear buds) and cells experiencing death either by 
apoptosis or necrosis are also counted. A positive association shown by various 
studies between MN, nuclear buds and nucleoplasmic bridges indicated these 
genomic instability biomarkers are mechanically linked to each other. 
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Figure 1.4 Possible fates of cykinesis-blocked cultured cells after exposure to chemical 
(cytotoxic/genotoxic) agents (Fenech, 2007) 
 
 Western blotting 
 
Western blotting, also called protein immunoblot is a widely used technique in 
cellular and molecular biology, immunogenetics, biochemistry and other 
disciplines of biology, for protein detection and to quantify the protein 
expression. It enables researchers to identify particular proteins from a complex 
mixture of various proteins, extracted from cells. The technique is comprised of 
three parts to complete the task i.e. parting by size based on the molecular 
weight and type of proteins using gel electrophoresis, then blotting to a solid 
matrix producing a band for each protein and finally, visualising/marking target 
protein using correct primary and secondary antibodies. Unbound antibodies 
are washed off as specific antibodies bind only to corresponding proteins. Thus, 
only one band should be visible for each protein while developing the film. The 
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thickness of the band corresponds to the quantity of protein present in the 
sample which could be indicated using a standard. Western blotting could 
detect as low as 1ng of proteins due to its high resolution gel electrophoresis, 
strong specificity and greater sensitivity. 
 Real Time-PCR 
 
Polymerase chain reaction (PCR) is an abundantly used technique in 
biomedical studies which enables quick and easy production of a large quantity 
of DNA from relatively smaller starting material. It amplifies a single or few 
copies of DNA to millions of copies of a specific DNA sequence. The method 
was developed by Kary Mullis in 1983 who later on won the Nobel Prize for this 
innovative invention in 1993. This easy, economic and reliable concept of 
replicating a focused DNA segment is widely applicable in various fields of 
science and probably is the most commonly used technique in molecular 
biology (Bartlett and Stirling, 2003). PCR Is simply ‘targeted’ DNA replication. 
DNA polymerases need a primer to provide a 3-OH group for DNA synthesis, 
and by having a ‘sense’ primer and an ‘antisense’ primer it is possible to 
specifically produce DNA in between the two primers (amplification). DNA 
polymerases synthesise a complementary strand in a 5’ to 3’ direction using one 
of the strands as a template. By using 2 primers, that are complementary to the 
two strands, both strands act as templates and are copied. Most PCR methods 
rely on thermal cycling which involves exposure of reactants to repeated 
heating and cooling cycles comprising three basic steps: Denaturation (melts 
the duplex into ssDNA), annealing (primers base-pair with ssDNA) and 
extension (DNA synthesis from primers). For denaturation the PCR reaction is 
heated to 94°C for 30 s to 2 mins to physically separate the DNA double helix 
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then followed by annealing at between 45°C to 72°C for 30 s where two DNA 
strands become a template for polymerase for selective amplification of target 
DNA. This temperature depends on the sequence of the primers and is 
determined by experiment (one temp at a time or some machines produce a 
temp gradient). Then extension at 72 or 78°C, depending on the heat stable 
DNA polymerase (Saiki et al., 1985). PCR represents an efficient in vitro cloning 
system that can produce as well as alter the defined DNA fragments in most 
simplified automatic reactions. PCR is extensively used in various applications 
including medical, infectious diseases diagnosis, forensics, DNA isolation, DNA 
amplification and quantification and research field etc. It is a powerful research 
tool bearing many advantages as being simple, rapid and a highly sensitive 
method producing billions of copies of target product. 
 Immunofluorescence (IF)/immunocytochemistry (ICC) 
 
ICC/IF is widely used technique for light microscopy to stain specific proteins 
and antigens and visualise the cellular view of spacial and temporal dynamics of 
various metabolic processes (Bennett et al., 2009). It uses particular 
mono/polyclonal primary antibodies with fluorescent secondary antibodies 
against various proteins and utilizes fluorescent dyes to highlight the interaction 
and is visualised under epifluorescence microscope, allowing the naked eye to 
quantify the cells with DNA damage. 
 
1.12  Aims and Objectives 
 
Although myricetin is a well-researched antioxidant flavonoid which has 
tremendous health beneficiary effects against various types of cancers and 
cardiovascular diseases however, there is no evidence of research about its 
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effects on lymphocytes from pre-cancerous and MM patients. Therefore this 
study is conducted to determine the genoprotective and genotoxic effects of 
myricetin bulk (MYR B) and myricetin nano (MYR N) in lymphocytes from pre-
cancerous and MM patients compared to those from healthy individuals. 
These aims will be achieved through following objectives: 
• To compare the protective effects of myricetin bulk & nano forms on 
peripheral blood lymphocytes from healthy individuals and pre-cancerous 
patients. This will be achieved through assessing cytotoxicity using the 
MTT assay and DNA damage using the Comet & micronucleus assays as 
well as evaluation of p53 and ATM pathway. 
• To investigate the in vitro protective role of MYR B and MYR N against 
ROS induced oxidative damage in lymphocytes from healthy individuals 
and pre-cancerous blood patients. This will be achieved by measuring 
cytotoxicity using the MTT assay, DNA damage caused by H2O2 in the 
Comet assay, the change in intracellular ROS and GSH levels, and 
assessment of DSB formation using immunocytochemistry.  
• To determine the modulating effect of MYR B (10µМ) and MYR N (20µМ) 
on PhIP-induced DNA damage in lymphocytes from healthy individuals and 
pre-cancerous patients using the Comet and micronucleus assays to 
determine genotoxicity and DNA damage, and through studying P53, Bcl-2 
and ATR pathways. 
• To study the effect of MYR B (10µМ) and MYR N (20µМ) in lymphocytes 
from myeloma cancer patients compared to those from healthy individuals 
and investigate causative molecular mechanisms and pathways. This will 
be achieved through studying DNA damage using the Comet assay and 
cytotoxicity using the MTT assay. In addition analysis of P53, Bcl-2 and 
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Bax expression at the gene and protein level, and monitoring of ROS levels 
will also be carried out. 
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Chapter 2: Materials and Methods 
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2.1 Materials 
 
All the chemicals, reagents and other materials used in various techniques in 
current project are listed in the table 2.1 below. 
Chemicals, reagents, media, kits and 
antibodies 
Suppliers 
 
CAS number 
Dimethyl sulphoxide DMSO BDH, Poole, UK 67-68-5 
Ethidium bromide Sigma-Aldrich, UK 1239-45-8 
Ethylenediaminetetraacetic acid Sigma-Aldrich, UK 6381-92-6 
Hydrogen peroxide Sigma-Aldrich, UK 7722-84-1 
Low melting point agarose Invitrogen, UK 39346-81-1 
Normal melting point (NMP) agarose Invitrogen, UK 9012-36-6 
PBS phosphate buffer saline Sigma-Aldrich UK 79382 
RPMI medium 1640 (with 2m M L-
glutamine and 25 m M HEPES) 
Invitrogen, UK 11875-093 
Rothwell Dark RPMI 1640 medium with 
L-glutamine 
Sigma-Aldrich UK N/A 
Sodium Chloride BDH, Poole, UK 7647-14-5 
Sodium Hydroxide BDH, Poole, UK 1310-73-2 
Triton X-100 BDH, Poole, UK 9002-93-1 
Trizma base Sigma-Aldrich, UK 77-86-1 
Tween 20 Sigma-Aldrich, UK 9005-64-5 
Trypan blue 0.4% Sigma Aldrich, UK 72-57-1 
MTT dye Fisher Scientific, UK M6494 
Acetic acid VWR, UK 72-31-15 
Cytochalasin B Sigma-Aldrich UK 14930-96-2 
DPX mountant for histology Sigma-Aldrich UK 44581 
Disodium hydrogen phosphate 
(Na2HPO4) 
VWR 7558-79-4 
Ethanol Sigma , UK 64-17-5 
Formaldehyde Sigma-Aldrich UK 50-00-0 
Glacial acetic acid Fisher Scientific , UK 64-19-7 
Giemsa Stain improved R66 solution 
Gurr 
VWR 51811-82-6 
Mitomycin C Sigma-Aldrich UK 50-07-7 
Methanol Fisher Scientific , UK 67-56-1 
Phytohemagglutinin (PHA) Invitrogen, Ltd 9008-97-3 
Potassium chloride VWR 7447-40-7 
Penicillin-Streptomycin Invitrogen Ltd 11528876 
Sodium dihydrogen phosphate 
(NaH2PO4) 
VWR 7558-80-7 
Ammonium persulfate (APS) Sigma Aldrich, UK A1924 
Anti-Mutant p53 antibody [Y5] Rabbit 
monoclonal 
Abcam, UK Ab32049 
Anti-Bcl-2 antibody [E17] Rabbit 
monoclonal 
Abcam, UK Ab32124 
Anti-Bax antibody [E63]  Rabbit 
monoclonal 
Abcam, UK Ab32503 
Acrylamide/Bis Acrylamide solution 
30% 
Sigma Aldrich, UK A3699 
Bovine serum albumin (BSA) Sigma Aldrich, UK 9048-46-8 
Bromophenol blue Sigma Aldrich, UK 115-39-9 
Bradford dye reagent Bio Rad, UK 5000205 
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Donkey Anti-Rabbit IgG H&L (HRP) 
Polyclonal antibody 
Abcam, UK Ab205722 
ECL 1, 2 BioRad, UK 1705060 
Foetal bovine serum (FBS) Sigma Aldrich, UK 9014-81-7 
GADPH primary antibody, Rabbit 
monoclonal 
Abcam, UK Ab8245 
Glycine VWR, UK 56-40-6 
Halt TM Protease inhibitor cocktails 
(100X) 
Fisher scientific, UK 78430 
Low Fluorescence Western Membrane 
(PVDF) 
Abcam, UK Ab133411 
Laemmli sample buffer 2X concentrate Sigma Aldrich, UK S3401 
Lymphoprep Stem cell Technologies, UK 07851 
2-Mercaptoethanol Sigma Aldrich, York, UK 60-24-2 
Non-fat dried milk (NFDM) powder Tesco, Ltd, UK 3024250 
Precision Plus Protein™ Dual Colour 
Standards,. Ladder 
Bio Rad, UK 1610374S 
Ripa lysis buffer Fisher scientific, UK 89900 
SDS Sigma Aldrich, UK 75-05-8 
N,N,N′,N′-Tetramethylethylenediamine 
(TEMED) 
Sigma Aldrich, UK 110-18-9 
DCFDA / H2DCFDA - Cellular Reactive 
Oxygen Species Detection Assay Kit 
Abcam, UK Ab113851 
96-well black plates PerkinElmerTM 6005660 
GSH/GSSG Ratio detection assay kit 
(fluorometric green) 
Abcam, UK Ab138881 
AurumTM Total RNA mini kit  Bio-Rad, UK 732-6890 
 iScriptTM c DNA synthesis kit  Bio-Rad, UK 170-8890 
Fast SyBRR green master mix  Thermo Fisher, UK 4385612 
Nuclease free water  Qiagen, UK 129114 
Primers Sigma Aldrich, UK - 
MicroAmp® Fast Optical 96- 
Well Reaction Plate, 0.1 mL 
Thermo Fisher, UK 4347907 
Goat Anti-Mouse IgG H&L (Alexa 
Fluor® 488), polyclonal secondary 
Abcam, UK ab150113 
Dapi Invitrogen, UK D1306 
Gold antifade reagent with Dapi Invitrogen, UK 8961 
Anti-gamma H2A.X (phospho S139) 
antibody [9F3]  Mouse monoclonal 
Abcam, UK ab26350 
 
Table 2.1 Materials along with their suppliers and CAS numbers 
2.2 General Methods 
2.2.1 Ethical approval 
 
The current project which involves the use of human peripheral lymphocytes 
has been granted ethical approval by Leeds East Ethics Committee (Reference 
No.:12/YH/0464) and the University of Bradford’s Sub-Committee for Ethics in 
Research involving healthy Human Subjects (Reference No.: 0405/8). All 
peripheral blood samples were collected after informed consent from patients 
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and healthy individuals. The research support and governance office of 
Bradford Teaching Hospitals NHS Foundation also agreed the research (REDA 
number 1202). 
2.2.2 Blood collection 
 
All the basic information (age, gender, medicines and food supplement intake, 
lifestyle factors, diet etc.) was obtained through the questionnaire filled in by the 
patients and healthy individuals (Please refer to Appendix 1, 2 and 3 for the 
forms used to collect the data). 
Blood samples from healthy volunteers were collected in the phlebotomy room, 
University of Bradford, UK by trained phlebotomists. Whereas blood samples 
from patient groups were kindly collected and provided by the hospital staff at 
Bradford Royal Infirmary (BRI), Haematology Department, Bradford, UK.  
Whole blood was collected by venepuncture in anti-coagulant tubes from the 
healthy individuals and the patient group (see table 2.2 & 2.3).  Samples were 
diluted with1:1 ratio of RPMI 1640 medium (Sigma Aldrich) complemented with 
10% dimethyl sulphoxide (DMSO), aliquoted into labelled Eppendorf tubes and 
instantly stored at -800C to be used for the Comet assay and fresh blood was 
used to isolate lymphocytes for rest of the techniques used in the current study. 
No Age Ethnicity  Gender  Smoking 
history 
Family history 
1 48 CAUCASIAN M NO NONE 
2 28 CAUCASIAN M NO NONE 
3 27 AFRICAN M YES NONE 
4 38 CAUCASIAN M NO NONE 
5 60 CAUCASIAN F NO NONE 
6 40 ARAB M NO NONE 
7 45 CAUCASIAN M YES  NONE 
8 55 CAUCASIAN M NO NONE 
9 35 CAUCASIAN M YES NONE 
10 25 CAUCASIAN M NO NONE 
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11 44 ASIAN M YES NONE 
12 28 CAUCASIAN M NO NONE 
13 23 CAUCASIAN F NO NONE 
14 27 CAUCASIAN M NO KIDNEY CANCER 
15 33 ARAB M YES NONE 
16 47 ASIAN M YES NONE 
17 28 CAUCASIAN M NO NONE 
18 42 ASIAN M NO NONE 
19 48 ASIAN M NO NONE 
20 60 ASIAN M YES NONE 
21 24 ASIAN M NO NONE 
22 34 ASIAN M NO NONE 
23 34 CAUCASIAN F YES NONE 
24 34 ASAIN M NO NONE 
25 59 CAUCASIAN F YES NONE 
26  28 ASIAN M YES NONE 
27 61 CAUCASIAN F NO NONE 
28 36 CAUCASIAN F NO NONE 
29 52 CAUCASAIN F NO NONE 
 
Table 2.2 Brief information about the healthy blood samples 
No Age Ethnicity  Gender  Smoki
ng 
history 
Family history Medical condition 
1 79 CAUCASIAN M NO NONE MGUS, COPD, 
MONOCLONAL B 
CELL 
LYMPHOCYTOSIS 
2 80 CAUCASIAN F NO NONE- MGUS 
3 78 CAUCASIAN M NO NONE- MGUS 
4 73 - F YES CANCER MARGINAL ZONE 
LYMPHOMA 
5 56 - F YES LEUKAEMIA & BRAIN 
TUMOUR 
MGUS 
6 77 - M NO NONE MGUS 
7 75 - M NO NONE MGUS 
8 80 - M NO CANCER POSITIVE MGUS 
9 81 CAUCASIAN F NO BOWEL& STOMACH MGUS 
10 63 CAUCASIAN M YES NONE MGUS 
11 72 CAUCASIAN M NO NONE ARTHRITIS 
12 55 CAUCASIAN M NO NONE MGUS 
13 83 CAUCASIAN M NO NONE MGUS, BENIGN 
PROSTATIC 
HYPERPLASIA 
14 63 CAUCASIAN M YES NONE MGUS 
15 74 CAUCASIAN M NO NONE MGUS COPD 
16 63 CAUCASIAN F YES ARTHRITIS MGUS, COPD 
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17 66 CAUCASIAN F NO BREAST CANCER MGUS 
18 52 - M YES NONE MGUS 
19 62 - F YES LYMPHOMA & BRAIN 
TUMOUR 
MARGINAL ZONE 
LYMPHOMA 
20 63 - M YES NONE MGUS 
21 - CAUCASIAN M NO NONE MGUS 
22 74 CAUCASIAN F NO LUNG CANCER 
COPD 
MGUS 
23 83 CAUCASIAN M - NONE MGUS 
24 60 ASIAN F NO NONE MGUS 
25 62 - M NO NONE MGUS 
26 51 - F NO NONE MGUS  
27 74 - M NO NONE MGUS 
28 75 - F NO NONE MGUS 
+TYPE II DIABETES 
29 64 CAUCASIAN M NO NONE MARGINAL ZONE 
LYMPHOMA 
30 55 CAUCASIAN F NO NONE MULTIPLE MYELOMA 
31 56 CAUCASIAN M NO PANCREATIC CACNER MULTIPLE MYELOMA 
32       
33       
34 84 CAUCASIAN M NO NONE MANTLE CELL 
LYMPHOMA 
35 79 CAUCASIAN M NO BREAST CANCER MULTIPLE MYELOMA 
36 68 CAUCASIAN F NO NONE MGUS 
37 77 CAUCASIAN F NO OVARIAN AND BREAST 
CANCER 
MULTIPLE MYELOMA 
38 70 CAUCASIAN M NO NONE MULTIPLE MYELOMA 
39 50 ASIAN F NO NONE MGUS 
40 87 CAUCASIAN M NO NONE MULTIPLE MYELOMA 
41 61 CAUCASIAN M NO TESTICULAR AND 
BREAST CANCER 
MGUS 
42 75 CAUCASIAN F NO MASTECTOMY MGUS 
43 69 CAUCASIAN M NO STOMACH AND LUNG  MGUS 
 
Table 2.3 Brief information about the patient samples (MGUS stands for monoclonal 
gammopathy of undetermined significance, COPD for chronic obstructuve pulmonary diseases) 
2.2.3 Preparation of myricetin Nano-particles (NPs), myricetin bulk and 
PhIP 
 
Myricetin was purchased from Fisher Scientific, UK (529-44-2) as a powder. 
Suspensions of myricetin bulk and nanoparticles were made using 7% (w/w) 
solid loads of myricetin in a medium comprising of hydroxypropyl 
methylcellulose (HPMC) (0.5 % w/w), sodium lauryl sulphate (SLS) (0.1% w/w), 
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ethanol (0.8% w/w), polyvinylpyrrolidone (PVP) K-30 (0.5% w/w) and purified 
water. PhIP was prepared in double distilled water. The suspensions were 
transferred to an amber glass bottles and stored at 40C for the research 
duration. 
2.2.4 Microfluidic Procedure  
 
The nanoparticles of myricetin were prepared using a Y shaped microfluidic 
reactor in a precipitation technique. Five mls of ethanol containing the drug at a 
concentration of 5mg/ml was injected in one side of the channel and 10ml of 
water from other side at a rate of 30ml/hr and 60ml/hr, respectively. The liquid 
was then collected in a 50ml beaker, being stirred with a magnetic stirrer and all 
the above mentioned contents were added. The contents were stirred for 
another 10 mins after removing the precipitate. 
2.2.5 Particle size of mricetin bulk and nanoparticles 
 
The mean particle sizes of myricetin nanoparticles in the stock solutions were 
measured using a Zetasizer Nano ZS-90 Model ZEN3600 (Malvern Instruments 
Ltd, UK) by Photon Correlation Spectroscopy. Measurements were taken at 
room temperature. 
2.2.6 Transmission Electron Microscope (TEM) analysis of myricetin 
particles  
 
2.2.6.1 Morphology and visualization of myricetin bulk and NPs 
  
To visualise the individual particles and their shapes, transmission electron 
microscopy TEM Tecnai 12, (FEI Company, Netherlands) was used. The 
photographs were captured at different magnifications operated at 5 to 150K. 
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2.2.6.2 Preparation of TEM sample grids 
 
Equipment: Filter paper, glass petri dish, parafilm, self-closing tweezers, slass 
or plastic pipette, 3 tumblers, doubled distilled water (DD-H2O), timer, 
desiccator (silica gel), grids and uranyl acetate (TAAB Laboratories, UK). 
Method: Grids were placed onto the filter papers and a drop of each sample, in 
a correct dilution ratio was applied to them individually and left for 10 mins to 
dry. The grids were sequentially cleaned in the 3 tumblers with DD-H2O and 
placed on filter papers to dry. Parafilm was prepared in the petri dish to contain 
any uranyl acetate spills and grids were placed in uranyl acetate for 2mins. 
Grids were again sequentially cleaned in 3 tumblers of DD-H2O then placed on 
filter papers to dry overnight followed by visualization of particle sizes of 
myricetin bulk and nano at different magnifications using TEM.  
2.2.7 Stability of myricetin bulk and NPs 
 
The stability of the particles for both forms of myricetin was assessed by 
checking their particle size and the difference was less than 1%. Hence, these 
were considered stable to be used for the study. The suspensions were also 
sonicated for 10 mins before each use to avoid sedimentation and control 
aggregation. 
2.2.8 Myricetin and PhIP concentrations 
 
In the current study two forms of myricetin (NPs, bulk) and one form of PhIP 
(Toronto Research chemicals INC, Canada. A617000) (bulk) was used. The 
concentrations of myricetin bulk (MYR B) and NPs (MYR N) forms, used for in 
this research study were 10µM and 20 µM respectively determined by 
concentration dependent studies as non-genotoxic concentrations. The 
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concentration of PhIP used throughout the study was 100 µM and was 
determined by dose response curve. (Data shown in chapter 3 and chapter 5) 
2.2.9 Isolation of lymphocytes from whole blood  
 
Whole blood was diluted with 0.9% saline (by dissolving 9g of NaCl per 1000ml 
water) in 1:1 dilution and mixed thoroughly. Then diluted blood was overlaid on 
top of pre-filled lymphoprep (Invitrogen, UK) in a falcon tube (1:0.5 dilutions) 
without mixing the two. The tube was centrifuged at 800g for 20mins at room 
temperature (RT). The lymphocyte layer was carefully transferred to a saline 
solution and centrifuged for another 15mins at 500g. All the supernatant was 
tipped off and cells were suspended in RPMI-1640 (Sigma Aldrich, UK) media. 
2.2.10 Cell density calculations (Haemocytometer) 
 
Fifty µl of 0.4% trypan blue was added to 350µl RPMI media and 100µl of 
isolated lymphocyte stock together. Ten µl of this suspension was placed onto 
each chamber of a haemocytometer. Four big squares (within 4 small squares 
in each) were counted for cell numbers using following formulae:  
Dilution factor = final volume/volume of cells stock,  
Cell density =(No. of live cells per big square/volume of square per ml) x dilution 
factor. 
2.2.11 Cell viability using trypan blue exclusion 
 
One ml suspension of isolated lymphocytes was added to a micro centrifuge 
tube and treated with 10µl of test chemical followed by incubation at 370C for 
the desired time. After the incubation time was over the tubes were micro 
centrifuged for 5mins at 4000rpm. The supernatant was removed and the 
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remaining 50 µl pellet was re-suspended by pipetting up and down several 
times; 10 µl of this was transferred to an empty Eppendorf ® tube. Then 10 µl of 
Trypan blue (0.4%) was added to the tube containing cells, mixed well and left 
for 30 secs to settle. Then 10 µl of this suspension was transferred to a slide. A 
small coverslip was placed on top and observed under the light microscope. 
Live cells appeared transparent and the dead ones appeared blue. 100 cells 
were counted for each slide to check viability percentage. 
2.2.12 MTT assay  
 
To evaluate cytotoxicity and cell survival rate, the MTT assay was used as it is a 
standard sensitive, simple, reliable and qualitative method to determine 
cytotoxicity, using less material. To start the experiment 10-20,000 cells/well 
(lymphocytes isolated from whole blood) were seeded in a 96-well plate and 
incubated at 370C overnight in the cell culture incubator to let cells firmly attach 
to the bottom of the plate. The next day, treatment solutions were added to 
each well at the desired concentrations. In addition to test wells, one set 
included just culture media without any cells (blank) and one set included 
culture media with cells but not exposed to chemical compounds (negative 
control). The plate was left in the incubator for different periods (1, 24, 48 hrs). 
After the exposure time was over, the medium was replaced by fresh medium 
and 10 µl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
dye (5mg/ml of PBS) was added to each well and incubated for 4 hours at same 
conditions of incubation. After this the medium was gently aspirated from each 
well and 200 µl of DMSO was added to dissolve the formazan crystals 
(chromogenic products of the reduction of tetrazolium salts by dehydrogenases 
and reductases). The contents of each well were gently mixed by pipetting 
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DMSO up and down 4-5 times. Absorbance was read and recorded after 
10mins at 590nm using a plate reader. 
2.2.13 The Comet Assay 
 
2.2.13.1 Cell treatment 
 
A volume of 10µl of treatment solutions, 100 µl of whole blood and 890 µl 
suspension of RPMI medium were added in Eppendorf ® tubes with a final 
volume of 1000 µl and incubated at 370C for 30 min. The tubes were 
centrifuged for 3 min at 3000rpm and then 900 µl of the supernatant was 
removed and discarded. The remaining cell pellet was re-suspended and mixed 
with 100 µl of 0.5% low melting point (LMP) agarose (made in PBS w/v); then 
100 µl of this cell mixture was placed on a dry slide pre-coated with 1% normal 
melting point (NMP) agarose (1% w/v in ddH2O) and spread out using suitable 
glass coverslips. The agarose was allowed to set on ice for few minutes. 
2.2.13.2 Lysis  
 
Once the agarose layers were set, the cover slips were removed and slides 
were incubated in freshly prepared lysis solution (89% lysis buffer, 10% DMSO, 
1% triton X-100) overnight. Lysis buffer is a detergent containing high salt 
solution (2.5 M NaCl, 100 mM EDTA and 10 mM Trizma base at pH 10).  
2.2.13.3 Electrophoresis 
 
The slides were kept horizontally on the gel electrophoresis tank and incubated 
in fresh cold alkaline electrophoresis solution (10mls of 200mM EDTA & 60mls 
of 10M NaOH mixed in 1930mls of ddH2O at pH > 13) for 30 min at 4°C for 
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unwinding the DNA then electrophoresis was run at same conditions for another 
30 min at about 300mA current and 25 Volts. 
2.2.13.4 Neutralisation 
 
The slides were removed from the electrophoresis solution and washed in 
neutralisation buffer (0.4 M Trizma base in ddH2O at pH 7.5) three times at 
5min intervals. 
2.2.13.5 Staining 
 
The DNA was visualized by staining the slides with 60 µl of ethidium bromide 
(EB) (20µg/ml) and covered with the cover slips. 
2.2.13.6 Scoring of Slides 
 
All slides were correctly coded according to different treatment groups and 100 
cells were scored per slide using a fluorescence microscope equipped with the 
CCD camera and computer system. Data were produced measuring two 
parameters: Olive tail moment (OTM) and % Tail DNA by using Komet 6 
software, Kinetic imaging (Andor Technology Ltd, Belfast, UK) (Magnification: 
X20, Image calibration: X81: Y*1). 
2.2.13.7 Statistical Analysis 
 
The normality of data obtained was tested using the Kolmogorov – Smirnov 
test. The data was analysed by one-way ANOVA to determine the significance 
figure. All values P < 0.05 were considered significant. Statistical analysis was 
performed using Graph Pad Prism 7.02. 
2.2.14 Micronucleus Assay 
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Fresh blood was obtained from 5 patients and 5 healthy volunteers. The 
samples were collected in heparinised tubes and used for the cell cultures. 
2.2.14.1 Cell culture medium preparation 
 
A fume hood was used for all the culture steps under sterile conditions. The 
basic culture medium (RPMI 1640 with 25mM HEPES and L-Glutamine, 1% 
penicillin-streptomycin and 15% foetal bovine serum(FBS)) 4.5ml, was 
transferred into each 25cm3 corning vented cap culture flask and was stored at -
20°C until needed. Prior to use, the flasks were equilibrated at 37°C (with 5% 
CO2) for at least 30min. 
2.2.14.2 Culturing blood and Treatment 
   
To start the culture, 130 µl of phytohaemagglutinin (PHA) and 370 µl of fresh 
blood was added to the flasks containing the basic medium at 0 h. The flasks 
were gently shaken to mix the contents and incubated for 24 h at 37°C in the 
presence of 5% CO2. At 24 h, 50 µl of each chemical was added to the cultures. 
Plain medium was used for the negative control (NC), 0.4 µM mitomycin C was 
added to the positive control (PC) and flasks were further incubated for 20 h 
under the same conditions. After 44 h of treatment, 30 µl of cytochalasin B (cyt-
B) (1mg/ml) was added to each culture to block cytokinesis. The flasks were left 
for incubation for another 28 hrs. 
The flasks were removed from incubation at 72 hrs and contents shifted to 15 
ml falcon tubes. Sterile conditions were no longer required. The tubes were 
centrifuged at 800rpm for 8 min, the supernatant was removed from each 
culture until 500 µl remained, using a vacuum pump. To give cells the hypotonic 
shock, 5ml of cold 90mM KCL was added to each tube while being stirred 
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gently on a vortex then incubated for 15mins at 4°C to allow the cells to relax. 
The tubes were centrifuged and the supernatant was discarded until 500 µl 
remained.  
2.2.14.3 Fixation steps 
 
A 5ml freshly prepared Carnoy’s solution (3 parts methanol and 1 part glacial 
acetic acid) was added to each tube drop by drop while being gently mixed on a 
vortex tailed by 3 drops of formaldehyde (38%)   and stirred well by a Pasteur 
pipette (Fisher Scientific) . The cell suspensions were centrifuged at 800rpm for 
8 min, the supernatant was discarded until 500 µl remained and cells were re-
suspended by patting the tubes. The fixation step was repeated twice without 
the addition of formaldehyde and tubes were left overnight at 4°C.  
2.2.14.4 Slide preparation and staining 
 
The next day, tubes were centrifuged for 8min; the supernatant was removed 
and discarded until approximately 100 µl remained. Then about 200-600 µl of 
Cornoy’s solution was added depending on the cell density and pellet size. A 
volume of 20µl of cell suspension was placed twice on pre-labelled frosted glass 
slides (centre left and centre right) and allowed to air-dry. For each treatment 
group four slides were prepared and the cell density was checked using a 
phase contrast microscope (Nikon Eclipse Ti-S) and left overnight to dry. The 
following day, slides were stained with Giemsa solution (5% Giemsa solution 
made in phosphate buffer at pH 6.8) for 20min and smoothly washed in water 
for 2min and left to dry. Three drops of DPX mountant for histology were placed 
and cover slips 24 x 50 mm2 (VWR) were mounted on to the prepared slides 
and dried overnight at room temperature. 
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2.2.14.5 Micronuclei (MNi) Scoring 
 
To determine the frequency of MN, 1000 cells were scored for each treatment 
group under 40 x magnifications using a light microscope, according to criteria 
characterized by Fenech (2007) Table 2.4.  The nuclear division index (NDI) 
was calculated using the frequency of MN in 1000 binucleated (BiNC) 
lymphocytes.  
NDI = (M1 + 2(M2) + 3(M3) / N 
Where M1-M3 represent number of cells with 1-3 nuclei and N = the total 
number of viable cells scored (i.e. 1000 cells per treatment group). The NDI 
shows the effect of a compound on the cell cycle of viable cells. Its value 
normally lies between 1.0 and 2.0 but could vary and be even greater than 2.0 if 
the cells were able to complete more than one nuclear divisions and MultiNC 
number increased while MoNC number decreased. 
2.2.14.6 Statistical Analysis 
 
Each experiment was repeated 3 times in 3 individuals and values are 
presented as the mean and standard deviation (SD). The differences between 
various treatment groups were determined by performing normality checks. 
Data were analysed using One-way ANOVA and t-test on Graph Pad Prism 
7.02 
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 Scoring criteria 
 
Criteria for scoring viable mono-, bi- and multinucleated cells 
 Mono-, bi and multinucleated cells are viable cells with an intact cytoplasm and normal 
nucleus morphology containing one, two and three or more nuclei, respectively. 
Criteria for scoring apoptotic cells  
 Apoptotic lymphocytes are cells undergoing programmed cell death. They have the 
following characteristics: Early apoptotic cells can be identified by the presence of 
chromatin condensation within the nucleus and intact cytoplasmic and nuclear 
membranes. 
 Late apoptotic cells exhibit nuclear fragmentation into smaller nuclear bodies within an 
intact cytoplasm/cytoplasmic membrane. 
 Staining intensity of the nucleus, nuclear fragments and cytoplasm in both kinds of 
apoptotic cell is usually greater than that of viable cells. 
Criteria for scoring necrotic cells  
 Early necrotic cells can be identified by their pale cytoplasm, the presence of numerous 
vacuoles (mainly in the cytoplasm and sometimes in the nucleus), damaged 
cytoplasmic membrane and a fairly intact nucleus 
 Late necrotic cells exhibit loss of cytoplasm and damaged/irregular nuclear membrane 
with only a partially intact nuclear structure and often with nuclear material leaking from 
the nuclear boundary. 
 Staining intensity of the nucleus and cytoplasm in both types of necrotic cell is usually 
less than that observed in viable cells.  
Criteria for selecting BN cells suitable for scoring MNi, NPBs and NBUDs  
 The cells should be binucleated. 
  The two nuclei in a  binucleated cell should have intact nuclear membranes and be 
situated within the same cytoplasmic boundary. 
  The two nuclei in a binucleated cell should be approximately equal in size, staining 
pattern and staining intensity. 
  The two nuclei within a BN cell may be attached by a nucleoplasmic bridge, which is no 
wider than 1/4th of the nuclear diameter. 
  The two main nuclei in a BN cell may touch but ideally should not overlap each other.  
Criteria for scoring micronuclei  
 The diameter of MNi in human lymphocytes usually varies between 1/16th and 1/3rd of 
the mean diameter of the main nuclei, which corresponds to 1/256th and 1/9th of the 
area of one of the main nuclei in a BN cell, respectively. 
 MNi are non-refractile and they can therefore be readily distinguished from artifact such 
as staining particles. MNi are not linked or connected to the main nuclei. 
  MNi may touch but not overlap the main nuclei and the micronuclear boundary should 
be distinguishable from the nuclear boundary. 
  MNi usually have the same staining intensity as the main nuclei but occasionally 
staining may be more intense . 
Criteria for scoring nucleoplasmic bridges  
 The width of an NPB may vary considerably but usually does not exceed 1/4th of the 
diameter of the nuclei within the cell. 
  NPBs should also have the same staining characteristics as the main nuclei. 
  On rare occasions, more than one NPB may be observed within one binucleated cell. 
  A binucleated cell with an NPB may contain one or more MNi. 
  BN cells with one or more NPBs and no MNi may also be observed. 
Criteria for scoring nuclear buds 
 NBUDs are similar to MNi in appearance with the exception that they are connected 
with the nucleus via a bridge that can be slightly narrower than the diameter of the bud 
or by a much thinner bridge depending on the stage of the extrusion process. 
  NBUDs usually have the same staining intensity as MNi  
Calculation of nuclear division index (NDI) 
 The NDI provides a measure of the proliferative status of the viable cell fraction. It is 
therefore an indicator of cytostatic effects and, in the case of lymphocytes,  
 It is also a measure of mitogenic response, which is useful as a biomarker of immune 
function.  
 Score 500 viable cells to determine the frequency of cells with 1, 2, 3 or 4 nuclei, and 
calculate the NDI using the formula NDI = (M1 + 2M2 + 3M3 + 4M4)/N,  where M1–M4 
represent the number of cells with 1–4 nuclei and N is the total number of viable cells 
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scored (excluding necrotic and apoptotic cells).  
 The NDI is a useful parameter for comparing the mitogenic response of lymphocytes 
and cytostatic effects of agents examined in the assay.  
 The lowest NDI value possible is 1.0, which occurs if all of the viable cells have failed to 
divide during the cytokinesis-block period and is therefore all mononucleated.  
 If all viable cells completed one nuclear division and are therefore all binucleated, the 
NDI value is 2.0.  
 An NDI value can only be greater than 2.0 if a substantial proportion of viable cells have 
completed more than one nuclear division during the cytokinesis-block phase and 
therefore contain more than two nuclei.  
 
Table 2.4 MN scoring criteria adapted from Fenech 2007 
2.2.15 Western Blotting 
 
2.2.15.1 Cell culture 
 
Isolated lymphocytes (106) were placed in 6 well plates for each treatment 
group, RPMI medium supplemented with 15% foetal bovine serum (FBS) and 
1% penicillin streptomycin was added to the cells producing the total volume of 
5ml. Then 130µl of Phytohaemagglutinin (PHA) was added to the wells and 
incubated at 370C for 24 hrs in the presence of 5% CO2. After the incubation 
time was over, the medium was exchanged with fresh medium and cells were 
treated with chemicals for 24hrs.  
2.2.15.2 Cell lysis for protein extraction 
 
(All steps were done on ice in the tissue culture hood) 
Culture medium was carefully removed from each well and cells were washed 
twice with 1ml ice cold phosphate buffered saline (PBS) while being mixed 
gently. PBS was discarded and 150 µl lysis buffer supplemented with 15µl of 
fresh protease inhibitor cocktail was added to the cells. Then cells were scraped 
and transferred to cold Eppendorf ® tubes, vortexed and centrifuged for a few 
seconds and made ready for measuring the protein concentration. 
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2.2.15.3 Protein quantification assay with Bio-Rad Bradford assay 
 
Five dilutions of bovine serum albumin (BSA) were prepared in PBS as follows 
and used as standards: 
(2mg/ml, 1mg/ml, 0.5mg/ml, 0.25mg/ml, 0.125mg/ml) 
5µl of each sample and standard was pipetted into 96-well plates in triplicates. 
250µl of Bio-Rad dye reagent was added to each well and incubated for 
30mins. The absorbance was measured by a spectrophotometer using 
wavelength of 595nm with a microplate reader. The resulting absorbance value 
was used to quantify the protein concentration. 
2.1.15.4 Sample preparation 
 
Using the formulae: concentration = mass/volume, the volume of protein extract 
was determined to ensure the same weight in each well. 10µl of Laemmli 
sample buffer was added to each sample and the volume in each lane was 
equalized. A very minute amount of bromophenol blue was added to each 
sample (to aid in observing the dye front while the gel is running) and was 
thoroughly mixed. The samples were boiled at 1000C for 5mins prior to loading. 
2.2.15.5 Preparation of gels and solutions: 
 
Separating gel: 5ml of distilled water (dH2O) was taken in a universal tube and 
added in it was 6.67ml of 30% acrylamide/bis-acrylamide solution. Then 4ml of 
Tris (pH8.8) was added to the solution. It was further mixed in 160µl of 10% 
SDS followed by the addition of 16 µl of TEMED. Immediately prior to pouring 
the gel, was added 160 µl of 10% ammonium persulfate (APS) and mixed well. 
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Stacking gel: 5.3ml of ddH2O was taken to begin with and 2ml of 30% 
acrylamide/bis-acrylamide solution was added to it. Then 2.5ml of 0.5M Tris 
(pH6.8) and 100 µl of 10% SDS were mixed in the solution. When ready to use, 
10 µl of TEMED was added and immediately before pouring the gel, 100 µl of 
APS was mixed in. 
APS 10%: Made up fresh each day by adding 100mg of APS powder in 1ml of 
distilled water. 
Running buffer: Tris base (3g), glycine (14.4g) and SDS (1g) were dissolved on 
a magnetic stirrer to prepare 1 litre of running buffer in distilled water (dH2O).  
Blotting or transfer buffer: Tris base (3g) and glycine (14.4g) was mixed in 
800ml of dH2O. Methanol (200ml) was added to the solution to get a final 
volume of 1litre. Blotting buffer has to be made freshly for each use. 
TBS-T (Tris Base Saline – T): To prepare 1 litre of TBST, NaCl (8.78g), Tris 
base (2.42g) and Tween (300µl) was added to dH2O and pH was set to 7.4 
while being mixed on a magnetic stirrer. 
2.2.15.6 Protein polyacrylamide gel electrophoresis (PAGE)  
 
It is a powerful analytical method used to characterize individual or multiple 
proteins in a complex sample. Mini-PROTEAN® Tetra Handcast Systems with 
Power PackTM Basic (Bio Rad, UK) was used to run the electrophoresis. To 
start the procedure, glass plates were cleaned with wet tissue to remove dirt 
residues and assembled with spacers in the rack assuring that there is no 
leakage. The separating gel was poured to about 1cm below the wells of comb 
avoiding any air bubbles and allowed to dry for 30mins. Once the separating gel 
was dried, the stacking gel was carefully poured on top and combs were 
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inserted. The gel was left for 15-30mins to settle. Glass plates with hardened 
gel were positioned into the gel holder assembly and immersed into the tank 
filled with cold running buffer. Combs were removed in the tank so that wells get 
quickly filled with running buffer. Protein samples were vortexed and 10-30µl of 
samples was carefully loaded into each well. Pre-stained protein ladder (5µl) 
was loaded as a control in the first lane to keep the track of protein migration of 
samples. A lid was placed on the tank and electrophoresis was run at 120V for 
90mins.  
2.2.15.7 Protein transfer to PVDF membrane 
 
PVDF membrane was activated by placing it in methanol for 30secs and then in 
water for 30secs without touching the membrane with fingers. The cassette was 
assembled in the following order from the white side: sponge, 2 filter papers (cut 
to the size of the gel), PVDF membrane, resolving gel, 2 filter papers, sponge 
and black cover. Each component was soaked in transfer buffer before 
assembling to keep the membrane moist. Air bubbles were removed by rolling a 
pen across the second layer of sponge. The cassette was closed and placed in 
the tank already prepared with blotting buffer and ice pack. (It was made sure 
that black was to black and red to clear as gel runs from cathode to anode). Gel 
was run using power pack at 120V for 90mins. 
2.2.15.8 Blocking the membrane 
 
To prevent the non-specific binding of antibodies to the membrane and avoid a 
high background problem, the membrane was blocked as follows. The blocking 
buffer was prepared by dissolving 5% non-fat dried milk (NFDM) or 5% bovine 
serum albumin (BSA) in TBS-T and filtered twice. After electrophoresis was 
over the membrane was carefully taken to a square petri dish with 15ml of 
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blocking buffer and left on the rotator overnight in the cold room for blocking or 
blocked for 2hours at room temperature. The membrane was washed for 3 
times with TBS-T (5 mins each).  
2.2.15.9 Primary antibody preparation and incubation 
 
The primary antibody (7.5µl) was added to 15ml of TBS-T with 5% BSA in a 
plate (1:2000). The membrane was inserted in the primary antibody dilution and 
left overnight on the cold room shaker. Then it was washed for 3times at room 
temperature with TBS-T (5mins each).  
2.2.15.10 Secondary antibody preparation and incubation 
 
7.5µl of secondary antibody was added to 15ml of TBS-T with 5% BSA in a 
plate (1:2000). The membrane was inserted and put on a shaker for 1 hour at 
room temperature while being covered with a foil. After the incubation time was 
over, the membrane was washed 3 times for 5mins each with TBS-T. 
2.2.15.11 Visualisation 
 
The membrane was incubated with equal volume of ECL solution 1 and 2 for 
90secs before being taken to the developing cassette and visualized for bands 
using G-Box SYNGENE system and GeneSys software. Images were captured 
and saved to be analysed later. 
2.2.15.12 Re-probing the membrane 
 
The membrane was washed once with dH2O and then 3 times with TBST-T (for 
5mins each), blocked for 1 hour at RT and incubated with primary antibody 
overnight on a shaker in the cold room. The next day the membrane was 
washed again for 15mins and incubated with secondary antibody for 1 hour 
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while shaking at RT in the dark. It was washed after incubated and then 
visualised with the steps described above. 
2.2.15.13 Statistical analysis 
 
All the data were analysed using image j software to determine the protein 
expression levels and normalised against the internal gene, GAPDH. Each 
experiment was repeated 3 times in isolated lymphocytes from 3 individuals 
each from healthy and patient groups and values are presented as the mean 
and standard deviation (SD). The differences between the various treatment 
groups were determined by performing normality checks. Data were analysed 
using One-way ANOVA and the t-test on Graph Pad Prism 7.02. 
2.2.16 Cellular ROS Detection Assay  
 
(All steps to be carried out in the fume hood) Isolated lymphocytes 
supplemented with complete medium (RPMI 1640 no phenol red with 1% 
penicillin-streptomycin and 15% foetal bovine serum) were grown in a 96-well 
plate overnight. The next day the media was removed and cells were washed 
with 1X buffer (provided with the kit) then new media along with treatments was 
added and incubated for 1 hour at 370C in the presence of 5% CO2. Once 
incubation was over the medium was again removed and cells were washed 
with 1X buffer following the addition of DCFDA dye into each well and incubated 
again for 45mins under the same conditions. Then dye was replaced by new 
media and fluorescence was measured at 485/535nm using Promega Glomax 
explorer version 2.4. Data were analysed using the t-test on Graph Pad Prism 
7.02. 
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2.2.17 GSH/GSSG Ratio Detection Assay 
 
(All step to be carried out in the fume hood and on ice) Isolated lymphocytes 
(10,000-100,000/well), supplemented with complete medium (RPMI medium 
along with with 15% foetal bovine serum (FBS) and 1% penicillin streptomycin) 
were harvested overnight in 6-well plate. The following day the cells were 
treated with chemicals for 1 hour. Then the media was carefully removed and 
cells were washed with cold PBS and re-suspended in 100µl of cold lysis buffer 
supplemented with 10µl of protease inhibitors. Cells were thoroughly mixed by 
pipetting and centrifuged at 400g for 5mins to remove insoluble. The 
supernatant (sample) was collected and kept on ice for further use. 50µl of each 
GSH and GSSG standards (kit components) were added to 96-well plates in 
duplicates. 50µl of sample was also added in duplicate corresponding to each 
standard. For GSH detection, 50µl of the GSH assay mixture (GAM) (provided 
with the kit) was added to each GSH standard and sample. For GSSG 
detection, total GSH assay mixture (TGAM) was added to each GSSG standard 
and sample. Incubated for 60mins at RT in the dark and then fluorescence was 
measured at 490/520nm using Promega Glumax explorer version 2.4. Data 
were analysed using t-test on Graph Pad Prism 7.02. 
2.2.18 Real Time Polymerase chain reactions (q PCR) 
 
2.2.18.1 Cell culturing 
 
Isolated lymphocyte suspension (2 x 106 cells/ml) was incubated in 6-well plates 
with chemicals for 24 hrs at 370C in the presence of 5% CO2.  
2.3.18.2 RNA extraction (using kit) 
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According to the manufacturer’s instruction, cells were rinsed with PBS and 
transferred to 2ml centrifuge tubes then centrifuged at 400g for 3 mins. The 
supernatant was discarded and 350µl of lysis buffer was added to the palette 
while mixing thoroughly to lyse the cells. Then 350µl of ethanol (70%) was 
added in the tubes and the whole suspension was pipetted in the RNA binding 
column (inserted into a 2ml capless wash tube) and centrifuged for 3 mins. The 
supernatant was discarded and 700µl of low stringency wash solution was 
added to the binding column, centrifuged again and exultant was discarded. 
80µl of diluted DNase I was pipetted to the membrane stack on the bottom of 
each column and incubated at RT for 15mins to allow digestion. Washing steps 
were carried out again; first with high stringency solution followed by a lower 
one. After centrifugation for 3mins, the binding column was transferred to a new 
tube and 40µl of the elution buffer was added onto it and further centrifuged for 
2mins to elute the total RNA. 
2.2.18.3 RNA concentration and quality 
 
The RNA concentration and A260/A280 ratio (absorbance at these values) was 
determined using IMPLEN, Nano photometer P330. The reading for blank (RNA 
diluent) and samples was calculated. The RNA A260/A280 ratio within 1.8-2.1 
range was used for the c DNA synthesis. 
2.2.18.4 c DNA Synthesis 
 
The reagents provided with the c DNA synthesis kit (Bio Rad) were added to the 
RNA template in variable amounts making a final volume up to 20µl. The 
complete reaction mix was incubated in the thermal cycler using the following 
protocol: priming for 5min at 250C, reverse transcription for 20 min at 460C, RT 
inactivation for 1min at 950C and holding at 40C. 
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2.2.18.5 Setting up the reaction 
 
In a PCR reaction plate, template c DNA, forward primer, reverse primer, 
SYBR® Green master mix and nuclease free water were added in each 
reaction well, forming the final volume of 10µl. The plate was sealed and placed 
in micro centrifuge for the contents to evenly mix. The reactions were run in the 
real time PCR machine (CFX96 TM Real-Time System, Bio-Rad, UK). 
2.2.18.6 Statistical analysis 
 
All the data were analysed using CFX software to determine the gene 
expression levels and normalised against the internal gene, GAPDH according 
to Livak and Schmittgen, 2001 using delta CT methods. Each experiment was 
repeated 3 times in 3 individuals and values are presented as mean and 
standard deviation (SD). The differences between various treatment groups 
were determined by performing normality checks. Data were analysed using 
One-way ANOVA and t-test on Graph Pad Prism 7.02. 
2.2.19 Immunocytochemistry (ICC)/Immunofluorescence (IF) 
 
2.2.19.1 Cell Culture 
 
Isolated lymphocytes were counted and re-suspended in complete media 
(RPMI 1640 with 25mM HEPES and L-Glutamine, 1% penicillin-streptomycin 
and 15% foetal bovine serum) and treated with chemicals for 24 hrs. The next 
day the cells were pelleted and washed with cold PBS twice followed by re-
suspension in 100µl PBS and dropped on clean glass slides.  
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2.2.19.2 Fixation 
 
Dried slides were fixed in 4% formaldehyde for 15 mins at RT. Then cells were 
washed with cold PBS 3 times for 5 mins each.  
2.2.19.3 Permeabilisation 
 
The lymphocytes were incubated in permeabilisation buffer, PBST (0.1% Triton 
X-100 in PBS) for 10mins at RT followed by washing steps with PBS. 
2.2.19.4 Blocking 
 
Unspecific sites were blocked in blocking buffer containing 5% BSA in TBS 
(0.1% Tween 20 in PBS) for one hour at RT followed by the washing steps. 
2.2.19.5 Immunodetection 
 
Cells were incubated with primary antibody overnight at 40C and then washed 
with PBS 3 times for 5 mins each. Secondary antibody incubation was carried 
out in the dark at RT for one hour followed by the washing steps. 
2.2.19.6 Immunostaining 
 
Slides were stained with Dapi (5mg/ml) for 1 min and rinsed with PBS. Gold 
antifade reagent was used as a slide mountant and coverslips were placed on 
top and allowed to dry in the dark. 
2.2.19.7 Statistical Analysis 
 
Duplicate slides were produced for each treatment group. 100 cells per slide 
were counted at 100X magnification (with oil immersion) using a fluorescence 
microscope with fitted CCD camera (Nikon Digital Sight DS-SMC, Surrey, UK)  
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2.2.20 Analysis of confounding factors 
 
Confounding factors such as age, gender, ethnicity, lifestyle (diet, smoking and 
drinking habits) and environmental factors are very important and need to be 
considered when assessing the DNA damage in humans because these may 
contribute towards the damage and therefore could induce genotoxicity 
(Fenech, 2007). Lifestyle variables such as smoking and alcohol consumption 
may render individuals susceptible to cancer and other diseases because they 
are known carcinogens. Age could also contribute towards the DNA damage 
due to compromised immune system and DNA repair mechanism. Therefore, 
we determined the effects of these variables on comet values in both the 
healthy individuals and pre-cancerous patients.  In the present study, we found 
no relationship among the confounding factors regardless of the treatment 
groups and these do not seem to be contributing much towards DNA damage 
as shown in results from healthy individuals which have little basal damage. All 
patients were suffering from various diseases which were the main cause of a 
high level of damage in the patient groups.  
Myricetin in both forms has not shown any significant genotoxicity. Moreover, 
MYR N has shown protective effects in patient groups but the values are not 
significant. 
2.2.20.1 Age 
 
Age varies greatly between both the groups the healthy individuals and pre-
cancerous patients. Most of the healthy individuals were under 50 years of age 
whereas all the patients were above 55 years old. There could be some 
contribution due to age in the patient group. However, these were the patients 
available at the time of study and it was not possible to match them better to the 
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controls. The effect of age was determined in healthy individuals, pre-cancerous 
patients and MM patients (Figure 2.1). Our data from the Comet assay show no 
significant difference on DNA damage in any of the age group. 
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Figure 2.1 Shows the means of % tail DNA and Olive tail moment OTM in the peripheral 
blood lymphocytes of different age groups in (A) healthy individuals, (B) pre-cancerous 
and (C) MM patients in the Comet assay after different treatments with the PC (H2O2)(50µМ), 
MYR B (10µМ) and MYR N (20µМ) as well as the negative control of untreated lymphocytes 
(NC). Bars indicate standard errors (SEs). Not significant: ns. Statistics show the comparison 
between the OTM of one investigative group with OTM of other and between % tail DNA of one 
group with % tail DNA of other.  
 
2.2.20.2 Gender 
 
There were no significant differences observed between the groups in 
lymphocytes of healthy (figure 2.2a) neither patient (figure 2.2b) males nor 
females when treated with various treatments.  
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Figure 2.2a Histogram showing the means of Olive tail moment and % tail DNA in the 
peripheral blood lymphocytes of males and females healthy individuals in the Comet 
assay after different treatments with the PC (H2O2)(50µМ), MYR B (10µМ) and MYR N (20µМ) 
as well as the negative control of untreated lymphocytes (NC). Bars indicate standard errors 
(SEs). Not significant: ns, Statistics show the comparison between the OTM of one investigative 
group with OTM of other and between % tail DNA of one group with % tail DNA of other.  
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Figure 2.2b Histogram showing the means of Olive tail moment and % tail DNA in the 
peripheral blood lymphocytes of males and females pre-cancerous patients in the Comet 
assay after different treatments with the PC (H2O2)(50µМ), MYR B (10µМ) and MYR N (20µМ) 
as well as the negative control of untreated lymphocytes (NC) for 30 minutes. Bars indicate 
standard errors. ns:  Not significant, Statistics show the comparison between the OTM of one 
investigative group with OTM of other and between % tail DNA of one group with % tail DNA of 
other.  
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2.2.20.3 Smoking habits 
 
The healthy (figure 2.3a) and patient (figure 2.3b) smoker groups have shown 
more DNA damage at basal levels when compared to respective non-smoker 
groups but the value are not statistically significant. The PC control has induced 
significant levels of DNA damage; however MYR B and MYR N have not shown 
any differences regardless of group types. 
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Figure 2.3a Shows the means of % tail DNA (A) and Olive tail moment OTM (B) in the 
peripheral blood lymphocytes of smokers and non-smokers healthy individuals in the 
Comet assay after different treatments with the PC (H2O2)(50µМ), MYR B (10µМ) and MYR N 
(20µМ) as well as the negative control of untreated lymphocytes (NC). Bars indicate standard 
errors (SEs) and the horizontal lines indicate the differences between the groups. Not 
significant: ns, *** p < 0.001. Statistics under the horizontal lines show comparison with NC. 
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Figure 2.3b Shows the means of % tail DNA and Olive tail moment OTM in the peripheral 
blood lymphocytes of smokers and non-smokers pre-cancerous patients in the Comet 
assay after different treatments with the PC (H2O2)(50µМ), MYR B (10µМ) and MYR N (20µМ) 
as well as the negative control of untreated lymphocytes (NC). Bars indicate standard errors 
(SEs). Not significant: ns. Statistics show the comparison between the OTM of one investigative 
group with OTM of other and between % tail DNA of one group with % tail DNA of other.  
 
 
 
2.2.20.4 Ethnicity 
 
The figure below demonstrates no statistically significant differences between 
the healthy (Figure 2.4a) and patient (figure 2.4b) different ethnic groups.  
Asian patients showed more basal DNA damage than Caucasians but the 
values were not significant.  
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Figure 2.4a Histogram showing the means of Olive tail moment and % tail DNA in the 
peripheral blood lymphocytes of Asian and Caucasian healthy individuals in the Comet 
assay after different treatments with the PC (H2O2)(50µМ), MYR B (10µМ) and MYR N (20µМ) 
as well as the negative control of untreated lymphocytes (NC) for 30 minutes. Bars indicate 
standard errors. Not significant: ns. Statistics show the comparison between the OTM of one 
investigative group with OTM of other and between % tail DNA of one group with % tail DNA of 
other.  
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Figure 2.4b Histogram showing the means of Olive tail moment and % tail DNA in the 
peripheral blood lymphocytes of Asian and Caucasian pre-cancerous patients in the 
Comet assay after different treatments with the PC (H2O2)(50µМ), MYR B (10µМ) and MYR N 
(20µМ) as well as the negative control of untreated lymphocytes (NC) for 30 minutes. Bars 
indicate standard errors. ns:  Not significant, Statistics show the comparison between the OTM 
of one investigative group with OTM of other and between % tail DNA of one group with % tail 
DNA of other.  
 
 
  
84 
 
 
                              
 
 
 
 
Chapter 3: Protective effects of myricetin bulk and nanoparticle forms on 
peripheral lymphocytes from pre-cancerous patients compared to those 
from healthy individuals 
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3.1 Introduction  
 
Myricetin belongs to the family flavonoids; flavonols, with various antioxidant 
properties. The three OH-groups in ring B (3′,4′,5′-position) make it a stronger 
antioxidant by scavenging ROS through oxidation of these hydroxyl groups. 
Myricetin is usually contributed by vegetables, berries, tea, fruits, nuts and red 
wine to our diet (Ross and Kasum, 2002). It is mainly found in plant derived 
foods especially tea, cranberries and grapes (Büchter et al., 2013).  Its average 
intake varies, subject to the diet consumed and lifestyle factors. Myricetin is 
made from parental compound taxifolin through an intermediate, 
dihydromyricetin and can also be directly produced from kaempferal (Flamini et 
al., 2013). Structurally it is very similar to quercetin bearing dihydroxyl groups at 
position 3’ and 4’. It has an extra hydroxyl group at position 5’ which makes it an 
even better antioxidant. H atom from 4’ is easily abstracted by radical species 
forming a flavonoid radical and remaining O- radical is efficiently stabilised due 
to neighbouring hydroxyl groups on both sides. Myricetin exhibits many health 
beneficiary effects including, antioxidant, anti-photo aging, anti-cancer, anti-
hypertension, immunomodulatory, anti-inflammatory, anti-allergic, analgesic, 
antimicrobial, anti-diabetic and protective against cardiovascular diseases 
(Semwal, 2016). 
Maintaining homeostasis between the damage and repair mechanisms is 
crucial for our genome integrity. For this a eukaryotic cell bears a highly 
specialised system called ‘cell cycle checkpoints’ that keeps check on every 
step of the cell cycle and guarantees a healthy and smooth progression (Ciccia 
and Elledge, 2010; Hartwell and Weinert, 1989). The tumour suppressor 
protein, P53, is the key regulator of the cell cycle and is considered as the main 
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mediator of checkpoint triggered arrest in G1 phase and its function is critical for 
defence against cancer development. Various cellular stress signals including 
hypoxia, DNA damage, nucleotide deprivation, different infections and oxidative 
stress etc. lead to the initiation of P53 as a transcription factor (Cox and Lane, 
1995). Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related kinase 
(ATR) are phosphatidylinositol-3-like kinases crucial for detecting the DNA 
damage and initiating the cell cycle checkpoints, repair and apoptosis (Sarkaria 
et al., 1999). ATM kinase is considered as an important mediator of H2AX 
phosphorylation in reaction to double strand breaks (DSB) formation (Bakkenist 
and Kastan, 2003). The main pathway which regulates the ATM expression is 
through DSBs but can possibly be triggered in all cell cycle stages (Savitsky et 
al., 1995). Following DNA damage, ATM is required to efficiently stimulate the 
cell cycle checkpoints and homologous recombination including checkpoints 
protein P53 and checkpoint kinase 2 (Chk2) (Kastan and Lim, 2000). ATM has 
previously been shown triggering, P53-induced cell cycle arrest following DNA 
damage (Kang et al., 2005). ATM and ATR both directly stabilize p53 on Ser15 
and Ser37 respectively, by phosphorylation in vivo (Siliciano et al., 1997).  
Germline ATM mutations can result in increased sensitivity to ionising radiation, 
a predisposition to cancer and immunodeficiency (Barzilai and Yamamoto, 
2004). Upon activation, ATM goes through dimer separation and auto- 
phosphorylation at Ser 1981 (Bakkenist and Kastan, 2003). 
Although, past studies have successfully demonstrated characteristics of 
myricetin against different diseases (Semwal, 2016), this is t h e  first study to 
our knowledge that the effects of the particle size of myricetin have been 
investigated at the cellular level ex vivo/in vitro. In the present study, DNA 
damage in peripheral lymphocytes of pre- cancerous patients and healthy 
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individuals have been compared after treatment with myricetin nanoparticle 
(MYR N) and bulk (MYR B) forms in the Comet and micronucleus assays. 
Effects of MYR B and MYR N on protein expression of the tumour suppressor 
gene, P53 were investigated using Western blotting. Their effects on gene 
expression of ATM and P53 were analysed at m RNA level using the real-time 
PCR technique. 
3.2 Materials and methods  
 
The blood samples from healthy individuals and pre-cancerous patients used in 
this experimental chapter are listed below in table 3.1 and 3.2, respectively. 
No Age Ethnicity  Gender  Smoking 
history 
Family history 
1 48 CAUCASIAN M NO NONE 
2 28 CAUCASIAN M NO NONE 
3 27 AFRICAN M YES NONE 
4 38 CAUCASIAN M NO NONE 
5 60 CAUCASIAN F NO NONE 
6 40 ARAB M NO NONE 
7 45 CAUCASIAN M YES  NONE 
8 55 CAUCASIAN M NO NONE 
9 35 CAUCASIAN M YES NONE 
10 25 CAUCASIAN M NO NONE 
11 44 ASIAN M YES NONE 
12 28 CAUCASIAN M NO NONE 
13 23 CAUCASIAN F NO NONE 
14 27 CAUCASIAN M NO KIDNEY 
CANCER 
15 33 ARAB M YES NONE 
16 47 ASIAN M YES NONE 
17 28 CAUCASIAN M NO NONE 
18 42 ASIAN M NO NONE 
19 48 ASIAN M NO NONE 
20 60 ASIAN M YES NONE 
 
Table 3.1 Healthy blood samples used in this chapter 
 
 
 
88 
 
No Age Ethnicity  Gender  Smoking 
history 
Family history Medical condition 
1 79 CAUCASIAN M NO NONE MGUS, COPD, 
MONOCLONAL B CELL 
LYMPHOCYTOSIS 
2 80 CAUCASIAN F NO NONE- MGUS 
3 78 CAUCASIAN M NO NONE- MGUS 
4 56 CAUCASIAN F YES LEUKAEMIA & 
BRAIN TUMOUR 
MGUS 
5 77 CAUCASIAN M NO NONE MGUS 
6 75 CAUCASIAN M NO NONE MGUS 
7 80 CAUCASIAN M NO CANCER POSITIVE MGUS 
8 81 CAUCASIAN F NO BOWEL& 
STOMACH 
MGUS 
9 63 CAUCASIAN M YES NONE MGUS 
10 55 CAUCASIAN M NO NONE MGUS 
11 83 CAUCASIAN M NO NONE MGUS, BENIGN PROSTATIC 
HYPERPLASIA 
12 63 CAUCASIAN M YES NONE MGUS 
13 74 CAUCASIAN M NO NONE MGUS COPD 
14 63 CAUCASIAN F YES ARTHRITIS MGUS, COPD 
15 66 CAUCASIAN F NO BREAST CANCER MGUS 
16 52 CAUCASIAN M YES NONE MGUS 
17 83 CAUCASIAN M NO NONE MGUS 
18 60 ASIAN F NO NONE MGUS 
19 75 CAUCASIAN F NO MASTECTOMY MGUS 
20 69 CAUCASIAN M NO STOMACH AND 
LUNG  
MGUS 
 
Table 3.2 Brief information about pre-cancerous patients samples used in this chapter 
3.2.1 Preparation of myricetin bulk and nanoparticle forms, their 
concentration determination and zeta potential of nanoparticles 
 
Myricetin was purchased from Fisher Scientific, UK, as a powder (˃96% purity). 
Suspensions of myricetin bulk and nano form were made in an excipient mixture 
(containing 7% (w/w) solid loads of myricetin in a different medium comprising 
of hydroxypropyl methylcellulose (HPMC) (0.5 % w/w), sodium lauryl sulphate 
(SLS) (0.1% w/w), ethanol (0.8% w/w), polyvinylpyrrolidone (PVP) K-30 (0.5% 
w/w) and purified water). Dose–response experiments were used to determine 
the optimal doses which were used throughout the study. These were 10µM for 
myricetin bulk and 20µM for myricetin nano form.  H2O2 (50µM) was used 
throughout the study as the positive control. The mean particle sizes of 
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myricetin nano in the stock solutions were measured using a Zetasizer Nano 
ZS-90 Model ZEN3600 (Malvern Instruments Ltd, UK) by Photon Correlation 
Spectroscopy. 
3.2.2 Transmission electron microscopy (TEM) Analysis 
 
To visualise the individual particles and their shapes, transmission electron 
microscopy TEM Tecnai 12, (FEI Company, Netherlands) was used. Please 
refer to 2.2.6 from chapter 2 for the full procedure. 
3.2.3 Isolation of lymphocytes and Cell viability measurement 
 
Isolated lymphocytes were treated with chemicals for 1, 24 and 48 hrs and 
subjected to trypan blue dye exclusion to measure all membrane viability and 
integrity. Please refer to (chapter 2) 2.2.9 and 2.2.11 for comprehensive 
procedures followed.  
3.2.4 Cell survival rate and cytotoxicity determination 
 
The cytotoxicity of chemicals was determined by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) dye absorbance. Please refer to 2.2.12 
(chapter 2) for details. 
3.2.5 DNA damage determination using the Comet assay 
 
The patient blood samples were kindly provided by the department of 
haematology, Bradford Royal Infirmary (BRI), Bradford, UK.  The healthy blood 
samples were collected from healthy volunteers. The blood was diluted (1:1) 
with RPMI medium (Invitrogen, UK) and supplemented with 10% DMSO and 
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instantly stored at -800C. Please refer to 2.2.13 (chapter 2) for the assay 
procedure.  
3.2.6 Micronucleus (MN) assay 
  
Lymphocytes from patients and healthy individuals were treated with 10 and 
20µM of MYR B and MYR N respectively to determine the frequency of MNi, 
which was used as a marker of DNA damage. The drug concentrations used for 
the assay were optimum doses, chosen from dose response experiments which 
induced no cytotoxicity. Please refer to 2.2.14 (chapter 2) for the assay 
procedure. 
3.2.7 Western blot analysis 
 
Lymphocytes were seeded in 6-well plates at concentration of 106cells/well, 
incubated overnight and treated with chemicals (MYR B 10µМ and MYR N 
20µМ) for 24hrs. Refer to 2.2.15 (chapter 2) for detailed technique. 
3.2.8 Real-time RT-PCR analysis 
 
Isolated lymphocytes were seeded in 6-well plates and treated with chemicals 
for 24 hrs. Please refer to 2.2.18 (chapter 2) for details.The primers used are 
listed in table 3.3 below.  
Genes Primer Sequence 5’-3’ 
ATM   ACCATTGTAGAGGTCCTTC 
  GTCTCATTAAGACACGTTCAG 
P53 CTCCTCAGCATCTTATCCGAGT 
GCTGTTCCGTCCCAGTAGATTA 
 
GAPDH TGCACCACCAACTGCTTAG 
AGTAGAGGCAGGGATGATGTTC 
 
 
 
Table 3.3 Primers used for Real-Time PCR analysis 
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3.2.9 Statistical analysis 
 
Results were expressed as mean ± standard error of mean (SEM). Graph Pad 
prism was used to perform statistical calculation. The results were analysed 
using t-tests, one-way analysis of variance (ANOVA) and two-way ANOVA to 
test differences between each treatment and control. A p-value of <0.05 was 
considered statistically significant. 
3.3 Results 
 
3.3.1 Particle size determination of Myricetin bulk and nanoparticles 
 
Although, the particle size determined for myricetin NPs was ˃100nm, we still 
refer to them as NPs of myricetin. Nano particles of myricetin suspended in 
excipient mixture were compared to the solution prepared from its bulk powder 
in the same excipient mixture. Results show the average particle of myricetin 
bulk and nanoparticles as 1737 and 161nm, respectively (table 3.4 and 3.5). 
Nanoparticles of myricetin were much smaller compared to the bulk particles. 
Although both preparations were at a concentration below the solubility of 
myricetin in the final cell culture media, it has been shown none the less that 
nanoparticles do provide higher bioactivity and enhanced dissolution rate than 
the bulk form. This is because upon addition to the cell culture media, 
nanoparticles are capable of providing higher concentration of the drug in the 
immediate vicinity (or inside) the cells. Nanoparticles have been shown to 
penetrate cell membranes via phagocytosis and endocytosis and thus provide a 
higher effective dose within the cells (Gradinaru et al., 2010). It is reported that 
particles in the size range of 250 nm to 3μm are mainly internalised by 
phagocytosis whereas those below 200nm are mainly up taken by endocytosis 
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(Amit et al., 2014). Nano medicine has been shown to exhibit different biological 
activity compared to solutions of the same drug. 
 
Table 3.4 The peak obtained for myricetin NPs during the procedure 
Suspension name Zeta average particle 
size (nm) 
Polydispersity 
Index 
Intercept Quality 
Myricetin nano 161.0 0.501 0.961 Good 
Myricetin bulk 1737 - - Good 
 
Table 3.5 Average particle size of Myricetin bulk and NPs 
3.3.2 TEM analysis of Myricetin bulk and nanoparticles 
 
TEM analysis was used to visualise myricetin bulk and NPs at different 
magnifications ranging from 10-150k. The scale bar at the bottom left of each 
image below gives the approximate length of respective particle shown in that 
image. To reduce and avoid the possibility of dust particles’ clinging to the 
surface of charged TEM grids, sample preparation was carried out in a clean 
fume hood cabinet using covered petri dishes and other equipment. Hence, 
chances of dust particles overlapping with myricetin particles were made 
limited, enhancing the effectiveness of TEM visualization of myricetin bulk and 
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NPs. Results have revealed an irregular shaped aggregate of one or 2 NPs of 
myricetin shown in figure 3.1 A and B. However, myricetin bulk particles are 
more irregular in shape (single particle shown in figure 3.1 C) and found to form 
colonies by sticking with each other shown in figure 3.1 D. 
 
A. Myricetin NP (150 k magnification)  
 
B. Myricetin NPs cluster (150 k magnification)  
94 
 
 
   C. Myricetin bulk particle (20 k magnification) 
 
D. Myricetin bulk cluster (10 k magnification) 
Figure 3.1 (A-D) The transmission electron microscopy (TEM) of MYR B and MYR N particles 
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3.3.3 Concentration dependent responses of myricetin bulk (MYR B) and 
myricetin nano (MYR N) to determine genotoxicity 
 
Genotoxicity was assessed using a range of concentrations (10µМ to 80µМ) of 
MYR B and MYR N. Results shown below using two parameters of the Comet 
assay, % tail DNA and OTM have demonstrated that myricetin in both forms 
has caused significant dose dependent genotoxicity in lymphocytes at higher 
concentrations except for MYR B 10µМ and MYR N at 20µМ, which did not 
induced any significant levels of genotoxicity determined by both parameters. 
Although % tail DNA data shows that MYR N (10µМ) and MYR B (20µМ) also 
caused non-significant levels of genotoxicity but in current study, we only used 
the optimal concentrations for MYR B and MYR N, 10µМ and 20µМ respectively 
which have induced no significant genotoxicity confirmed by both parameters of 
the Comet assay. Flavonoid compounds have this ability to cause adverse 
effects at slightly different concentrations as evaluated in figure 3.2 where MYR 
N 20µM has been shown safer than MYR N 10µM, therefore; we used the safer 
concentrations with no significant genotoxicity. As we are conducting an in vitro 
study so these chosen concentrations are safe and acceptable to use on 
lymphocytes knowing that the in vivo physiological concentration range of 
myricetin is from 5-10µМ (Peng and Kuo, 2003). Compilation of various studies 
presented by Semwal (2016) has shown wide concentration ranges used for 
myricetin which are well above its physiological range and produced protective 
effects against different cancers and cardiovascular diseases. 
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Figure 3.2 Concentration dependent responses of MYR B and MYR N in healthy 
lymphocytes showing mean % tail DNA (A) and OTM (B). All data have been expressed as 
mean ± standard errors (SE) in 20 healthy individuals, measuring 100 cells each. In vitro 
treatment of healthy lymphocytes with different concentrations of MYR B and MYR N in the 
Comet assay has shown that MYR B (10µM) and MYR N (20µM) produced non-significant 
levels of the DNA damage which was comparative with the negative control (NC). Therefore 
these optimum concentrations have been used throughout the study. Other treatment groups 
included, excipient mixture (EM) (0.1%) and PC (H2O2 50µМ).  The stars indicate significant 
difference between NC and various treatment groups (P<0.05 significantly different), ns 
indicates not significant, ***P<0.001, **P=0.006, *P<0.01 
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3.3.4 Cytotoxicity of Myricetin bulk and nanoparticles in lymphocytes 
from healthy vs patient groups 
This assay can be used to determine the cytotoxicity of different chemical 
agents. The MTT dye, a yellow tetrazol is reduced to purple formazan by the 
NAD(P)H-dependent cellular oxidoreductase enzymes under certain conditions, 
in the living cells. Then DMSO is added to dissolve the formazan crystal in the 
solution and absorbance of this coloured solution can be measured at a certain 
wavelength, usually 560nm, using a spectrophotometer. The results have 
revealed a significant (P<0.01, P<0.003) time and concentration-dependent 
cytotoxicity which was measured at 570nm by optical density after exposure to 
different treatment groups i.e. MYR B (10-40µМ), MYR N (10-40µМ), PC 
(50µМ) and EM (0.1%) for various time periods. Optical density represents the 
mean ± SE of triplicate MTT assays on isolated lymphocytes cells from patients 
and healthy individuals treated with the above mentioned chemicals as well as 
the untreated group. Fig 3.3 shows the effects of various treatment groups on 
the viability of healthy and pre-cancerous patients’ lymphocytes at different 
times (1, 24 and 48hrs) compared to the respective untreated group where 
H2O2 significantly reduced the viability after 48hrs. MYR B and MYR N also 
exhibited a time and concentration dependent decrease in cell viability. MYR B 
(40µМ) and MYR N (40µМ) reduced the viability in lymphocytes to 88% and 
86% from healthy individuals and to 86% and 83% from pre-cancerous patients 
respectively, after a 48 hours treatment. Neither of the concentrations of MYR B 
and MYR N reduced viability less than 80% in either group. 
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Figure 3.3 Shows the % cell viability of lymphocytes from healthy volunteers (age, 50-60) 
(A) and from pre-cancerous patients (age, 50-60) (B), after treating the different treatment 
groups: NC (untreated cells), excipient mixture (EM)(0.1%), MYR B (10-40µМ), MYR N (10-
40µМ), PC (H2O2 50µМ) for 1, 24 and 48 hours   measured using the MTT assay. The 
percentage cell survival was evaluated for various concentrations of the test chemicals, while 
compared to the untreated group (NC). The values represent the mean of 3 separate 
experiments. (ns=not significant, *P<0.01, **P<0.003) 
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3.3.5 Viability of lymphocytes 
 
The viability is calculated as the number of live/viable cells over the total 
number of cells present within the haemocytometer’s grids. Non-viable cells 
take up the trypan blue whereas viable cells disregard trypan blue dye due to 
the cells intact membrane (Henderson et al., 1998). Various concentrations of 
all chemicals used in this study were tested for their cytotoxicity before and after 
drug treatment. Cells which expressed viability ≥75% were used for the study. 
The concentrations of flavonoid used (determined by dose response curve) 
were non-toxic to the lymphocytes and the vehicle substance, excipient mixture 
(EM) used throughout the study had no effect on the DNA damage. Neither of 
the chemicals had a significant effect on lymphocyte cell viability at different 
time periods when compared to the untreated group (NC) (figure 3.4).  
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Figure 3.4 Shows mean % viability of lymphocytes from healthy individuals (age, 50-60) 
(A) and pre-cancerous patients (age 50-60) (B) from 3 independent experiments counting 
(100 cells each/treatment) using trypan blue dye. Treatment groups used were untreated 
(NC), excipient mixture (EM)(0.1%), positive control (PC) H2O2 50µМ, MB (10 µМ) and MN (20 
µМ). There was no significant difference on viability of cells on different time periods when 
compared to respective NC group. Ns=not significant 
 
3.3.6 Assessment of DNA damage by using the Comet Assay  
 
3.3.6.1 Direct comparison between the effects of myricetin nanoparticles 
and bulk forms on DNA damage of lymphocytes from healthy volunteers 
 
After treating lymphocytes from healthy individuals with MYR B (10µМ) and 
MYR N (20µМ) using the Comet assay, there was no significant effect observed 
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in DNA damage when compared against the untreated control. However, the 
PC induced significantly levels of genotoxicity (Figure 3.5a, b). 
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Figure 3.5 (a) The response of bulk and nano forms of myricetin on lymphocytes’ DNA 
from healthy individuals using %Tail DNA. The figure shows the mean of experiments in 20 
individuals, counting 100 cells each for four different groups of treatments; an untreated 
lymphocyte group (NC), excipient mixture (EX), positive control (PC) 50µM H2O2, myricetin bulk 
(MYR B 10µM) and myricetin nano (MYR N 20µM). All treatment groups were compared to the 
NC group. The mean control value was 8 and the PC had the maximum mean value of 34 for % 
Tail DNA.( ****P<0.001,ns means not significant).  (b) The response of bulk and nano forms of 
myricetin on lymphocytes DNA from healthy individuals using Olive tail moment (OTM). 
The mean OTM of four treatment groups from experiments in 20 individuals is plotted in the 
graph with 100 cells counted for each. Treatment groups include the negative control, excipient 
mixture (EX), the positive control (50µM H2O2), myricetin bulk (MYR B 10µM) and myricetin 
nano (MYR N 20µM). While comparing to the negative control both MYR N and MYR B did not 
show any significance difference. The mean control value of OTM was 0.8 and that for PC was 
9. ( ***P< 0.001, ns represents not significant). (c) Control lymphocyte. (d) MYR N (20µМ) 
treated lymphocyte. (e) MYR B (10µМ) treated lymphocyte. (f) H2O2 (50µМ) treated lymphocyte 
cell showing DNA damage in Comet tail at mag X20. 
 
3.3.6.2 Comparison between myricetin nano and bulk form responses on 
DNA of lymphocytes from pre-cancerous patients 
 
In vitro treatment of lymphocytes taken from pre-cancerous patients with MYR B 
(10µМ) and MYR N (20µМ) showed no significant difference from the control 
group. (Figure 3.6a, 3.6b) 
C. d. 
e. f. 
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Figure 3.6 a The response of MYR B and MYR N, on lymphocytes from pre-cancerous 
patients using % Tail DNA. This graph shows the mean and standard errors of experiments on 
20 individuals (measuring 100 cells each) in which four  treatment groups were tested for DNA 
damage in patient lymphocytes as follows: an untreated lymphocyte group (NC), excipient 
mixture (EX), positive control (PC) 50µM H2O2, myricetin bulk (MYR B 10µM) and myricetin 
nano (MYR N 20µM).   All other groups were compared to the negative control. The mean 
negative control and positive control values for % Tail DNA were 14 and 26, respectively. (***P< 
0.001, ns represents not significant).b Response of MYR B and MYR N, on pre-cancerous 
patient lymphocyte using Olive tail moment. The data is expressed as mean and standard 
errors of experiments on 20 individuals, where dose dependent effects of the excipient mixture 
(EX), the positive control (50µM H2O2), MYR B (10µM) and MYR N (20µM) were compared 
against the negative control group on lymphocytes from the patient group. (***P< 0.001, ns 
means not significant). (c) Untreated lymphocyte from pre-cancerous patient. (d) MYR N 
(20µМ) treated lymphocyte from pre-cancerous patient. (e) MYR B (10µМ) treated lymphocyte 
from pre-cancerous patient at mag X20 
 
3.3.7 Determination of micronuclei (MNi) and other DNA damage 
 
3.3.7.1 Introduction 
 
Treatment of lymphocytes from healthy volunteers with MYR B and MYR N has 
induced MNi in binucleated cells (BiNC) when compared to the controls but the 
induction was not significant. In patient lymphocytes, MNi frequency in BiNC 
treated with MYR B was the same as the negative control. After treatment of 
C. D. 
E. 
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healthy lymphocyte with MYR B, the MNi number in mononucleated cells 
(MoNC) increased but there was no difference seen with MYR N, when 
compared to the negative control group. MNi frequency in MoNC seemed to 
reduce in patient lymphocytes with both forms. 
3.3.7.2 MNi frequency in BiNC 
 
The number of MNi in BiNC from pre-cancerous patients (aged between 55 and 
65) was higher than those from healthy individuals (aged between 45 and 60). 
MYR B and MYR N have induced MNi formation in healthy lymphocytes at a 
non-significant level. However, in patient lymphocytes, both forms of myricetin 
have shown a trend towards lowering the induction of MNi in BiNC when 
compared to respective untreated group. Again the levels were not significantly 
different (Figure 3.7a).  
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Figure 3.7a Shows the average of BiNC MNi scored per 1000 cells per culture from 5 
independent experiments, n=1000. Data are expressed as means ± standard deviations (SD). 
* Shows significant difference between the groups, ns = not significant. Four treatment groups 
included the negative control, a positive control group (Mitomycin C {0.4µM MMC}), MYR B 
(10µM) and MYR N (20µM) group.( *** represents P< 0.0001, ** represents P< 0.01). Horizontal 
lines with the statistics above them show the differences between the groups. The statistics 
below horizontal lines show the comparison of treatment groups with respective untreated 
group. 
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3.3.7.3 MNi frequency in MoNC 
 
Again the frequency of MNi in MoNC from patient’s lymphocytes was higher 
than healthy group at basal levels. Mitomycin significantly induced MNi 
formation in both groups. MYR B has not shown significant effect on MNi 
induction on either of the groups. However, MYR N has reduced MNi formation 
MoNC from pre-cancerous patients. There are significant differences between 
the two groups (healthy and patient) for both MYR B and MYR N treatments 
which have been shown using the horizontal bars in the graph below (figure 
3.7b). 
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Figure 3.7b Shows, MNi frequency observed in MonoNC cells. Average of 5 independent 
experiments in 5 individuals for each healthy and patient group. Treatment of lymphocytes with 
the positive control (Mitomycin C {0.4µM MMC}), MYR B and MYR N, compared to the 
respective untreated groups. Stars represent significant differences. (***P< 0.001,* P< 0.02 and 
**P< 0.006). Horizontal lines with the statistics above them show the differences between the 
groups. The statistics below horizontal lines show the comparison of treatment groups with 
respective untreated group. 
3.3.7.4 Other determinants of MN 
 
The following table (3.6) shows the other important biomarkers of damage 
assessed in the micronucleus assay. There is no significant difference between 
the NDI and BiNC percentage among all the treatment groups. Untreated 
cultures of patient group shows higher number of MNi both in MoNC and BiNC 
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as compared to the groups treated with MYR B (10µМ) and MYR N (20µМ). 
MYR B and MYR N have shown trend to reduce MNi regardless of group 
difference and cell type but the values are not significantly different except for 
MYR N (20µМ) which has significantly reduced MNi formation in MoNC from 
pre-cancerous patients (Statistics presented in Fig 3.7a and b). EM did not 
cause any damage in healthy lymphocytes. However, MNi formation seen in 
lymphocytes from pre-cancerous patients is lower than the respective untreated 
group which indicates that EM does not induce MNi or any other chromosomal 
damage. MYR B and MYR N at selected non-genotoxic concentrations did not 
induce any nuclear bridges or buds in both investigative groups. 
BiMNi BiNPB BiBuds 
Healthy 
individual
s 
Untreated 
lymphocyte
s 
1.85 62 0 0 0 0 
0.4 µM 
MMC 
1.73 
(P<0.01) 
58 (ns) 24 
(P<0.0001) 
5 
(P<0.001) 
3 
(P<0.01) 
8 
(P<0.001) 
EM 1.84 
(ns) 
60 (ns) 0 (ns) 0 (ns) 0 (ns) 0 (ns) 
MYR B 1.82 
(ns) 
63 (ns) 2 (ns) 0 (ns) 0 (ns) 1 (ns) 
MYR N 1.85 
(ns) 
64 (ns) 1 (ns) 0 (ns) 0 (ns) 0 (ns) 
Pre-
cancerou
s patients 
Untreated 
lymphocyte
s 
1.81 61 6 1 0 6 
0.4 µM 
MMC 
1.85 
(ns) 
61 (ns) 18 
(P<0.001) 
4 
(P<0.04) 
2 
(P<0.05) 
11 
(P<0.001) 
EM 1.80 
(ns) 
62 (ns) 4 (ns) 0 (ns) 0 (ns) 6 (ns) 
MYR B 1.84 
(ns) 
64 (ns) 5 (ns) 0 (ns) 0 (ns) 5 (ns) 
MYR N 1.87 
(ns) 
62 (ns) 3 (ns) 0 (ns) 0 (ns) 3 
(P<0.02) 
Table 3.6 The average of various markers of chromosomal damage in micronucleus 
assay. Showing NDI per treatments on healthy and patient cells, mean % of BiNC, mean 
number of MNI,NPBs and NBUDS per 1000 BiNC and MNi frequency in MoNC. Five treatment 
groups included the negative control, a positive control group (Mitomycin C {0.4µM MMC}), 
excipient mixture (0.1 %) (EM), MYR B (10µM) and MYR N (20µM). ns=not significant 
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3.3.8 Myricetin activates the P53 signalling pathway independent of DNA 
damage in lymphocytes  
 
Based on our previous results from the Comet and micronucleus assays we 
established that MYR B (10µМ) and MYR N (20µМ) have shown anti-genotoxic 
effects in lymphocytes from healthy individuals and pre-cancerous patients. 
MYR N (20µМ) exhibited genoprotective effects in lymphocytes from pre-
cancerous patients by significantly reducing the MNi induction in MoNC. To 
identify the molecular mechanisms involved in this effect, we studied the 
influences of MYR B and MYR N on the gene expression levels of P53, a 
tumour-suppressor multi-functional gene in patients versus healthy lymphocytes 
and ATM kinase mRNA in patient lymphocytes. Tumour-suppressor P53 gene 
encodes for proteins that prevent genome mutations by interacting with DNA 
and regulating gene expression. Thus, plays significant role in prevention of 
carcinogenesis. It is most frequently mutated gene in various cancers (Surget et 
al., 2013). ATM kinase also plays a crucial role in maintenance of genome 
stability and facilitates DDR, initiating many physiological responses particularly 
in reaction to the formation of DNA DSBs; hence, it is used as biomarker of 
DSBs (Boohaker and Xu, 2014). This is why we studied P53 and ATM at the 
gene level. Total RNA was isolated from lymphocytes pre-treated with both 
forms of myricetin and subjected to quantitative real-time PCR analysis. The 
results (fig 3.8a) have shown that myricetin bulk has induced non-significant 
upregulation of P53 gene in lymphocytes from both groups, healthy and 
patients. However, myricetin nanoparticles significantly up-regulated the gene 
expression of P53 in patient lymphocytes compared to those from healthy 
individuals. This indicates that the protective effects caused by myricetin might 
be dependent on the tumour-suppression activity of the P53 gene. The ATM 
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gene expression has not shown significant effect in lymphocytes from both 
groups when treated with MYR B and MYR N (fig 3.8b). 
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Figure 3.8a The influence of MYR B and MYR N, on the expression of P53 mRNA in 
lymphocyte from healthy individuals and pre-cancerous patients. GAPDH was used as an 
internal control   gene. Gene expression analysis was performed on lymphocytes after 24-hour 
treatment. P53 mRNA expression was significantly increased in lymphocyte from pre-cancerous 
patient after exposure to MYR N. Values are the means ± standard errors (SE)  of three 
independent experiments, and the error bars represent SDs. The p values are **p=0.008, 
ns=not significant. All values were compared against respective control (C) and normalised 
against GAPDH reference gene. 
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Figure 3.8b The influence of MYR B and MYR N, on the expression of ATM mRNA, in 
lymphocyte from pre-cancerous patients. GAPDH was used as an internal control   gene. 
Gene expression analysis was performed on lymphocytes from pre-cancerous patients after 24-
hour treatment. ATM mRNA expression was increased in lymphocyte treated with MYR B but 
values are not significant. Values are the means of three independent experiments/individuals, 
and the error bars represent SDs. ns=not significant. All values were compared against control 
(C) and normalised against GAPDH reference gene. 
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3.3.9 Analysis of p53 protein expression in lymphocytes 
  
P53 plays a vital role in regulation of various cellular outcomes and responses 
such as angiogenesis, cell cycle arrest in the presence of DNA damage, DNA 
repair, apoptosis and transcription (Shaw, 1996; Haupt and Haupt, 2017). As 
cell cycle arrest and DNA repair are essential processes to protect cells against 
further DNA damage and pre-existing damage, we investigated the effects of 
myricetin nanoparticles and bulk forms on P53 protein expression in the 
lymphocytes from pre-cancerous patients compared to those from healthy 
subjects. We carried out Western blot procedure and analysed protein 
expression in lymphocytes from three healthy and three pre-cancerous patient 
samples. We restricted our study to only three experiments for each 
experimental group due to limited patient blood samples. The results obtained 
were consistent with our PCR data. P53 protein expression is significantly 
increased by 2.3-fold (P<0.0001) with MYR B (P<0.0001)) and 2.0-fold with 
MYR N treatment in healthy lymphocytes (fig 3.9 A, B). Also, p53 showed a 1.3-
fold increase in the lymphocytes of pre-cancerous patients treated with MYR B, 
a 1.4-fold-increase (P=0.0140) after treatment with MYR N (P=0.0036). 
 
               
                    
 
                    
 
                    
 
 
53 kDa 
53 kDa 
37 kDa 
 NC MYR B MYR N 
Healthy (P53) 
 
 Patient (P53) 
GAPDH 
A. 
111 
 
C
M
Y R
 B
 (1
0 µ
Μ
)  
M
Y R
 N
 (2
0 µ
Μ
)
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
P 5 3  p ro te in  e x p re s s io n  in
is o la te d  ly m p h o c y te
T re a tm e n t
F
o
ld
 C
h
a
n
g
e
H e a lth y
P a tie n t
B .
* * *
* * *
* *
*
 
Figure 3.9 Myricetin Bulk and nanoparticles significantly up-regulate the P53 protein 
levels in lymphocytes from pre-cancerous patients and healthy individuals (A) 
Immunoblot analysis of the p53 protein in lymphocyte treated with MYR B and MYR N. P53 
expression was increased to 2.3-fold by MYR B and 2-fold by MYR N in the healthy group. In 
pre-cancerous patient MYR B induced 1.3-fold increase and MYR N treatment caused 1.4-fold 
increase in P53 expression.  GAPDH was used as an internal control protein to normalise the 
data. (B) Bar graphs exhibiting fold changes in protein expression levels. Data are represented 
as the mean ± SEM of three experiments. ***P<0.0001, **P=0.0036, *P=0.0140 
 
3.4 Discussion 
 
The current in vitro study investigated the effect of myricetin bulk and 
nanoparticle forms on human lymphocytes from pre-cancerous patients and 
those from healthy individuals. 
Various in vivo and in vitro studies have demonstrated the promising health 
benefits of myricetin including anti-inflammatory, anti-oxidative, anti-
proliferative, cytoprotective effects, anti-carcinogenic, anti-viral and anti-
microbial properties. Research has shown that myricetin  inhibits the growth of 
human promyelocytic leukaemia (HL-60) cells by induction of apoptosis 
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(Hibasami et al., 2005), decreases the viability of HL-60 cells via apoptosis 
through a ROS independent and mitochondria dependent pathway (Ko et al., 
2005) and  induces pancreatic cell death in vitro (Phillips et al., 2011). Research 
has also indicated that myricetin is a strong inhibitor of the prostate cancer cell 
line PC-3 (Xu, 2013). However, none of the previous studies have tested in 
vitro, the effect of myricetin bulk and nano forms on the DNA of human 
lymphocytes from pre-cancerous patients. Genetically compromised DNA repair 
mechanisms might contribute to raised levels of DNA damage in lymphocytes 
from patients (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011) 
hence; lymphocytes are the focus of the current study. Peripheral lymphocytes 
represent an excellent model for examining the genome sensitivity (a factor of 
susceptibility to cancer) (Collins, 2004). If other somatic cell types are not 
accessible then lymphocytes can be used as surrogate cells to investigate the 
DNA damage and lymphocytes circulate in the blood stream across the body 
hence; are vulnerable to both endogenous and exogenous DNA damage by 
physio-chemical genotoxic insults (Najafzadeh et al., 2009). The alkaline Comet 
assay has been used to assess the DNA damage in lymphocytes from 
leukaemia patients (Collins, 2009). It has been proven a reliable method to 
assess the genotoxicity of NPs (Azqueta and Dusinska 2015). 
The Comet assay results from our study show that exposing lymphocytes from 
healthy individuals and pre-cancerous patients to myricetin nano and bulk at 
lower concentrations (20µM and 10µM, respectively) did not induce any 
significant DNA damage when compared to their respective negative control 
groups (Fig 3.5a, b and 3.6a, b). The anti-genotoxic behaviour of MYR B and 
MYR N at selective lower concentrations of 10µМ and 20µМ, respectively 
shown in this research is consistent with an earlier study which has shown that 
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myricetin is a non-toxic and anti -mutagenic flavonoid (Wang, 2010). However, 
myricetin has induced dose dependent genotoxicity at higher concentrations 
which might be possible due to the fact that flavonoids can potentially exhibit 
various activities at slightly different concentrations depending on the stimulus 
and environment they interact with. Therefore we only used non-genotoxic 
concentrations of both forms of myricetin to avoid any artefact due to toxicity.  
Due to the wide range of physio-chemical properties of NPs, various 
characteristics (shape, size, solubility, composition, surface properties, stability, 
uptake and aggregation) of these compounds need to be considered to be able 
to assess their genotoxic effects, but the specific properties responsible for 
genotoxicity, are still uncertain. These properties have direct impact on the 
biological activities of NPs (Chan, 2006). The unique chemical composition of 
myricetin containing hydroxyl group at positions 3, 5 and three consistent 
hydroxyl groups at 3’, 4’ and 5’ positions can enhance the effectiveness of its 
antioxidant behaviour (Li and Ding, 2012).  
DNA damage can occur as a result of primary and secondary genotoxic or 
mutagenic events. This can be characterized as DNA adducts, DNA base 
modifications, single and double strand breaks, structural DNA changes or 
cross links (Karlsson et al., 2008). This damage can be repaired by various 
repair systems: base excision repair (BER), nucleotide excision repair (NER), 
homologous recombination or non-homologous end joining (NHEJ). If the DNA 
damage is not repaired by any of these possible mechanisms, it can cause 
mutations which can eventually lead to cancer development. Hence, repairing 
the DNA and chromosomal damage is crucial for sustenance of particular organ 
or system (Sharma et al., 2012). 
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The cytokinesis-block micronucleus assay, a test, to determine the capability of 
genotoxic substance to induce aneugenic and clastogenic effects on cell cycle 
and cellular division (Fenech, 2002) was used in the present study, for the first 
time to investigate the effects of myricetin bulk and nano forms on lymphocytes, 
particularly from pre-cancerous patients. A micronucleus (MN) is formed during 
anaphase and could represent chromosomal fragments or lost chromosomes 
when the nucleus divides (Magdelenova et al., 2012). The sensitivity of the 
assay is enhanced by cytochalasin B to block the cytokinesis, but not the 
mitosis, to facilitate binucleated cells accumulation. The MN in binucleated cells 
only shows the damage caused after the treatment and reduces the probability 
of scoring the pre-existing damage (Magdelenova et al., 2012). Mitomycin C 
(MMC), known as a clastogen, genotoxic and anti-cancerous agent, was used 
as a positive control as its already experimented in our laboratory and it worked 
as expected by inducing MNi typically in binucleated cells rather than 
mononucleated (Elhajouji et al., 1998). Lower mean NDI and lower 
mononucleated cells were observed by treatment with MMC, which is consistent 
with previous studies performed at this laboratory (Najefzadeh, 2012).  
The normal range of BiNC and NDI in the healthy control is 30-60% and 1.3-2.2 
respectively. Variations in these readings could be due to confounding factors: 
age (more MNi in older people), gender (MNi are common in females) or simple 
lifestyle factors (smoking, illness, drinking and medications etc.) along with 
concentrations of the drug under test (Fenech, 2007; Houhannisyan et al., 
2009).  
Most of the NDI for the treatment groups were within the normal range but a few 
were elevated possibly because of other factors but were not significantly raised 
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indicating the division (Table 3.6). Evaluation of the assay shows that the 
frequency of MNi in MoNC from pre-cancerous patients significantly decreased 
when treated with MYR N (20µM) but not with MYR B (10µM), compared to the 
untreated group. This may be possibly due to either van der Waals forces or 
electrostatic interaction of NPs with nuclear proteins for example repair proteins 
and facilitated repair (Magdelonova, 2012). The double concentration of MYR N 
compared to MYR B could also contribute towards its effective behaviour, and 
in moving this work forward it would be important to directly compare MYR N 
and MYR B at both 10μM and 20μM. Also, the potential explanation for this is 
that NPs due to their very small size can easily reach the nucleus through 
diffusion across the nuclear membrane or transportation via the nuclear pores 
and gain direct interaction with the DNA (Magdolenova et al., 2014). The shape 
of NPs also plays a vital role in their internalisation and penetration into the cells 
(Guo et al., 2011). NPs can also enter the cell by endocytosis and eventually 
gain access to nuclear DNA (Chen et al., 2013). As the size of NPs decreases, 
the surface area and the numbers of atoms on the surface enormously increase 
and this makes NPs more reactive in biological systems. This property 
enhances their dispersion across the body and some can enter individual cells 
(Chan, 2006; McNeil, 2005).  Different surface changes including charge and 
chemistry, enable the attachment of NPs to molecular, chemical or other 
biological bodies. This results in their different behaviours in solution (McNeil, 
2005). The solubility and stability of NPs also affect their activity by affecting 
their bioavailability in living systems (Franklin et al., 2007). 
Myricetin in both forms did not induce any nuclear bridges or buds. There were 
few MNi in MoNC seen in healthy lymphocytes treatment which indicates little 
pre-existing DNA damage due to lifestyle factors or any other medical 
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procedure carried out.  However, this number was raised in pre-cancerous 
patients due to increased levels of basal damage.  
Several studies have focused on understanding the cellular mechanisms 
involved in controlling the cell cycle changes, in reaction to DNA damage 
(Kastan et al., 1992; Kuerbitx et al., 1992).   The critical molecular role played 
by P53 in DNA damage induced-cell cycle arrest is well distinct (Kastan et al., 
1991). Upon sensing the DNA damage P53 gene up-regulate the expression of 
p21WAF1 gene which then inhibits the activity cyclin CDK complexes leading to 
G1 arrest  blocking the progression of cell cycle and transcription. The down-
regulation of cyclin  A expression initiated by P53 could stop the entry into and 
through S phase. Without P53 normal function, DNA integrity could be 
compromised causing high mutational rates (Shaw, 1996).   It has been well 
documented that P53 stimulated p21WAF1 interacts with a complex called 
proliferating cell nuclear antigen (PCNA), involved in inhibition of replicative 
DNA synthesis (Waga et al., 1994) yet promoting the excision repair 
mechanism (Shivji et al., 1994).  Mutations in P53 genes are the most common 
genetic lesions found in all types of human tumours leading to the uncontrolled 
proliferation of tumour cells and cell cycle progression.  However, a complete 
loss of normal P53 function is required for a tumour to develop (Ventura et al., 
2007).  
Evident from previous work on P53 and its various functions in maintaining the 
cellular integrity we understand that by increasing the amount of P53, cellular 
proliferation of tumour cells may be suppressed through DNA repair, cell cycle 
arrest and apoptosis. This could be a new strategy for treating and preventing 
cancer development.   Our results demonstrate that 24-hour treatment with both 
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the nanoparticles and bulk forms of myricetin activates and stabilises the p53 
protein at the post-translational level (Figure 3.9), suggesting that myricetin may 
ensure p53-dependent action—for instance, cell cycle arrest and DNA repair in 
pre-cancerous patients. 
ATM deletions or mutations are linked with the development of periodic human 
cancers, for instance leukaemia and mantle cell lymphoma (Stilgenbauer et al., 
1997; Schaffner et al., 2000).  Previous studies proposed that the ATM gene 
express a protein that detects DNA damage and directs signals to the cells for 
stimulating apoptosis (Shiloh, 1997; Marinoglou, 2012). Research also indicates 
the ability of ATM kinase to trigger defence systems against oxidative injury and 
reduce DNA damage by inhibiting ROS (Chen et al., 2003; Semlitsch et al., 
2011; Shiloh, 2014).  
However, our results have not shown any significant change in ATM gene 
expression levels in lymphocytes from pre-cancerous patients after exposure to 
myricetin bulk and nano forms (figure 3.8b).  
3.5 Conclusion 
 
Our results from the Comet and micronucleus assays showed that MYR B 
(10µМ) and MYR N (20µМ) did not induce significant DNA damage in the 
lymphocytes from healthy individuals and pre-cancerous patients. However, 
both forms of myricetin do induce concentration dependent genotoxicity at 
higher concentrations. MYR N (20µМ) has shown genoprotective effects in 
lymphocytes from pre-cancerous patients by significantly inhibiting MNi 
induction in MoNC. This could be possible due the double concentration used 
for MYR N than MYR but also due to the enhanced properties of NPs including 
the effectiveness of diffusing through the biological membranes and interacting 
118 
 
directly with nucleus. These findings suggest that MYR B and MYR N can 
potentially exhibit both genotoxic and anti-genotoxic properties depending on 
the concentration, the stimulus applied and the substrate. However, at non-
genotoxic concentration myricetin could protect the lymphocytes of healthy 
individuals and pre-cancerous patients against DNA damage and possibly 
facilitate repair through a P53-mediated pathway.  
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Chapter 4: Reactive oxygen species (ROS) induced oxidative damage 
in lymphocytes from healthy individuals and those from pre-
cancerous patients: Protection by myricetin nanoparticles and bulk 
forms by stimulating endogenous anti-oxidative defence mechanism 
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4.1 Introduction 
 
Oxidative stress is a major factor contributing towards the development of 
various illnesses and it is a key inducer of cellular lesions. It is triggered by a 
disparity between the production of ROS and the capacity of biological system 
to cleanse the reactive intermediates. Mitochondria are the main supply of 
intracellular ROS and ROS have been considered as a second carrier and 
partial participant in different physiological processes including proliferation and 
apoptosis. ROS have been shown to induce proliferation in tumour cells and 
mediate the proliferation initiated by epidermal growth factor (EGF) or platelet 
derived growth factor (PDGF) (Burdick et al., 2003; Chao-Wei Chen et al., 
2004). Thus, anti-oxidants show an effective preventative effect against cancer 
development by reducing the ROS levels and inhibiting their production. In 
addition, intracellular ROS production has been associated with the mediation 
of the effects caused by anti-cancer drugs like taxol (Perkins et al., 2000; 
Varbiro et al., 2001). Hence data suggests a two-sided role of ROS. It has been 
suggested that cellular redox potential may be regulated through increasing 
glutathione (GSH) pools to the mitochondria, hence, preventing ROS formation 
and cellular injury caused by oxidative stress (Slikker et al., 2001; Imam et al., 
2001). 
Oxidative stress produced by tertiary-butyl hydro peroxide (TBHP) and 
hydrogen peroxide (H2O2) is well documented. TBHP is a toxic compound and 
causes extreme discomfort to various organs and systems (Zavodnik et al., 
1988; Sarkar and Sil, 2010; Bhattacharya et al., 2011). Exposure of cellular 
components to TBHP results in an increase of membrane permeability along 
with hyperpolarization.  Reaction of TBHP with haemoglobin forms t-butoxyl 
radicals, which then initiate peroxidation by interacting with membrane lipids 
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(Deuticke et al., 1987; Zavodnik et al., 1988)).  Extensive lipid peroxidation 
leads to membrane disturbance (Benatti et al., 1982). Cellular antioxidant 
enzymes like glutathione, to some level inhibit membrane disruption by 
scavenging the t-butoxyl radicals.  
Myricetin (3,5,7,3',4',5'-hexahydroxyflavone), an important flavonol, is widely 
found in berries, fruit and vegetables (Wang et al., 2010). A large body of data 
has been published regarding the anti-oxidant potential of myricetin, leaving no 
doubt that the compound is a strong anti-oxidant.  It depicts anti-oxidant activity 
by scavenging reactive oxygen species (ROS) through oxidation of the three 
hydroxyl groups (3',4',5'-position) attached in its B ring. It may also act as an 
anti-oxidant by chelating redox-active metal ions such as Fe2+ thus stops the 
progression of Fenton reactions and their harmful products (Chobot and 
Hadacek, 2011). Studies have demonstrated that the physiological 
concentrations range of myricetin (5-10µМ) (Peng and Kuo, 2003) could 
significantly inhibit the production of peroxynitrite- induced double strand breaks 
(DSBs) (Chen et al., 2011) and protect against the oxidative damage caused in 
neurodegenerative disorders (Laabich et al., 2007; Shimmyo et al., 2008).  
Myricetin has been demonstrated to prevent the tertiary-butyl hydro peroxide 
(TBHP)-induced chemiluminescence of mouse liver homogenates (Fraga et al. 
1987). Myricetin also mitigated TBHP induced oxidative stress in erythrocytes 
from Type-2 diabetic patients in vitro (Pandey et al., 2009). 
H2O2 –induced oxidative stress and DNA strand breaks caused in human 
lymphocytes and human colonocyte cells have been demonstrated and shown 
to be reduced upon myricetin treatment (Duthie et al., 1997).  
Whenever DNA damage occurs whether endogenous or exogenous, it forms 
DSBs. Upon formation of DSBs in DNA, hundreds or thousands of H2AX 
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proteins  present in chromatin are rapidly phosphorylated in the position Ser139 
by kinases such as ataxia telangiectasia mutated (ATM) and ATM-Rad3-related 
(ATR) in the PI3K pathway, adjoining the break site, providing signalling within 
the DNA DSB repair (Kuo and Yang, 2008). The newly phosphorylated 
derivative of H2AX is called gamma-H2AX. Measuring DSBs in human 
lymphocytes by immunolabelling the gamma-H2AX foci is an established 
method (Löbrich et al., 2005; Rogakou et al., 1998; Rogakou et al., 1999).  The 
number of foci therefore could be used as a relative parameter to estimate DNA 
damage and repair.  
Although myricetin is a well-established antioxidant, little is known about its 
beneficial role in countering the TBHP induced cytotoxicity in lymphocytes. The 
aim of the present study was, therefore, to investigate the in vitro protective role 
of myricetin nanoparticles (MYR N) and myricetin bulk (MYR B) against TBHP 
induced oxidative damage in lymphocytes from healthy individuals and pre-
cancerous patients. The effect of myricetin nano and bulk forms against H2O2 
induced damage, change in intracellular ROS due to oxidative stress caused by 
TBHP and change in GSH levels was also investigated. The study also 
assessed the effect of myricetin nano and bulk forms on DSBs by analysing the 
gamma H2AX protein expression immunocytochemically.  
4.2 Methodology 
 
4.2.1 Chemicals 
 
Please refer to 2.1 (chapter 2) for details about the chemicals and materials 
used. 
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4.2.2 Blood samples 
 
Healthy blood was collected from healthy individuals in sterile anticoagulant 
containing blood collection tubes. Patient blood was kindly provided by the 
Department of Haematology, Bradford Royal Infirmary (BRI), UK. Please refer 
to Table 3.1 and 3.2 for information about healthy and patients’ blood samples 
used in current study. 
4.2.3 In vitro experimental design 
 
Isolated lymphocytes were maintained in complete media containing RPMI 
1640 (without phenol red) with 1% penicillin-streptomycin and 15% foetal bovine 
serum. Different sets of lymphocyte suspensions were used for various 
experiments. The optimal dose for TBHP was determined by treating 
lymphocytes with different concentrations of TBHP followed by incubation at 
370C in the presence of 5% CO2. The intracellular ROS levels were assessed 
spectrofluorometrically after incubation with 10µl of DCFDA dye in the dark. The 
best incubation time for TBHP exposure was chosen as 60mins and used as 
standard for ROS related experiments.  
The optimal concentrations of MYR B, MYR N and H2O2 were determined by 
the dose response curve for all experiments. Doses for MYR B and MYR N 
ranging from 10µМ to 80µМ were used to assess the best one.  Untreated 
lymphocytes were set as the negative control (NC). The optimal concentrations 
for TBHP and H2O2 were used as positive controls (PC). After determining the 
doses for the test chemicals, PCs were simultaneously added to lymphocytes in 
suspension with either MYR B or MYR N in co-supplementation studies. TBHP 
was also considered as one of the positive control for co-supplementation 
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because there is not much known about the effects of Myricetin against TBHP-
induced oxidative stress.  
4.2.4 Cell viability and cytotoxicity 
Please refer to 2.2.11 and 2.2.12 (chapter 2) for the assay procedure of trypan 
blue DYE exclusion and MTT.  
4.2.5 The Comet Assay for determination of DNA damage  
Lymphocytes were treated with MYR B and MYR N in combination with H2O2 
(50 µM) for 1 h. The cell suspension was centrifuged at 3000 rpm (1000g). The 
supernatant was removed and the pelleted cells were subjected for the Comet 
assay as previously defined with some changes (Singh et al., 1988). Please 
refer to 2.2.13 (chapter 2). 
4.2.6 Cell culture and measurement of ROS accumulation in lymphocytes 
The fluorescent probe DCFDA was used to detect the intracellular ROS 
accumulation. (Refer to 2.2.16 chapter 2 for the procedure) 
4.2.7 Assay of cellular enzyme and total thiol content 
Reduced glutathione (GSH) is considered as the major tissue anti-oxidant. GSH 
levels and oxidised glutathione (GSSG) contents in experimental and normal 
lymphocytes were analysed using GSH/GSSG Ratio Detection Assay Kit 
(Fluorometric - Green) using the method described in 2.2.17 (chapter 2). 
4.2.8 Determination of histone-2AX (H2AX) phosphorylation (γ-H2AX) 
levels using Immunocytochemistry 
 
The method was based on (Schmid et al., 2010) and previously followed in our 
lab (Laubenthal et al., 2012). A total of 100 cells per treatment were examined 
under the fluorescence microscope connected with a CCD camera (Nikon 
Digital Sight DS-SMC, Surrey, UK) for gamma-H2AX foci expression, a marker 
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of DNA double strand breaks. Untreated cells were used as the negative control 
whereas doxorubicin, a known strand-break inducer (50µМ) was used as the 
positive control. Each experiment was done in triplicate with both controls 
included. (Refer to 2.2.19, chapter 2 for details) 
4.2.9 Statistical analysis 
 
Results were presented as mean ± SE and differences between the groups 
were analysed by one-way analysis of variance (ANOVA) and t-tests using 
Graph Pad prism 7 software.  Values of p<0.05 were considered significantly 
different.  
4.3 Results 
 
4.3.1 Preliminary treatment and concentration range study in lymphocytes 
 
Based on the dose response studies 10µM for MYR B and 20µM for MYR N 
were optimal doses with no cellular toxicity and were used for the experiments 
throughout the study.  H2O2 (50µM) was used throughout the study as the 
positive control and for co-supplementation in the Comet assay, determined by 
the dose response. TBHP is a known intracellular stress inducer and it was 
provided with the kit (Abcam, UK) as a positive control therefore we used it to 
determine the effects of MYR B and MYR N on intracellular ROS levels induced 
by TBHP. The increase in ROS production was used as a factor to choose the 
optimum concentration for TBHP i.e. 300µМ. 
The concentration dependent responses of TBHP are shown in the figure 4.1 
below. TBHP has induced significant levels of ROS at each determined 
concentration after 60mins of treatment. However, at 300µМ its activity was at 
highest when compared to the untreated group. 
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Figure 4.1 Average of 3 independent experiments showing, change in intracellular ROS 
after treatment with different concentrations of TBHP in healthy lymphocytes. All groups 
were compared against the untreated group. ***=P<0.001, *P=0.02. Results are expressed as 
mean ± SD. 
4.3.2 Lymphocyte viability  
 
Lymphocytes were treated with different chemicals and their % viability was 
determined after different time periods counting 100 cells each/ treatment group 
using the trypan blue exclusion method. Results show that there was no 
significant difference between the viability of lymphocytes at different time 
periods and that the concentrations of chemicals used for the study were non-
toxic for lymphocytes from healthy individuals. 
 
127 
 
N C E M
P C
 (H
2 O
2 )  
M
Y R
 B
 
M
Y R
 N
T B
H P
T B
H P
+ M
Y R
 B
T B
H P
+ M
Y R
 N
0
5 0
1 0 0
1 5 0
T re a tm e n t
%
 V
ia
b
le
 c
el
ls
1  h o u r
2 4  h o u rs
4 8  h o u rs
n s
n s
n sn s
n s
n sn sn s
n s
n s
n s
n s
n sn s
n s
n s
n s
n s
n sn s
n s
 
Figure 4.2 % viability per 100 cells counted/treatment of healthy lymphocyte after 1, 24 
and 48 hours. Treatment groups used were untreated (NC), excipient mixture (EM), positive 
control (PC) H2O2 50µМ, MYR B (10 µМ), MYR N (20 µМ), TBHP (300µМ), TBHP 
supplemented with MYR B and TBHP supplemented with MYR N. There was no significant 
difference on viability of cells at different time periods and was calculated more than 80% for all 
the treatment groups. 
 
4.3.3 Cytotoxicity of chemicals in lymphocytes 
 
Cytotoxicity of test chemicals was determined by culturing lymphocytes from 
healthy individuals and pre-cancerous patients and measuring the mean 
absorbance at 1 and 24 hrs using MTT dye. Results from the MTT assay 
showed that the test chemicals used in this study exhibited significant level of 
cytotoxicity when compared to the untreated cells. However, % cytotoxicity 
assessed for each group was lower than 6% after 1 and 24 hours of treatment 
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in lymphocytes from both healthy and patient group.  
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Figure 4.3 % Cytotoxicity in 2x104 cells of various test treatments in lymphocytes from 
healthy volunteers (A) and pre-cancerous patients (B) using MTT assay. Overall values 
were less than 5% which is not considered as cytotoxic. Error bars show mean values ± SD, n = 
3. *P=0.03, **P=0.002, ***P=0.0002, ns=not significant. 
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4.3.4   Effect of MYR N & B on Hydrogen peroxide (H2O2) induced DNA 
damage in lymphocytes from healthy vs patient group using the 
Comet assay 
 
In-vitro treatment of lymphocytes from healthy individuals and patients with 
MYR B (10µM) and MYR N (20µM), co-supplemented with 50µM H2O2 , 
resulted in significant reduction of DNA damage when compared to the PC 
(50µM H2O2) alone. PC alone induced significant levels of DNA damage when 
compared to the NC. MYR N and NC show same level of DNA damage in 
healthy lymphocytes both in %Tail DNA and OTM. The H2O2 induced DNA 
damage was significantly reduced by MYR B and MYR N in both groups, 
whereas MYR N was more effective against H2O2 induced DNA damage in 
healthy group when compared to the PC, giving the value almost similar to the 
untreated group.  
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Figure 4.4 (A) Mean % Tail DNA showing effect of MYR N & B on H2O2 induced DNA 
damage in lymphocyte taken from healthy individuals and pre-cancerous patients. Figure 
shows four groups of treatments including the negative control, excipient mixture, positive 
control, MYR B (10µM) co-supplemented with H2O2 and MYR N (20µM) co-supplemented with 
H2O2. All treatments were compared against the PC. The mean control values for the % tail 
DNA of NC and PC group for healthy individuals and patients were 9, 22 and 18, 29 
respectively, measuring 100 cells each per experiment. * shows significant difference between 
the groups. The horizontal lines on top of the graph show the significance difference the positive 
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control and the treatment groups. (For healthy groups ** P< 0.009, *** P< 0.005. For patient 
groups, *** P< 0.003). 
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Figure 4.4 (B) Mean OTM showing the effect of MYR B & N on H2O2 induced DNA damage 
in lymphocytes from healthy volunteers and pre-cancerous patients. Figure shows four 
groups of treatments including the negative control, positive control, MYR B (10µM) co-
supplemented with H2O2 and MYR N (20µM) co-supplemented with H2O2. All treatment groups 
were compared to the PC group. The mean NC values for the OTM of healthy and patient 
groups were 0.9 and 4.5 respectively. The mean maximum values of the PC of healthy and 
patient groups were 5 and 8 respectively. The horizontal lines on top of the graph show the 
significance difference between the positive control and the treatment groups. (* P< 0.05, ** P< 
0.007 shown on healthy groups and ** P< 0.002, **P< 0.002 for patients groups). 
 
4.3.5 Anti-oxidant effects of myricetin  
 
The study used a cell permeant reagent 2’,7’ –dichlorofluorescin diacetate 
(DCFDA) that measures total intracellular ROS activity and levels. Once 
diffused into the cells, cellular esterases deacetylate DCFDA as a non-
fluorescent form which is later oxidized to a highly fluorescent compound, 2’, 7’ 
–dichlorofluorescein (DCF) by interacting with ROS and easily detected by 
fluorescence spectroscopy. The effect of MYR B (10µМ) and MYR N (20µМ) on 
basal ROS levels was determined in lymphocytes from the healthy group and 
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pre-cancerous patients. Results showed that MYR N has significantly reduced 
the ROS levels in lymphocytes from both groups.  
4.3.5.1 TBHP-induced oxidative injury in lymphocytes: Protection by 
myricetin 
 
TBHP, a known stress inducer was used as the PC in this case instead of H2O2 
because it was provided with the kit. 
Exposure of healthy and patient lymphocytes to TBHP alone induced a 
significant increase in ROS levels by 40%. However, upon treatment with MYR 
B (10µМ) and MYR N (20µМ) a significant attenuation of TBHP-induced ROS 
was observed in lymphocytes from both groups.  
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Figure 4.5 Average of 3 independent experiments showing, change in intracellular ROS 
before and after treatment with TBHP in healthy lymphocyte. The horizontal lines show the 
significant difference between the groups.  ***, ****=P<0.0001, ns=not significant. Six treatment 
groups included an untreated group (NC), MYR B (10µM), MYR N (20µM), TBHP ((300µM) as 
PC, TBHP + MYR B and TBHP + MYR N. 
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Figure 4.6 Average of 3 independent experiments showing, change in intracellular ROS 
before and after treatment with TBHP in lymphocyte from pre-cancerous patients. The 
horizontal lines show the significant difference between the groups.  ns = not significant,  stars 
shows P<0.001. Six treatment groups included an untreated group (NC), MYR B (10µM), MYR 
N (20µM), TBHP ((300µM) as PC, TBHP + MYR B and TBHP+ MYR N. 
 
4.3.6 Activity of intracellular anti-oxidant enzyme, GSH and change in 
GSH/GSSG ratio 
The effects of MYR B and MYR N on the basal levels of GSH were assessed by 
treating lymphocytes from healthy and patient group with both forms of 
myricetin alone. MYR B and MYR N have shown a trend to increase the basal 
levels of GSH/GSSG ratio in lymphocytes from pre-cancerous patients but 
levels are not significantly different. Hence, myricetin does not show any 
substantial effect on GSH levels in lymphocytes from healthy individuals and in 
those from pre-cancerous patients. 
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Figure 4.7 Levels of different forms of GSH in healthy lymphocyte (A) and those from pre-
cancerous patients (B). Cells lysed to the concentration of 1x 105 cells/ml. Various 
treatment groups included the NC (untreated), EX, MYR B (10µМ), MYR N (20µМ), H2O2 
(50µМ) as PC , MYR B+H2O2 and MYR N+ H2O2. The reduced and total GSH increased in 
healthy lymphocytes as compared to NC and GSH/GSSG ratio also increased by treating 
healthy lymphocyte with MYR B alone. However, co-supplementation of H2O2 with MYR B & 
MYR N significantly improved the level of reduced GSH and GSH/GSSG ratio when compared 
to the PC (H2O2).  
 
4.3.7 Effect of myricetin on DSB formation in lymphocytes at basal levels 
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DSBs in the nuclei of lymphocyte cells were immunocytochemically stained 
using the γH2AX protein and γH2AX foci inside each nucleus were counted in 
100 cells each. One DSB represented one γH2AX focus. Results showed that 
myricetin does not cause DSBs in healthy lymphocytes. Compared to the 
number of foci generated in the control, both forms of myricetin (MYR B, MYR 
N) have not shown any significant increase in foci formation. However, as 
shown in Figure 4.8 B, an increased number of γH2AX foci formation were 
observed after treatment of the healthy lymphocytes with doxorubicin, a known 
strand break inducer (PC) (p<0.001). Foci formation was observed at basal 
levels in untreated group from pre-cancerous patients and this incidence of the 
foci formation was significantly increased (p<0.001) after doxorubicin 
treatments. Upon treatment with MYR B (10µМ) and MYR N (20µМ) forms in 
lymphocytes from pre-cancerous patients, no significant effect was observed in 
γH2AX foci formation compared to the untreated group. This suggests that 
myricetin does not induce DSBs in healthy lymphocytes at basal levels and 
could potentially provide protection against DSBs formation in lymphocytes from 
pre-cancerous patients at basal levels. 
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Figure 4.8 γH2AX phosphorylation in lymphocytes from healthy individuals and pre-
cancerous patients presented in untreated cells (NC) and treated with doxorubicin (50 
μM), MYR B (10 Μm), MYR N (20 μM) at basal levels without any supplementation. 
(A)Merged Dapi and gamma-H2AX stains in blood lymphocytes from healthy individuals and 
pre-cancerous patients. Number of phosphorylated H2AX-foci corresponds with DSBs. (B) 
γH2AX foci induction in lymphocytes with different treatment groups. Data were analysed by 
two-way ANOVA followed by multiple comparison test for significant differences compared to 
the untreated control for each group (***p < 0.001, ns=not significant). 
 
4.4 Discussion 
 
The Comet assay is a sensitive and reliable method for detection and 
quantification of DNA damage and DNA strand breaks in single cells. In this 
study we determined the effects of myricetin against H2O2 induced DNA 
damage by simultaneously exposing the cells to H2O2 (50µМ) in the presence or 
absence MYR B or MYR N. The Comet assay results have shown the protective 
effect of myricetin bulk and nanoparticles (NPs) against H2O2 induced ROS 
related oxidative damage in the lymphocytes of healthy individuals and pre-
cancerous patients. The basal DNA damage was significantly inhibited when 
compared to the positive control (Figure 4.4a, 4.4b). Both forms of myricetin 
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have shown inhibitory effects whereas MYR N was more effective in causing 
the reduction in DNA damage, may be due to its enhanced physio-chemical 
characteristics (p<0.005). The potential explanation for this could be that NPs 
due to their minute size can easily reach the nucleus through diffusion across 
the nuclear membrane or transportation via the nuclear pores and gain direct 
interaction with the DNA (Magdolenova et al., 2012; Magdolenova et al., 2014). 
This could be further investigated and confirmed by studying the sub-cellular 
distribution of these particles using TEM. 
DSBs are most dangerous type of cellular lesions which if left impaired can 
ultimately lead to cell death. ROS play a crucial role in stimulating DNA strand 
breaks formation and causing oxidative stress (Tanaka et al., 2007). 
Accumulation of the DNA damage induced by ROS can lead to various 
deleterious processes including the stimulation of neoplasms production and 
eventually tumour development (Tanaka et al., 2007; Vilenchik and Knudson, 
2003).To evaluate the anti-oxidant potential of myricetin we investigated its anti-
oxidant effects in lymphocytes from healthy individuals and pre-cancerous 
patients by measuring overall cellular ROS contents. The basal levels of ROS 
and the effect of myricetin against TBHP-induced ROS were evaluated. Results 
have demonstrated that myricetin has reduced the basal damage in 
lymphocytes from both the investigated groups as well as the insults introduced 
by TBHP treatment (figure 4.5, 4.6)  Both forms of myricetin have shown strong 
anti-oxidant defence by scavenging the free radicals caused by ROS and by 
reducing their levels intracellularly. However, when two forms were compared, 
MYR N (20µМ) demonstrated more protective effects than MYR B (10µМ). Our 
results are consistent with previous studies (Wang et al., 2010; Kang et al., 
2010). Inhibition of ROS may prevent its accumulation, also the interaction of 
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floating radicals with cellular contents and DNA fragmentation, avoiding DNA 
lesions and strand breaks. Hence, myricetin shows anti-mutagenic and anti-
carcinogenic properties by preventing mutations at non-genotoxic 
concentrations used for both forms of myricetin. These results are consistent 
with previous studies conducted on various cells lines using myricetin. It has 
been previously shown that myricetin protect cells from H2O2 damage by 
inhibiting ROS production and by stimulating the antioxidant enzymes. It 
restored the function of antioxidant defence enzymes such as catalase (CAT), 
superoxide dismutase (SOD) and glutathione peroxidase (GPx) which was 
reduced by H2O2 treatment (Wang et al., 2010).  
Although we used the fluorescent probe DCFDA to detect ROS levels, the 
formamido pyrimidine glycosylase (FPG) protein could also be considered to 
assess oxidative DNA damage using the Comet assay (Müller, et al., 2013). 
Furthermore, this study also investigated the effect of myricetin on intracellular 
GSH levels by using a highly sensitive proprietary non-fluorescent dye which 
becomes fluorescent when reacted with GSH. Glutathione occurs in two forms; 
reduced (GSH) and oxidized form, glutathione disulphide (GSSG). Reduced 
glutathione (GSH) is a key tissue antioxidant and presents first line of defense 
against ROS. Reduced Glutathione (GSH) is the smallest intracellular protein 
thiol molecule present in the cells that inhibits ROS (such as free radicals and 
peroxides) induced cell damage. Oxidized glutathione (GSSG) is produced by 
the formation of a disulfide bond between two GSH molecules in the glutathione 
peroxidase (GPx) catalyzed reaction. The enzyme glutathione reductase (GR) 
reprocesses GSSG to GSH. In healthy cells, the total glutathione pool is mostly 
in the reduced form (GSH). However, when cells are exposed to increased 
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levels of oxidative stress, GSSG starts gathering and the ratio of GSSG to GSH 
rises. Hence, a bigger ratio of GSSG-to-GSH is an indication of oxidative stress 
(Roy and Sil, 2012).  
Our results have demonstrated no significant effect on GSH levels after 
treatment with MYR B and MYR N in lymphocytes from healthy and patient 
groups (figure 4.7). 
Gamma-H2AX is used as an effective biomarker of DSBs. An accumulating 
body of evidence suggests that the crucial role of γH2AX phosphorylation for 
nuclear foci formation at DBS sites and stimulation of DNA repair (Rogakou et 
al., 1998; Podhorecka et al., 2010).  To evaluate the effect of myricetin on DSBs 
formation in lymphocytes from healthy individuals and those from pre-cancerous 
patients we quantified γH2AX foci intensity using immunofluorescence.  Our 
results have shown that myricetin does not induce DSBs formation in healthy 
lymphocyte and those from the pre-cancerous patients at basal levels which is 
consistent with our previous results from the Comet assay where no significant 
DNA damage was caused upon exposure to MYR B (10µМ) and MYR N 
(20µМ)(figure 4.8). However, a trend to lower an overall intensity of γH2AX foci 
was observed in the lymphocytes from pre-cancerous patients treated with MYR 
B and MYR N when compared to the untreated group.  This marks the current 
study as the first one to demonstrate the effect of MYR B (10µМ) and MYR N 
(20µМ) on DSBs development in lymphocytes from healthy individuals and 
those from pre-cancerous patients at basal levels. 
In conclusion, this work demonstrates for the first time (to our knowledge) that 
myricetin bulk and nano at selective non-genotoxic concentrations protect the 
lymphocytes (from healthy individuals and pre-cancerous patients) from 
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damaging effects of TBHP and H2O2 primarily by inhibiting ROS-induced 
oxidative stress. Besides this, MYR B (10µМ) and MYR N (20µМ) do not induce 
formation of DSBs in lymphocytes from healthy individuals and pre-cancerous 
patients at basal levels and could possibly protect the lymphocytes from 
extensive cell damage by inhibiting DSBs formation and ultimately help in cell 
survival and DNA damage repair. DNA repair capacity of lymphocytes after 
treatment with myricetin could possibly studied using the Comet assay simply 
by assessing the damage at different time periods (Collins, 2004)  The overall 
results have demonstrated that MYR N (20µМ) has shown better antioxidant 
and genoprotective effects against the oxidative damage in lymphocytes from 
healthy individuals and pre-cancerous patients when compared to MYR B 
(10µМ). 
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Chapter 5:  The protective effect of myricetin bulk and nanoparticles on 
PhIP (2- amino-1-methyl-6 phenylimidazo [4,5-b] pyridine)-induced DNA 
damage in  lymphocytes from healthy individuals and pre-cancerous 
patients 
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5.1 Introduction 
 
Recently, the consumption of processed and overcooked red meat has been 
associated with causing carcinogenicity in humans (Bouvard et al., 2015), 
attributed to the production of food-related carcinogens including heterocyclic 
amines (HCAs) (Sugimura et al., 2004). HCAs are strong DNA-damaging 
complexes which are formed when meat and other related products are cooked 
at very high temperature (Turesky and Le Marchand, 2011). 2-amino-1-methyl-
6-phenylimidazo [4,5-b]pyridine (PhIP) is considered as most commonly 
occurring HCA in our diet (Sugimura et al., 2004). It is metabolically activated by 
cytochrome P450 1A2 (CYP1A2) producing toxic intermediate, 2-hydroxyamino-
1-methyl-6- phenylimidazo [4,5-b]pyridine (N-OH-PhIP), followed by additional 
sulfonation by sulfotransferases (SULTs) or acetylation by N-acetyl-transferases 
(NATs) (Turesky, 2007). It has been suggested that these compounds reach the 
distal colon through the bloodstream and are actively released into the lumen 
(Nicken et al., 2013). C8-PhIP-dG adducts, bulky DNA lesions are formed due 
to the instability of these esters by releasing a DNA-reactive arylnitrenium ion. 
These adducts undergo nuclear excision repair (NER) to fix the damage. 
Unrepaired C8-PhIP-dG adducts primarily cause single nucleotide deletions and 
G:T conversion mutation, hence are pre-mutagenic (Morgenthaler and 
Holzhauser, 1995; Yadollahi et al., 1996) ). It has been stated that increasing 
PhIP doses cause cellular death while surviving cells exhibit high levels of 
mutations, determined in the hypoxanthine-guanine phosphoribosyl transferase 
(hprt) locus (Gooderham et al., 2002). Several in vivo (Cheung et al., 2011; 
Choudhary et al., 2012; Li et al., 2012) and epidemiological studies (Cross et 
al., 2005; Voutsinas et al., 2013) reported the contribution of PhIP towards the 
induction of mammary, gastrointestinal and prostate cancers in rodents. C8-
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PhIP-dG adducts are said to interfere with the DNA replication process 
triggering a cellular stress response called replication stress mainly through 
DNA damage which ultimately gives rise to single stranded DNA (ssDNA) (Byun 
et al., 2005). The ssDNA quickly forms ssDNA-RPA complex by adjoining with 
the replication protein A (RPA) which are then detected by ATR-interacting 
protein (ATRIP) recruiting kinase ATR. Thus, this process triggers DNA damage 
response (DDR) by activating ATR (Zou and Elledges, 2003; Ball et al., 2005). 
ATR plays a significant role in phosphorylation of various downstream effectors 
such as the checkpoint kinase CHK1, histone H2A (H2AX) and the cell cycle 
protein, RAD17 (Zeman and Cimprich, 2014). ATR in cooperation with RPA, 
therefore, induces the repair pathways and facilitates the restart of hindered 
replication forks by stabilizing them (Cimprich and Cortez, 2008). Continuous 
replication stress leads to the formation of DNA double strand breaks (DSBs) 
(Zeman and Cimprich, 2014) and recruitment of kinase ATM (Shiloh and Ziv, 
2013).  
Myricetin, a well-studied flavonoid with diverse properties is primarily 
recognised due to its anti-oxidant, anti-cancer and anti-inflammatory activities 
(Ong and Khoo, 1997). Research studies present no doubt for the compound to 
be a strong anti-oxidant. It has also been regarded as a potent chemo 
preventative agent against various tumours (Androutsopoulos et al., 2011; Kim 
et al., 2014). Myricetin displayed anti-genotoxic effects against the food 
mutagens, 3-amino-1-methyl -5H-pyrido-(4,3-b) indole (Trp) and 2-amino-3-
methylimidazo-(4,5-f) quinoline (IQ) and decreased DNA damage without 
exogenous metabolic initiation in human lymphocyte cells (Anderson et al., 
1997). However, on the other hand the compound triggered the basolateral 
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uptake of PhIP through partly preventing the MRP2-regulated excretion of PhIP 
from intestine back to the lumen (Schutte et al., 2006). 
Diet is an important contributory factor towards the development of various 
cancers and knowing that lymphocytes express CYP1A2 and that the food 
mutagen, PhIP, activated by CYP1A2, contributes in many dietary tumours 
(Anderson, et al., 1997; Cheung et al., 2011; Voutsinas et al., 2013), we 
investigated for the first time in this study the effects of PhIP on basal levels as 
well as by co-supplementation with either MYR B or MYR N in lymphocytes 
from healthy individuals and pre-cancerous patients. This was conducted to 
determine if PhIP causes DNA damage in lymphocytes and whether dietary 
compounds like myricetin could help to reduce the harmful effects of PhIP and 
prevent cancer development in pre-cancerous patients. 
In this study we investigate and analyse the effects of PhIP treatment on the 
induction of DNA damage, strand breaks formation, intracellular glutathione 
(GSH) levels, kinase ATR regulation, p53 and Bcl-2 levels  in peripheral 
lymphocytes from pre-cancerous patients and healthy individuals and also the 
modulating effects of myricetin (MYR B and MYR N) on PhIP-induced metabolic 
changes of these factors. Using the Comet and micronucleus assays we 
investigated the effect of PhIP treatment in lymphocytes from healthy individuals 
and pre-cancerous patients and the modulating effects of myricetin. We also 
determined the anti-oxidant potential of myricetin in human lymphocytes against 
PhIP-induced oxidative stress by analysing the levels of intracellular anti-
oxidant enzyme, GSH. Using western blotting and real-time PCR we studied the 
influence of chemicals on ATR, P53 and Bcl-2 pathways at m RNA and protein 
levels in isolated lymphocytes. 
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5.2 Methodology 
 
For cell culture, reagents, cell viability, the Comet assay procedure, 
micronucleus assay, assay of cellular enzyme and total thiol content, Western 
blot analysis and the real-time RT-PCR analysis please refer to chapter 2 for 
more details. The blood samples from healthy individuals and pre-cancerous 
patients used for this study are listed in table 5.1 and 5.2 below.  
No Age Ethnicity  Gender  Smoking history Family history 
1 25 CAUCASIAN M NO NONE 
2 44 ASIAN M YES NONE 
3 28 CAUCASIAN M NO NONE 
4 23 CAUCASIAN F NO NONE 
5 27 CAUCASIAN M NO KIDNEY CANCER 
6 33 ARAB M YES NONE 
7 47 ASIAN M YES NONE 
8 28 CAUCASIAN M NO NONE 
9 42 ASIAN M NO NONE 
10 48 ASIAN M NO NONE 
11 60 ASIAN M YES NONE 
12 24 ASIAN M NO NONE 
13 34 ASIAN M NO NONE 
14 34 CAUCASIAN F YES NONE 
15 34 ASAIN M NO NONE 
16 59 CAUCASIAN F YES NONE 
17 28 ASIAN M YES NONE 
18 61 CAUCASIAN F NO NONE 
19 36 CAUCASIAN F NO NONE 
20 52 CAUCASAIN F NO NONE 
Table 5.1 Brief information on healthy blood samples used in this chapter 
No Age Ethnicity  Gender  Smoking 
history 
Family history Medical condition 
1 63 CAUCASIAN M YES NONE MGUS 
2 75 CAUCASIAN M NO NONE MGUS 
3 74 CAUCASIAN F NO LUNG CANCER MGUS 
4 83 CAUCASIAN M NO NONE MGUS 
5 60 ASIAN F NO NONE MGUS 
6 62 CAUCASIAN M NO NONE MGUS 
7 51 CAUCASIAN F NO NONE MGUS  
8 80 CAUCASIAN M NO CANCER POSITIVE MGUS 
9 81 CAUCASIAN F NO BOWEL& STOMACH MGUS 
10 63 CAUCASIAN M YES NONE MGUS 
11 63 CAUCASIAN M YES NONE MGUS 
12 74 CAUCASIAN M NO NONE MGUS COPD 
13 63 CAUCASIAN F YES ARTHRITIS MGUS, COPD 
14 66 CAUCASIAN F NO BREAST CANCER MGUS 
15 52 CAUCASIAN M YES NONE MGUS 
16 79 CAUCASIAN M NO NONE MGUS, COPD, MONOCLONAL B CELL 
LYMPHOCYTOSIS 
17 80 CAUCASIAN F NO NONE- MGUS 
18 78 CAUCASIAN M NO NONE- MGUS 
19 50 ASIAN F NO NONE MGUS 
20 69 CAUCASIAN M NO STOMACH AND 
LUNG  
MGUS 
Table 5.2 Brief information of pre-cancerous patients’ blood samples used in this chapter 
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5.2.1Statistical analysis 
 
Results were expressed as mean ± standard error of mean (SEM). Graph Pad 
prism 7 was used to perform statistical calculation. The results were analysed 
using t-tests, one-way analysis of variance (ANOVA) and two-way ANOVA to 
test differences between each treatment and control. A p-value of <0.05 was 
considered statistically significant. 
5.3 Results 
5.3.1 Viability of lymphocytes 
 
There was no significant effect observed on viability of lymphocytes from 
healthy individuals and those from pre-cancerous patients after 24 hours 
treatment with various treatment groups used in this study except PhIP + MYR 
N. However, viability for this group was also assessed more than 86% in both 
healthy and patient lymphocytes (figure 5.1). This suggests that the 
concentration of chemicals used throughout the study were non-toxic for the 
lymphocyte cells.  
N C E m
P h
IP  
(P C
)
P h
IP  
+  M
Y R
 B
P h
IP  
+  M
Y R
 N
0
5 0
1 0 0
1 5 0
T re a tm e n t
% 
Ce
ll s
ur
viv
al 
aft
er 
24
 ho
urs H e a lth y
P a tie n ts
ns ns ns ns
ns ns * * *
 
Figure 5.1 % viability per 100 cells counted/treatment after 24 hours. Treatments groups 
used were untreated (NC), excipient mixture (EM), positive control (PC) PhIP 100µМ, PhIP 
supplemented with MYR B (10µM) and MYR N (20µM). Viability was calculated as more than 
80% for all the treatment groups. (ns=not significant, *P<0.02, **P<0.004) 
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5.3.2 Dose response curve for PhIP and Myricetin 
 
The optimal dose of PhIP inducing maximum DNA damage was determined 
using the Comet assay in lymphocytes from healthy vs patient group. PhIP 
concentrations (50-200µМ) were considered for the test by comparing against 
the untreated group. 50µМ H2O2 was used as relative positive control. Results 
demonstrate that all doses of PhIP have induced significant (p<0.001) DNA 
damage in healthy lymphocytes and insignificant damage in patients 
lymphocytes (figure 5.2). Although there was little difference between the three 
concentrations (50, 100 and 200 µМ) I decided to use 100µМ as a standard 
which caused maximum genotoxicity in both groups. Hence, it was used 
throughout the study. 
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Figure 5.2 Concentration dependent responses of PhIP in lymphocytes from healthy 
individuals and pre-cancerous patient lymphocyte showing mean %Tail DNA. All PhIP 
doses induced genotoxic damage to the cells whereas 100µM seemed to produce maximum 
DNA damage in both groups. All data have been expressed as mean ± standard errors (SE). 
***p<0.001, **p<0.01, ns=not significant 
149 
 
The optimal doses for MYR B and MYR N, 10µМ and 20µМ respectively were 
determined using the dose response curve and used throughout in the current 
study as well. The data have already been shown in chapter 3.  
 
5.3.3 Modulating effects of MYR B and MYR N on PhIP-induced DNA 
damage in lymphocytes using the Comet assay 
 
To determine the in vitro effects of different particle sizes of myricetin on PhIP-
induced DNA damage, lymphocytes from healthy volunteers and pre-cancerous 
patients were treated with MYR B (10µM) and MYR N (20µM) simultaneously 
co-supplemented with PhIP (100µM). Results demonstrate a reduction in DNA 
damage overall, when compared against the PC (Phip 100µM). The damage 
was significantly decreased by both forms of myricetin in healthy lymphocytes 
as well those from pre-cancerous patients (Figure 5.3a,b and 5.4a,b) assessed 
using the two parameters of the Comet assay, Olive tail moment (OTM) and % 
Tail DNA. The levels were almost returning to those similar to the negative 
control.  This indicates that MYR B and MYR N exhibit similar protective and 
anti-genotoxic effects and can potentially protect the lymphocytes of healthy 
individuals and pre-cancerous patients against the DNA damage and 
genotoxicity caused by PhIP.  
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Figure 5.3a Modulating effect of MYR B & N on PhIP induced DNA damage in healthy 
lymphocytes using % Tail DNA The above figure shows five treatment groups including an 
untreated group, the positive control (PhIP 100µМ), MYR B (10µM)with PhIP, MYR N (20µM) 
supplemented with PhIP and excipient mixture (EM)(0.1 %). The PC and EM were compared 
against the NC while MYR B and MYR N against the PC. The mean NC and PC values for 
healthy groups were 10 and 25 respectively.  *** represents P< 0.001, ns = not significant. The 
horizontal lines on top of the graph show the significant difference between the treatment 
groups. 
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Figure 5.3b Modulating effect of MYR B & N on PhIP induced DNA damage in healthy 
lymphocytes using Olive Tail Moment  The above figure shows five treatment groups 
including an untreated group, the positive control (PhIP 100µМ), MYR B (10µM)with PhIP, MYR 
N (20µM) supplemented with PhIP and excipient mixture (EM)(0.1 %). The PC and EM were 
compared against the NC while MYR B and MYR N against the PC. The mean NC and PC 
values for healthy groups were 1 and 6 respectively.  *** represents P< 0.001, ns = not 
significant. The horizontal lines on top of the graph show the significant difference between the 
treatment groups. 
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Figure 5.4a Modulating effect of MYR B & N on PhIP induced DNA damage in pre-
cancerous patient lymphocytes using % Tail DNA  The above figure shows five treatment 
groups including an untreated group, the positive control (PhIP 100µМ), MYR B (10µM)with 
PhIP, MYR N (20µM) supplemented with PhIP and excipient mixture (EM)(0.1 %). The PC and 
EM were compared against the NC while MYR B and MYR N against the PC. The mean NC 
and PC values for healthy groups were 15 and 27 respectively.  ***, *** represents P< 0.001, P< 
0.002 ns = not significant. The horizontal lines on top of the graph show the significant 
difference between the treatment groups. 
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Figure 5.4b Modulating effect of MYR B & N on PhIP induced DNA damage in pre-
cancerous patient lymphocytes using Olive Tail Moment  The above figure shows five 
treatment groups including an untreated group, the positive control (PhIP 100µМ), MYR B 
(10µM)with PhIP, MYR N (20µM) supplemented with PhIP and excipient mixture (EM)(0.1 %). 
The PC and EM were compared against the NC while MYR B and MYR N against the PC. The 
mean NC and PC values for healthy groups were 3 and 7 respectively.  ***P< 0.001, ns = not 
significant. The horizontal lines on top of the graph show the significant difference between the 
treatment groups. 
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5.3.4 Determination of micronuclei (MNi) and other DNA damage 
 
5.3.4.1 MNi frequency in binucleated cells (BiNC) 
 
The effect of PhIP alone and combination of PhIP with MYR B and MYR N on 
micronuclei formation was assessed using the micronucleus assay. Our results 
show that the number of MNi in BiNC cells from pre-cancerous patients was 
higher than those from healthy individuals in their respective untreated 
groups.There were few MNi observed in the healthy NC group per 1000 cells 
counted, and this needs to be taken into consideration when evaluating these 
results. This frequency was further enhanced by exposing the cells to PhIP 
(100µМ) (p<0.001).  However, complementation of MYR B and MYR N has 
significantly reduced MNi formation induced by PhIP in BiNC cells from healthy 
individuals and pre-cancerous patients (figure 5.5). This has been shown on 
graph using the statistics under the horizontal bars where two supplemented 
groups were compared against the PC group (PhIP).  
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Figure 5.5 Shows the average of BiNC MNi scored per 1000 cells per culture from 5 
independent experiments, n=1000. Data are expressed as means ± standard errors (SE). 
Four treatment groups included the negative control (NC), a positive control PhIP (PC) (100µМ) 
MYR B (10µM) and MYR N (20µM) groups supplemented with PhIP (100µМ). (*represents P< 
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0.01, *** represents P< 0.001). Horizontal lines and the statistics above them show the 
comparison between the groups. 
 
5.3.4.2 Other elements of MN 
Table 5.3 below shows that there is no significant difference between the NDI 
and % of BiNC for all treatment groups when compared to the respective 
untreated group for healthy individuals and pre-cancerous patients. PhIP 
significantly induced MNi formation in both groups.  Untreated cultures of 
patient group have shown higher number of MNi both in MoNC and BiNC as 
compared to the groups treated with MYR B and MYR N. MYR B (10µМ) or 
MYR N (20µМ) addition with PhIP has significantly reduced the MNi induction 
regardless of group difference and cell type. 
Healthy 
individuals 
Untreated 
lymphocytes 
(NC) 
1.85 62 0 0 
PhIP (PC) 1.63 (ns) 62 (ns) 7 (P<0.001) 15 (P<0.001) 
MYR B + 
PhIP 
1.83 (ns) 61 (ns) 4 (P<0.01) 10 (P<0.01) 
MYR N + 
PhIP 
1.63 (ns) 61 (ns) 3 (P<0.01) 8 (P<0.001) 
Pre-
cancerous 
patients 
Untreated 
lymphocytes 
1.81 61 6 6 
PhIP (PC) 1.78 (ns) 61 (ns) 12 
(P<0.001) 
13 (P<0.001) 
MYR B + 
PhIP 
1.73 (ns) 60 (ns) 8 (P<0.01) 9 (P<0.01) 
MYR N + 
PhIP 
1.80 (ns) 60 (ns) 7 (P<0.01) 6 (P<0.001) 
 
Table 5.3 The average of various markers/parameters of chromosomal damage in the 
cytokinesis block micronucleus assay. Showing NDI per treatments on healthy and patient 
cells (all values compared against respective untreated group), mean % of BiNC (all values 
compared against respective untreated group), mean number of MNI in BiNC and MNi 
frequency in MoNC (For these two columns, the PC is compared against the untreated 
lymphocytes for both investigative groups and co-supplemented groups were compared against 
the PC).  
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5.3.5 Activity of intracellular anti-oxidant enzyme, GSH and change in 
GSH/GSSG ratio 
This test was carried out by using a highly sensitive proprietary non-fluorescent 
dye which becomes fluorescent when reacted with GSH. In-vitro treatment of 
lymphocytes from healthy individuals and patients with mutagen PhIP (100µM) 
alone and co-supplementation with MYR B (10µM) and MYR N (20µM) has 
shown non-significant effect on GSH levels or GSH/GSSG ratio. 
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Figure 5.6 Effect of phip on GSH levels and modulation of phip-induced oxidative stress 
by MYR B and MYR N in healthy lymphocyte (A) and those from pre-cancerous patients 
(B). Cells lysed to the concentration of 1x 105 cells/ml. Various treatment groups included the 
NC (untreated), PhIP (100µМ) as PC, MYR B (10µМ)+PhIP and MYR N (20µМ)+ PhIP.  
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5.3.6 Activation the P53 and ATR signalling pathway by myricetin bulk 
and nanoparticles following PhIP-induced oxidative stress 
 
Built on earlier results from the Comet and micronucleus assays we found that 
MYR B and MYR N have shown protective effects against PhIP induced DNA 
damage in lymphocytes from healthy individuals and pre-cancerous patients. To 
identify the molecular mechanism involved in this effect, we studied the 
influences of PhIP and then myricetin co-supplementation with PhIP on the 
gene expression levels of P53, a tumour-suppressor multi-functional gene and 
ATR kinase mRNA in lymphocytes. Total RNA was isolated from lymphocytes 
pre-treated with chemicals for 24 hours and subjected to quantitative real-time 
PCR analysis. The results (Figure 5.7) have shown that in healthy lymphocytes, 
PhIP treatment significantly decreased the P53 gene expression to 0.5-fold, 
however, this was significantly up-regulated upon supplementation with MYR B 
to 1.4-fold and with MYR N to an 1.75-fold increase. In lymphocytes from the 
patient group the P53 was slightly down-regulated with PhIP treatment whereas 
significantly up-regulated by MYR N co-supplementation (p<0.01). PhIP has 
shown different effects on gene expression levels of ATR in lymphocytes from 
healthy individuals to those from pre-cancerous patients. The ATR gene was 
significantly (p<0.001) up-regulated by PhIP in healthy lymphocytes and it was 
further enhanced by myricetin supplementation where MYR N has shown 
p<0.001 significance. However, PhIP has demonstrated reverse effects on ATR 
expression in lymphocytes from the patient group. It significantly down-
regulated the ATR gene levels (p<0.01) which were significantly up-regulated 
by myricetin addition.  These results indicate that protective effects caused by 
myricetin on PhIP-induced damage might be dependent on the tumour-
suppression activity of P53 gene. The mechanisms involved in diverse ATR 
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regulation by PhIP in lymphocyte from healthy individuals compared to those 
from pre-cancerous patients are not fully understood.  
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Figure 5.7 The expression of ATR and P53 mRNA in lymphocyte from healthy individuals 
(A) and pre-cancerous patients (B) after treating with PhIP (100µМ), MYR B (10µM) with PhIP 
and MYR N (20µM) supplemented with PhIP. GAPDH was used as an internal control   gene. 
Gene expression analysis was performed on lymphocytes after 24-hour treatment. Values are 
the means of three independent experiments, and the error bars represent SDs. (*p<0.01, ** 
p<0.01, ***p<0.001, ns=not significant). Horizontal lines on the graph represent the difference 
between the groups.  Data were compared against the control (C). All data were normalised 
against GAPDH reference gene. 
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5.3.7 Analysis of P53 and Bcl-2 expression in lymphocytes from    
healthy individuals  
 
As part of this study an investigation was carried out to determine the effect of 
PhIP treatment and co-supplementation of myricetin bulk and nanoparticles on 
the protein expression of major anti-apoptotic, Bcl-2 and tumour-suppressor, 
P53. The expressions were analysed using Western blotting. Results show (Fig 
5.8) that P53 and Bcl-2 levels were decreased by 0.6-fold and 0.7-fold, 
respectively when healthy lymphocytes were exposed to PhIP (100µМ). 
However, combination of PhIP with either MYR B or MYR N significantly 
increased the expression of both proteins. With MYR B administration, a 1.5-
fold increase was observed in P53 and 1.49-fold increase in Bcl-2 expression. 
MYR N enhanced the levels of former to 1.7-fold and Bcl-2 was up-regulated by 
1.52-fold. These results from Western blot analysis indicated that MYR B and 
MYR N might suppress the mutagenicity caused by PhIP in lymphocytes from 
healthy individuals by stimulating the expression levels of tumour-suppressor 
protein, P53 and anti-apoptotic Bcl-2, ultimately causing a protective and anti-
tumour effect. Moreover, MYR N has shown more protective results compared 
to MYR B.  
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Figure 5.8 Modulating effects of myricetin bulk and nanoparticles on PhIP-triggered 
alterations in protein expression of P53 and Bcl-2 in healthy lymphocytes (A) Immunoblot 
analysis of the p53, and bcl-2 proteins in lymphocyte from healthy individuals treated with PhIP 
(100µМ), MYR B (10µM) with PhIP and MYR N (20µM) supplemented with PhIP. P53 and Bcl-2 
expression was decreased after PhIP treatment. Supplementation of MYR B and MYR N 
significantly increased the expression levels of both proteins compared to PhIP alone treated 
group. GAPDH was used as an internal control protein to normalise the data. (B) Bar graphs 
exhibiting fold changes in protein expression levels. Data are represented as the mean ± SEM 
of three experiments. ***P<0.0001 
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5.4 Discussion 
 
This study focused on the effects of the food-mutagen, PhIP in lymphocytes 
from pre-cancerous patients compared to those from healthy individuals and the 
modulating effects of myricetin against PhIP-induced damage. PhIP has 
previously been shown to be genotoxic producing DNA adducts (Brown et al., 
2001) and contributing towards the formation of dietary cancers (Cheung et al., 
2011; Voutsinas et al., 2013). First we demonstrated that PhIP induces 
significant levels of DNA damage and strand breaks in lymphocytes from 
healthy and patient groups, determined by the Comet and micronucleus assays 
(p<0.001), supporting previous studies (Mimmler et al., 2016; Buonarati et al., 
1990; Boobis et al., 1994). Results from the micronucleus assay have shown a 
significant induction of MNi formation in BiNC after treatment with PhIP alone 
((p<0.001).  A MN formed in BiNC only depicts the damage caused after the 
treatment, hence reducing the probability of scoring the pre-existing damage 
(Magdelenova et al., 2012). In micronucleus assay we had to rely on results 
deducted from 1000 cells scored per treatment group due to manual scoring. 
However, in future, automated micronucleus scoring techniques could be 
applied to score a much greater number of cells making the effect more 
apparent.  
Our results confirms that PhIP being a genotoxic agent causes significant DNA 
damage in lymphocytes from healthy individuals and those from pre-cancerous 
patients. However, upon treatment with myricetin (MYR B 10µМ and MYR N 
20µМ), PhIP-induced damage was reduced to a substantial level presented by 
both the Comet and cytokinesis-block micronucleus assay (figure 5.3a, b, 5.4a, 
b, 5.5). MYR B was effective in reducing the damage moderately (P<0.004) 
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whereas, MYR N was more protective against the damage (P<0.002). Both the 
control lymphocytes and patient lymphocytes showed high sensitivity to PhIP in 
the Comet assay. Lymphocytes from the pre-cancerous patients had an 
increased level of basal damage, possibly due to overproduction of ROS and 
there was a greater difference between the damage measured in lymphocytes 
treated with PhIP alone and those supplemented with MYR B (10µМ) and MYR 
N (20µМ). It is believed that food mutagens damage the DNA by producing 
ROS and flavonoids act in an anti-oxidant manner to reduce this damage 
(Kurzawa et al., 2012). Therefore, DNA damage caused by PhIP in lymphocytes 
from both investigative groups could possibly be because of dual mechanisms: 
CYP1A2-induced or ROS-induced genotoxicity.   
The findings from the current study confirm that myricetin is effectively able to 
prevent the DNA of lymphocytes from healthy and pre-cancerous patients from 
PhIP induced-DNA damage. To find whether the protective effects of myricetin 
are due to its anti-oxidant properties we further investigated the effects of PhIP 
and co-supplementation of myricetin on the intracellular oxidative defence 
mechanisms by determining the levels of anti-oxidant enzyme GSH. GSH is 
major tissue anti-oxidant and the depletion of this crucial enzyme increases the 
susceptibility to oxidative stress, characterized by the accumulation of ROS 
(Gawryluk et al., 2011). Glutathione (GSH) is the smallest intracellular protein 
thiol molecule present in the cells that inhibits ROS (such as free radicals and 
peroxides) induced cell damage.  
GSH is present in two forms, oxidised (GSSG) and reduced (GSH). In healthy 
cells, the total glutathione pool is mostly in the reduced form (GSH). It is the 
reduced one which protects against ROS by donating an equivalent ion to the 
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one being detoxified. However, when cells are exposed to increased levels of 
oxidative stress, oxidized GSH (GSSG) starts accumulating and the ratio of 
GSSG to GSH rises. Hence, a bigger ratio of GSSG-to-GSH is an indication of 
oxidative stress (Roy and Sil, 2012). 
Hydrogen peroxide is cleansed through GSH peroxidase (GPx), giving rise to 
GSSG which is then recycled back to the reduced form by GSH reductase (GR) 
(Meister, 1988). Therefore, conservation of sufficient GSH levels is crucial for 
protection against oxidative damage. Our results did not show any effect on 
GSH levels. However, oxidative DNA damage can be effectively assessed 
using the FPG Comet assay in future to develop a more precise conclusion on 
this. FPG Comet can effectively analyze the potential of any compound to 
induce oxidative damage and DNA strand breaks (Müller, et al., 2013). 
Previous studies have shown that the apical DDR kinases such as ATR and 
ATM can be directly activated by DNA adducts apart from the replication 
dependent stimulation (Choi et al., 2007; Choi et al., 2009; Kemp et al., 2011). 
Based on our results from the Comet assay, we established that PhIP induces 
strand breaks and that myricetin protects against their induction. Hence, to 
understand the DDR elicited by PhIP and myricetin, we investigated the gene 
expression levels of ATR kinase and tumour-suppressor gene P53 in 
lymphocytes from healthy individuals and pre-cancerous patients. Similar 
patterns of results were obtained for the P53 gene in lymphocytes from both 
groups. P53 was down-regulated upon PhIP treatment whereas MYR B and 
MYR N supplementation has shown significant attenuation of PhIP-triggered 
effects and increased the expression of P53 to substantial levels.  
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However, PhIP has shown diverse effects on the ATR kinase activity in 
lymphocytes from healthy individuals compared to those from pre-cancerous 
patients. It has significantly increased the ATR gene regulation in healthy 
lymphocytes which was further enhanced by myricetin supplementation 
(p<0.001). This was in agreement with previous studies that upon provoking 
replication stress, PhIP activates ATR-CHK1 pathway in V79 CS cells (Mimmler 
et al., 2016).  
These results propose that myricetin may protect against the mutagenicity 
caused by PhIP in healthy lymphocytes by triggering the activation of ATR in 
P53-mediated DDR pathway. Hence, contribute towards the survival path by the 
balancing of pro-survival and pro-death signals and through repairing of the 
cells. To confirm this notion, the post-transcriptional protein levels of P53 and 
the anti-apoptotic protein Bcl-2 were investigated in healthy lymphocytes. The 
results demonstrated a significant down-regulation in the expression of both 
proteins upon PhIP treatment and significant attenuation of the PhIP-induced 
effects by myricetin supplementation.  
On the other hand PhIP significantly (p<0.01) down-regulated the ATR kinase 
activity, in lymphocytes from the patient group. However, myricetin effectively 
weakened the effects of PhIP and significantly increased ATR regulation.  Since 
the ATR inhibition and increased sensitivity caused by PhIP in patient 
lymphocytes and the protection shown by myricetin were both dependent on the 
P53 pathway.  This suggests that myricetin could potentially induce apoptosis in 
PhIP-treated lymphocytes from pre-cancerous patients. Also, the protection 
depicted by myricetin against PhIP-induced damage may be attributed to its 
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anti-tumour activity by stimulating the levels of the P53-tumour suppressor 
gene.   
Other possible mechanisms involved are still needed to be investigated further 
such as the self-repair capacity of lymphocytes by measuring the DNA damage 
at different time periods using the Comet assay. 
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Chapter 6: The anti-cancer potential of myricetin in lymphocytes from 
multiple myeloma cancer patients 
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6.1 Introduction 
 
Multiple myeloma is a cancer of plasma cells where abnormal plasma cells 
proliferate and stop producing important antibodies. It is more common in 
elderly people (Palumbo and Anderson, 2011). Around 1 in 100 people with its 
precursor disease, MGUS, develop myeloma each year (Rajkumar, et al., 
2014). Chemotherapy, steroids, biological therapies and possibly stem cell 
transplant are the treatment methods currently being utilised for the therapy of 
multiple myeloma. Initially chemotherapy combined with other treatments works 
effectively, but myeloma patients usually always have a relapse and these 
drugs cause various side effects as well including alopecia, nausea, 
neuropathy. Therefore more effective drugs and novel therapies are required for 
human cancers (Huang et al., 2015). 
Cell cycle is a fundamental process of a cell leading to its division and 
duplication and ensures the homeostasis in an organ, while a dysregulation in 
any of its step or components could lead to cancer development. The molecular 
targets involved in the cell cycle regulatory mechanisms are the main focus of 
investigational anticancer drugs (Diaz-Moralli et al., 2013). Apoptosis is a 
mechanism of programmed cell death (PCD) occurring in multicellular 
organisms. Maintenance of its balance is highly essential for normal growth as 
excessive apoptosis causes atrophy whereas faulty apoptosis leads to 
uncontrolled cellular growth which is implicated in various illnesses including 
cancer. Hence inducing apoptosis may be a promising strategy to overcome 
various problems related to cancer therapies (Hall et al., 2008). Various 
processes are involved in inhibition of apoptosis in cancer cells such as P53 
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mutations and expression of P-glycoprotein. Two major pathways associated 
with apoptosis are intrinsic (mitochondrial), driven by Bcl-2 family proteins by 
controlling mitochondrial membrane permeability and release of pro-apoptotic 
factors and extrinsic (receptor mediated), regulated by tumour necrosis factor-
related apoptosis inducing ligand (TRAIL) by mediating its receptors (Brunelle 
and Letai 2009). Mitochondria play a key role and apoptosis and other cellular 
metabolic processes. When apoptosis is induced, a variety of metabolic signals 
produced by mitochondria, cytosol and the membrane are triggered by stimuli. 
These signals can disrupt the energy metabolisms and modify the expression of 
Bcl-2 family proteins (Seo, et al., 2003). Upon sensing death signals, 
mitochondria may release death factors such as cytochrome complex (cyt c) 
which plays important role in stimulating apoptosis and regulating the oxidative 
phosphorylation of mitochondria. When released into the cytosol, cyt c binds 
with Apaf-1 to develop a complex with caspase 9 following the initiation of 
downstream caspases to slice cellular substrates (Katoh et al., 2004; McDonnell 
et al., 2003). Reactive oxygen species (ROS), mainly produced by mitochondria 
intracellularly, are considered to be the second messenger to participate in 
cellular mechanisms such as apoptosis and proliferation. The anticancer drugs 
including Taxol induce apoptosis in cancer cell mediated by increasing 
intracellular ROS levels (Perkins et al., 2000; Varbiro et al., 2001). These data 
show correlation between ROS, mitochondria and apoptosis but this still needs 
to be clarified whether cross-talks exist between these components. Anti-
apoptotic proteins such as Bcl-2 stop the occurrence of apoptosis by inhibiting 
the release of cyt c into the cytosol and by maintaining the mitochondrial 
homeostasis (Gabriel et al., 2003). Pro-apoptotic members of Bcl-2 family 
proteins such as Bax, forming mitochondrial transmembrane networks, trigger 
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mitochondrial dependent apoptosis by facilitating the release cyt c and other 
death factors into cytoplasm (Zhang et al., 2003). 
Many research studies associated with flavonoids have discussed and focused 
on their antioxidant properties but a number of epidemiological studies in 
various cell lines and models have shown a relationship between flavonoids 
intake in our diet and low risk of tumorigenesis and their anticancer properties. 
Flavonoids might have characteristic to prevent inflammation and oxidation, 
reduce cell proliferation and angiogenesis and stimulate apoptosis (Gates et al., 
2009).    Past studies have shown, in vitro cytotoxicity exhibited by flavonoids in 
various cell lines, including colon cancer cells (Takagaki et al., 2005), prostate 
cancinoma cell (Shukla and Gupta 2006), hepatoma cells (Chiang et al., 2006) 
and cervical carcinoma cells (Zheng et al., 2005).  
Many past studies have demonstrated that myricetin induces apoptosis in 
various cancer cell lines comprising hepatoma, colon carcinoma cells, 
oesophageal and pancreatic cancer (Phillips et al., 2011; Zhang et al., 2013; 
Zang et al., 2014). It has been previously shown that flavonoids have the ability 
to reduce the viability of tumour cells by the induction of apoptosis and that both 
ROS dependent and independent pathways may be involved (Chen et al., 2003; 
Ko et al., 2004). In the literature, there is no evidence of research on the 
mechanism of action of myricetin bulk and nanoparticles in lymphocytes of 
multiple myeloma patients. We have chosen MM as target blood cancer due to 
its association with MGUS. MGUS is a common condition where a small 
number of plasma cells start producing paraprotein, and it has been shown that 
patients with MGUS have a greater risk of developing MM (Rajkumar et al., 
2014) and our initial work involved those pre-cancerous patients who have this 
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condition. As MM originates from the plasma cells which are a type of B 
lymphocytes, hence, in our current study we used surrogate cells, lymphocytes, 
as model cells to examine the effects of different particle sizes of myricetin i.e. 
the bulk (MYR B 10µМ) and nanoparticle form (MYR N 20µМ), from multiple 
myeloma patients and also investigate the molecular mechanisms involved in 
their effects.  We further investigate the effects of myricetin on intracellular ROS 
levels in lymphocytes. 
6.2 Materials and Methods 
 
6.2.1 Cell culture and reagent 
 
Multiple myeloma patient blood was kindly provided by the Department of 
Haematology, Bradford Royal Infirmary BRI, Bradford, UK. Normal healthy 
blood was donated by healthy individuals. Ages for all individuals from both 
investigative groups were best matched and the Comet assay results show no 
significant difference in DNA damage due to age factor (figure 2.1, chapter 2).  
Lymphocytes from all the blood samples (table 6.1 and 6.2) were isolated and 
maintained in RPMI-1640 medium (Sigma Aldrich, UK), Supplemented with 
10% foetal bovine serum FBS (Invitrogen, UK) and 1% penicillin streptomycin 
(Invitrogen, UK) in a humidified incubator at 5% CO2 and at 370C. Myricetin was 
purchased from Sigma Aldrich, UK and was dissolved in excipient mixture to 
produce its bulk and nano forms. The primary antibodies against P53, Bcl-2, 
Bax and GAPDH were purchased from Abcam, Cambridge, UK. 
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No Age Ethnicity  Gender  Smoking 
history 
Family history 
1 60 ASIAN M YES NONE 
2 59 CAUCASIAN F YES NONE 
3 61 CAUCASIAN F NO NONE 
4 52 CAUCASAIN F NO NONE 
5 60 CAUCASIAN F NO NONE 
6 55 CAUCASIAN M NO NONE 
 
Table 6.1 Brief information of blood samples from healthy individuals used in this chapter 
No Age Ethnicity  Gender  Smoking 
history 
Family 
history 
Medical 
condition 
1 55 CAUCASIAN F NO NONE MULTIPLE 
MYELOMA 
2 56 CAUCASIAN M NO PANCREATIC 
CACNER 
MULTIPLE 
MYELOMA 
3 79 CAUCASIAN M NO BREAST 
CANCER 
MULTIPLE 
MYELOMA 
4 77 CAUCASIAN F NO OVARIAN 
AND BREAST 
CANCER 
MULTIPLE 
MYELOMA 
5 70 CAUCASIAN M NO NONE MULTIPLE 
MYELOMA 
6 87 CAUCASIAN M NO NONE MULTIPLE 
MYELOMA 
 
Table 6.2 Brief information of blood samples from MM patients used in this chapter 
6.2.2 Procedures used 
 
For detailed procedures of cell viability using MTT, determination of ROS 
production, DNA damage assessment using the Comet assay, Western blot 
analysis, and the real-time RT-PCR analysis, please refer to chapter 2. The 
primers used for RT-PCR are listed in table 6.3.  
6.2.3 Statistical analysis 
 
Results were expressed as mean ± standard error of mean (SEM). Graph Pad 
prism was used to perform statistical calculation. The results were analysed 
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using t-tests and one-way analysis of variance (ANOVA) to test differences 
between each treatment and control. A p-value of <0.05 was considered 
statistically significant. 
Genes Primer Sequence 5’-3’ 
Bcl-2                              
 
 
CTTTGAGTTCGGTGGGGTCA 
GGGCCGTACAGTTCCACAAA 
 
Bax  
AAGCTGAGCGAGTGTCTCAAG 
 
CAAAGTAGAAAAGGGCGACAAC 
 
P53   
CTCCTCAGCATCTTATCCGAGT 
GCTGTTCCGTCCCAGTAGATTA 
 
GAPDH  
TGCACCACCAACTGCTTAG 
AGTAGAGGCAGGGATGATGTTC 
 
 
 
Table 6.3 Primers used for Real-Time PCR analysis 
6.3 Results  
 
6.3.1 MTT assay 
 
The MTT assay was performed to assess the cytotoxic effects of both forms of 
myricetin and the results demonstrated a time and dose-dependent cytotoxicity 
in human lymphocytes. The effects of MYR B (10-40µМ) and MYR N (10-40µМ) 
on the viability of healthy lymphocytes at different times (1, 24 and 48hrs) 
compared to the respective untreated group have already been shown in figure 
3.4 A where MYR B and MYR N exhibited a time and concentration dependent 
decrease in cell viability. MYR B (40µМ) and MYR N (40µМ) reduced the 
viability in lymphocytes from healthy individuals to 88% and 86% respectively, 
after a 48 hours treatment. Neither of the concentrations of MYR B and MYR N 
reduced viability less than 80% in healthy group. However, MYR B and MYR N 
at 40µМ reduced the viability to 68% and 51% respectively after 48 hours of 
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treatment (Fig 6.1), in lymphocytes from multiple myeloma patients. Lower 
concentrations (10 and 20µМ) of both forms of myricetin did not reduce the 
viability less than 80% in lymphocytes from the patient group. The effects of the 
excipient mixture (the vehicle mixture for chemical preparation) were also 
considered to exclude any errors. Myricetin in both forms showed higher level of 
cytotoxicity in lymphocytes from myeloma cancer patients than in those from 
healthy individual at higher concentrations indicating that cancer cells are more 
sensitive to myricetin bulk and nanoparticles than the healthy ones possibly due 
to the compromised defense and repair mechanisms owing to the disease state. 
Hence, the current study was conducted using non-toxic concentrations of MYR 
B and MYR N so that any of the results obtained are not due to artefact of 
toxicity. The non-genotoxic concentrations used for MYR B and MYR N are 
10µМ and 20µМ respectively, determined by dose response curve (Figure 3.3) 
throughout the current in vitro study.  
 
172 
 
1  
H
o u
r
2 4
 H
o u
rs
4 8
 H
o u
rs
0
5 0
1 0 0
1 5 0
L y m p h o c y te s  f r o m  m y e lo m a
 p a t i e n t s
T im e  ( h o u r s )
C
e
ll
 V
ia
b
il
it
y
 (
%
 o
f 
c
o
n
tr
o
l) N C
E M  0 .1 %
M Y R  B  ( 1 0 µ Μ )
M Y R  N  ( 1 0 µ Μ )
M Y R  B  ( 2 0 µ Μ )
M Y R  N  ( 2 0 µ Μ )
M Y R  B  ( 4 0 µ Μ )
M Y R  N  ( 4 0 µ Μ )
n s
n s n sn sn s ***
***
n s
n s * * * ***
***
n s
n s
** **
***
***
***
 
Figure 6.1 Determination of cell cytotoxicity by MTT based assay. Lymphocytes from MM 
patients showing cell viability after treatment with different concentrations of myricetin 
bulk and nanoparticles Cell cytotoxicity was expressed as % of the control for 1, 24 and 48h. 
The treatment groups included untreated (NC), MYR B (10µМ, 20µМ and 40µМ), MYR N 
(10µМ, 20µМ and 40µМ) and EX (excipient mixture 0.1%). The best concentrations for MYR B 
and MYR N were determined by dose response curves.  Values are the means of three 
independent experiments and the error bars represent SDs. (ns=not significant, *P<0.01, 
**P<0.003, ***P<0.0001) 
6.3.2 The Comet assay 
 
DNA damage and strand breaks formation caused by MYR B (10µМ) and MYR 
N (20µМ) in lymphocytes from healthy individuals and myeloma cancer patients 
was assessed at basal levels without supplementation of any stress inducer 
using the Comet assay. Fig 6.2 (A, B) shows no significant DNA damage 
induced by MYR B and MYR N in healthy lymphocytes. However, results shown 
in fig 6.3 (A,B) indicate that  DNA damage was induced in the patient group by 
both forms of myricetin as compared to the untreated group but the levels were 
not significant when presented using two parameters; % Tail DNA and Olive 
Tail moment. 
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Figure 6.2 The response of bulk and nano forms of myricetin on lymphocytes DNA from 
healthy individuals using %Tail DNA (A) and olive tail moment (OTM) (B) The figure shows 
the mean of experiments in 6 individuals, counting 100 cells each for four different groups of 
treatments; an untreated lymphocyte group (NC), positive control (PC) 50µM H2O2, myricetin 
bulk (MYR B 10µM) and myricetin nano (MYR N 20µM). All treatment groups were compared to 
the NC group. The mean control value was 9 and the PC had the maximum mean value of 36 
for % Tail DNA.( ***P<0.001,ns means not significant analysed by one way ANOVA.. The mean 
control value was 0.7 and the PC had the maximum mean value of 11 for OTM. 
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Figure 6.3 The response of bulk and nano forms of myricetin on lymphocytes DNA from 
myeloma patients using %Tail DNA (A) and Olive tail moment (OTM) (B) The figure shows 
the mean of experiments in 6 individuals, counting 100 cells each for four different groups of 
treatments; an untreated lymphocyte group (NC), positive control (PC) 50µM H2O2, myricetin 
bulk (MYR B 10µM) and myricetin nano (MYR N 20µM). All treatment groups were compared to 
the NC group. The mean control value was 14 and the PC had the maximum mean value of 32 
for % Tail DNA. The mean control value was 2.7 and the PC had the maximum mean value of 
9.3 for OTM.  **P<0.0001,*P<0.001, ns means not significant) analysed by one way ANOVA. 
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6.3.3 Real-time PCR 
 
Based on the previous results from MTT and the Comet assay, we piloted that 
myricetin bulk and nanoparticle forms do not induce statistically significant DNA 
damage in lymphocytes from myeloma cancer patients compared to those from 
healthy individuals. To study the molecular responses mediated by myricetin on 
the apoptotic pathway, we investigated the effects of myricetin on gene 
expression of P53, Bax and Bcl-2, in lymphocytes from healthy individuals and 
myeloma cancer patients at the mRNA level.  Real-Time PCR analysis was 
conducted for the apoptosis related genes. The results from the real-Time PCR 
analysis show that MYR B (10µМ) and MYR N (20µМ) regulate the expression 
of some genes involved in intrinsic apoptosis at mRNA level. The expression of 
Bcl-2/Bax ratio increased in healthy lymphocytes. Bax was significantly down-
regulated by 0.6-fold and 0.74-fold by MYR B and MYR N, respectively while 
Bcl-2 was up-regulated by 1.2-fold with MYR B and minutely decreased by 0.8-
fold with MYR N. However, P53 gene was insignificantly down-regulated (Fig 
6.4). PCR analysis shows a different results pattern in lymphocytes from 
myeloma cancer patients.  The expression of the tumour suppressor genes, 
P53 and pro-apoptotic gene, Bax, was significantly up-regulated by 2.0-fold and 
1.9-fold respectively, upon treatment with MYR N. When treated with MYR B, 
the former was up-regulated by 1.4-fold and the latter by 1.7-fold.  The 
expression of anti-apoptotic gene, Bcl-2, was significantly down-regulated by 
0.75-fold with MYR N and by 0.7-fold with MYR B (Fig 6.5). Results show the 
alterations in these three genes (P53, Bax, Bcl-2), indicating the apoptotic 
potential of myricetin in lymphocytes from myeloma cancer patients might be 
dependent on expression levels of P53 gene.  
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Figure 6.4 The effect of MYR B and MYR N on the gene expression levels of Bax and Bcl-
2 and P53 in lymphocytes from healthy individuals. All results were compared against 
control group (C) and normalised against the internal gene, GAPDH, Bax is significantly 
decreased by both MYR B and MYR N treatments. However these treatments did not show any 
effect on P53 and Bcl-2 expression. Values are the means of three independent experiments. 
(ns=not significant, *P<0.01, ***P<0.002) 
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Figure 6.5 The effect of MYR B and MYR N on the gene expression levels of Bax and Bcl-
2 and P53 in lymphocytes from untreated multiple myeloma (MM) patients. All results were 
compared against control group (C) and normalised against the internal gene, GAPDH where 
n=4. The m RNA P53 and Bax expression increased with both form of myricetin whereas Bcl-2 
expression decreased. (ns=not significant, *P<0.01, ***P<0.001) 
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6.3.4 Effects of myricetin bulk and nanoparticles on the proteins involved 
in intrinsic apoptotic pathway in isolated lymphocytes 
 
A series of Western blot experiments were piloted to find whether the changes 
in the gene expression of Bcl-2, Bax and P53 at mRNA level ultimately leads to 
the alterations at the protein expression level. 
6.3.4.1 Western blotting 
 
An investigation was carried out in order to find whether the mitochondrial 
dependent intrinsic pathway was involved in apoptosis induction potential of 
myriceitn. The protein expression of major pro-apoptotic and anti-apoptotic 
protein levels, Bax and Bcl-2 respectively were analysed using Western blotting. 
Results show (Fig 6.6 A, B) that Bcl-2 levels were increased by 3.4-fold with 
MYR B and 2.1-fold with MYR N, in lymphocytes from healthy individuals.  
However, Bax seemed to be down-regulated, by 0.6-fold after exposing to MYR 
B and 0.4-fold with MYR N treatment. Fig 6.7 (A, B) show Bax levels were 
significantly increased by 2.9-fold with MYR B and 3-fold with MYR N, in patient 
lymphocytes.  However, Bcl-2 seemed to be significantly down-regulated, by 
0.6-fold after exposing to MYR B and 0.9-fold with MYR N treatment which is 
not significant. These results from Western blot analysis indicate that MYR B 
(10µМ) and MYR N (20µМ) might have a potential to induce apoptosis in 
lymphocytes from myeloma patients by altering the ratio of Bcl-2 family proteins 
expression. 
6.3.4.2 Role of P53 in myricetin-mediated regulation of apoptosis-
related proteins 
 
P53 is a tumour-suppressor protein which plays a vital role in several cellular 
processes including apoptosis and angiogenesis (Darcy, et al., 2008). Therefore 
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we examined P53 protein to verify if myricetin bulk and nanoparticles mediate 
effects in lymphocytes of MM patients through this protein. We found (Fig 6.6 
A,B)  that the P53 protein was up-regulated in the lymphocytes of healthy 
individuals after treatment with MYR B and MYR N, 2.2-fold and 1.8 fold, 
respectively when compared to the control. A representative immunoblot is 
shown in figure 6.6A, whilst the graph in figure 6.6B is average of three 
experiments. Fig 6.7 A, B. shows that p53 was up-regulated in the lymphocytes 
from MM patients as well, after treatment with MYR B and MYR N, 2.2-fold and 
3.2-fold, respectively when compared to the control. Increased in-vitro 
expression of P53 in lymphocytes, when exposed to myricetin, indicates that 
myricetin exhibits anti-cancer potential in lymphocytes from MM patients. All the 
results from Western blot analysis for these proteins were in agreement with the 
Real-time PCR data for the related genes. 
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Figure 6.6 The effect of Myricetin Bulk and nanoparticles on apoptosis-related proteins in 
healthy lymphocytes (A) Immunoblot analysis of the P53, Bax and Bcl-2 proteins in 
lymphocyte from healthy individuals treated with MYR B and MYR N. P53 and Bcl-2 expression 
was increased while Bax expression decreased. GAPDH was used as an internal control 
protein to normalise the data. (B) Bar graphs exhibiting fold changes in protein expression 
levels. Data are represented as the mean ± SD of three experiments. (*P<0.01, **P<0.002, 
***P<0.0001) 
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Figure 6.7 The effect of Myricetin bulk and nanoparticles on apoptosis-related proteins in 
lymphocytes from myeloma patients (A) Immunoblot analysis of the P53, Bax and Bcl-2 
proteins in lymphocyte from MM cancer patients treated with MYR B and MYR N. P53 and Bax 
expression was increased whereas Bcl-2 expression was decreased. GAPDH was used as an 
internal control protein to normalise the data. (B) Bar graphs exhibiting fold changes in protein 
expression levels. Data are represented as the mean ± SD of three experiments. (*P<0.01, 
***P<0.0001, ns=not significant) 
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6.3.5 Myricetin and ROS production 
 
We investigated if ROS has a role in alteration of apoptotic genes in 
lymphocytes from MM cancer patients in vitro compared to those from healthy 
individuals. Results demonstrate that MYR N (Fig 6.8) has significantly 
increased the endogenous peroxide levels indicated by an increase in 
fluorescence intensity compared to the untreated group. However, results 
indicate that ROS levels are decreased upon MYR B and MYR N treatment to 
statistically non-significant levels in lymphocytes from healthy individuals. These 
data suggest that the alteration in the ratio of Bcl2/Bax by myricetin in 
lymphocytes from MM patients might be dependent on ROS production. Data 
also suggests pro-oxidant activity of myricetin in lymphocytes from MM cancer 
patients. 
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Figure 6.8 Myricetin induce Reactive oxygen species (ROS) in lymphocytes from MM 
patients. Isolated lymphocytes from healthy individuals and MM cancer patients were treated 
with MYR B (10µМ) and MYR N (20µМ) while compared against the respective untreated group 
(0 µМ myricetin). The intracellular ROS levels were assessed using DCF-DA assay. Values are 
the means of three independent experiments and the error bars represent SDs, analysed by the 
two-way ANOVA. (ns=not significant, ***p<0.001) p<0.05 values were considered significant 
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6.4 Discussion 
 
Cancer is a life-threatening disease in current world and its occurrence is 
alarmingly increasing with passage of time and the main therapeutic strategies 
being utilised are chemotherapy and radiotherapy. Due to high rates of adverse 
effects and chemo resistance related to chemotherapy, there is an urgent need 
to develop some novel drugs which could address these issues (Yang et al., 
2011). Various flavonoids have been shown to induce cytotoxicity in different 
cancer cell lines such as cervical (Chiang et al., 2006), lung (Leung et al., 
2007), colon (Chen et al., 2004) and prostate cancer cells (Vijayababu et al., 
2006). However, the potential protective effects of myricetin on the lymphocytes 
from MM cancer are rarely reported. Similarly many past studies have reported 
myricetin causing apoptosis in various cancers including colon, hepatoma, 
esophageal and pancreatic etc. (Zhang et al., 2013; Phillips et al., 2011; Zang 
et al., 2014; Kim et al., 2014). Conversely, its effects on MM are currently not 
known. 
Myricetin is found extensively in vegetables and fruits and has health beneficial 
effects but its apoptotic effects are still unclear (Pérez-Cano and Castell 2016). 
It was found that myricetin in both forms (MYR B 10µМ, MYR N 20µМ) has not 
induced any statistically significant DNA damage in lymphocytes from MM 
patients compared to the healthy lymphocytes determined by the Comet assay 
results. The results from the Comet assay also revealed that there were no 
significant differences in DNA damage of patient group due to the age factor 
(figure 2.1). 
Apoptosis, a process of programmed cell death is an important factor to get rid 
of cancer cells. A mechanism through which cancer cells form resistance to 
183 
 
chemotherapy is by avoiding apoptosis and enhancing proliferation. Two main 
pathways involved in apoptosis are; intrinsic (mitochondrial dependent) and 
extrinsic (receptor-mediated) pathways. Upon activation of the intrinsic pathway, 
the mitochondria permeability and the release of cytochrome complex (cyt c) 
into the cytosol increase. This forms a multi-protein complex called apoptosome 
which then triggers the initiation of caspase-9. The Bcl-2 family proteins play a 
vital role in regulation of this process by monitoring the permeability of the 
mitochondrial membrane and through the release of pro-apoptotic elements. 
The fate of cells to undergo apoptosis or not mainly depends on the balance 
between the pro (e.g. Bax, Bad) and anti-apoptotic (e.g. Bcl-2, Bcl-xl) factors of 
the Bcl-2 family (Brunelle and Letai, 2009). Extrinsic apoptotic pathway involves 
receptor DR5, caspases 8 and 10 regulation. Whether the apoptosis is initiated 
by intrinsic or extrinsic pathway, it ultimately leads to activation of caspase 3 
and 7 respectively, concluding the apoptosis. In the current study myricetin bulk 
and nano forms were found to significantly up-regulate Bax/Bcl-2 protein ratio in 
lymphocytes from MM patients (likely to affect apoptosis) but not in those from 
healthy individuals. This might be due to differential effects of myricetin on 
healthy and patient lymphocytes. This suggests that myricetin could potentially 
induce intrinsic mitochondrial dependent apoptosis in lymphocytes from MM 
patients. In future, the possibility of looking at apoptotic cell numbers using 
various techniques including TUNEL assay and flow cytometry analysis of 
apoptotic markers following treatment of lymphocytes with myricetin, could help 
to confirm the apoptosis-inducing potential of myricetin bulk and nano forms in 
lymphocytes from MM patients. 
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Our results are consistent with a previous study where myricetin induced 
apoptosis in colon cancer cells by increasing the ratio between Bax and Bcl-2 
protein levels (Kim et al., 2014).  
The functional association between the ROS and mitochondria are not 
understood but various studies have shown the positives and negatives on this 
aspect. A variety of stimuli triggers cyt c release and apoptosis through ROS 
production. However, ROS also play a mitogenic role by inducing proliferation 
and protecting cells against oxidative stress-induced apoptosis (Kim et al., 
2001; Kops et al., 2002). Hence, data suggest a dual function of ROS. In our 
study the increase in the ratio between Bax and Bcl-2 in lymphocytes from 
myeloma patients was also dependent on ROS production as ROS levels 
increased slightly with myricetin bulk and significantly increased with myricetin 
nano treatment when compared to the untreated control and healthy control 
group (fig 6.8).  
P53, a multiple functional tumour suppressor protein plays a key role in 
regulation of various cellular processes including apoptosis, controlling cell 
cycle progression, transcription, angiogenesis, DNA repair and senescence 
(Darcy et al., 2008). In presence of DNA damage, P53 inhibits the proliferation 
of damaged cells by different regulatory processes (Haupt et al., 2003; Haupt 
and haupt, 2017). In a number of human cancers, this house-keeper gene is 
inactivated (loss of normal function) by mutation leading to unmonitored cell 
growth. Genetic lesions of P53 occurring one on each of the two alleles in every 
cell, leads to complete inactivation of P53 and development of a tumour. Hence 
the cancer cell is usually a condensed hemizygous mutant for P53 gene. The 
alterations in the P53 gene are connected with failure in chemotherapy and 
radiotherapy in various human cancers (Kong et al., 2012). Reintroduction of 
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wild type P53 into cancer cells which possess its mutant form, leads to either 
apoptosis or cell cycle arrest (Martinez et al., 1991).  The ability of P53 to inhibit 
cell proliferation, causing cell cycle arrest and apoptosis depends mainly on its 
binding to the target genes involved in these processes (Moll and Slade 2004). 
Recently, the concept of cell-cycle regulated apoptosis is gaining increasing 
emphasis for eliminating cancer cells (Calcabrini et al., 2006). Increasing the 
amount of P53 may be a new strategy for treating cancer as it regulates the 
intrinsic apoptosis pathway such as Bax (kuo et al., 2006). Flavonoids such as 
myricetin are considered as promising chemicals with ability to selectively 
eliminate cancer cells by cell-cycle arrest or/and apoptosis (Choi et al., 2001; 
Wang et al., 2004; Hsu et al., 2004; Ujiki et al., 2006; Mu et al., 2007; Shukla 
and Gupta, 2007; Pérez-Cano and Castell 2016). 
In the present study, myricetin bulk and nanoparticles were observed to 
increase the level of P53 gene in lymphocytes from myeloma patients at mRNA 
and protein level (fig 6.5, 6.7). 
Also, the structural properties of myricetin (OH groups at C3’, 4’ and 5’) might 
have possibly played a role in its anticancer and apoptosis-inducing potential, 
supported by a past study (Ko et al., 2004). 
In conclusion, myricetin bulk and nanoparticles have exhibited anticancer 
potential and pro-oxidant activities in lymphocytes from MM cancer patients. It 
has altered the levels of Bcl-2 family proteins, regulated by P53 and somehow 
dependent on ROS production. This is indicative of the potential of myricetin to 
induce apoptosis in lymphocytes from MM patients and to be possibly used as 
an anticancer drug for MM. Moreover, MYR N (20µМ) has collectively shown 
more effective responses than its larger particles (i.e. MYR B 10µМ) in 
lymphocytes from both investigated groups. 
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7.1 General Discussion 
 
The present study was conducted to investigate the genoprotective and 
genotoxic effects of myricetin bulk and nano forms in lymphocytes from pre-
cancerous and MM patients while compared to those from healthy individuals. 
Also, to determine the anti-oxidant potential of myricetin bulk and nano forms in 
lymphocytes form pre-cancerous patients and healthy individuals by measuring 
their effect against ROS-induced oxidative stress. The modulating effects of 
myricetin against PhIP-induced DNA damage were also studied. 
Cancer presents a major public health threat in both the developed and 
developing world. Prevention of cancer, by use of natural dietary constituents, is 
a promising strategy to overcome the dogma linked with a constantly growing 
number of cancers worldwide (Tsao and Edward, 2004). Plant derived phenolic 
compounds are probably the most studied natural compounds due to their vast 
potential health beneficial effects, as proposed by various studies (Del Rio et 
al., 2010). Flavonoids, tanins and phenolic acids are major classes of phenolics 
and reflect the main ones consumed in our diet (Balasundram et al., 2006). 
Flavonoids constituting the largest group of plant phenolics exhibit a diverse 
spectrum of pharmacological activities including their possible anti-cancer and 
anti-oxidant property (Bhuyan and Basu, 2017). A positive association has been 
shown in the past between the flavonoids enriched diet and lower risk of many 
cancers including colon, breast and prostate cancer (Batra and Sharma, 2013). 
Flavonoids are subdivided into different classes; flavones, flavanols, flavonols, 
anthocyanins, flavonones and isoflavonols depending on their chemical 
structure. Among these, flavonols, anthocyanins and flavanols are those 
occurring most  in the human diet (obtained from plant origins) and could be 
responsible for prevention against cancer development, neurodegeneration and 
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cardiovascular diseases (Bazzano et al., 2002; Xiao et al., 2011; Atmani et al., 
2009; Fang et al., 2010). 
Myricetin (3,3’,4’,5,5’,7-hexahydroxyflavone), a major flavonol, mainly found in 
red wine, berries and vegetables, has been recently utilised as a health 
supplement owing to its significant anti-oxidant and anti-tumour activities (Miean 
and Mohamed, 2001; Hobbs et al., 2015; Miyazaki et al., 2017). Myricetin has 
been extensively studied investigating its anti-cancer potential and its 
mechanism of action against fighting different cancers (Maggiolini et al., 2005; 
Devi et al., 2015; Lu et al., 2006; Kumamoto et al., 2009; Sun et al., 2012,). For 
example, myricetin induces cell death in colon cancer cells through the Bax/Bcl-
2 dependent pathway (Kim et al., 2014). It prevents MMP- 2 protein expression 
and enzyme activity in colorectal carcinomas cells (Ko et al., 2005). Moreover, 
myricetin suppresses and attenuates the neoplasm transformation of the tumour 
cells by interacting with various oncoproteins such as protein kinase B (PKB) 
(Kumamoto et al., 2009; Sun et al., 2012; Devi et al., 2015). Studies have 
shown myricetin to display an anti-HIV-1 activity on HIV-1 infection (Pasetto et 
al., 2015) and therapeutic potential against diabetes mellitus (Li and Ding, 
2012). The diverse activities and effects exhibited by myricetin indicate that it 
interacts with numerous target proteins in divergent cell types.  
The effects of the major dietary factors (fruits, vegetables, meat, and fat) and 
other nutrients (such as vitamins, phytochemicals, minerals etc.) on 
carcinogenesis is a complex area. As well as, studying the association between 
these dietary essentials and the risk of cancer development, it is important to 
determine the underlying processes through which these elements affect 
carcinogenesis. From this perspective the Comet assay presents an excellent 
method and is a relatively easy, simple, sensitive and inexpensive way to 
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determine DNA damage and repair. Moreover, it can be used to study the 
effects of nutrition and diet on cancer. The Comet assay with its various 
modifications can be potentially used to study the nutritional-related biomarkers 
of cancer and can possibly detect cancer at an early stage in every individual 
(Wasson et al., 2008; Anderson et al., 2018). Therefore, we used this highly 
sensitive and reliable method to study the basal effects of myricetin (bulk and 
nanoparticles form) on lymphocytes from pre-cancerous (chapter 3) and 
multiple myeloma patients (chapter 6) compared to those from healthy 
individuals. Also, to determine the repair capacity of lymphocytes and 
modulating effects of myricetin on H2O2 (chapter 4) and PhIP-induced DNA 
damage (chapter 5). 
Since many studies have proposed that the combination of the Comet assay 
along with the CBMN assay is best test to evaluate the mutagenic potential and 
possible risk of cancer (Araldi et al., 2015). The CBMN assay can 
simultaneously provide substantial information about different chromosomal 
damage parameters such as gene amplification, chromosomal breakage and 
rearrangement (Fenech, 2002b). It has been used successfully worldwide as an 
approved biomarker of in vitro and in vivo genome stability studies due to its 
sensitivity, reliability and low cost (Fenech, 2001). MN determination in 
peripheral lymphocytes is widely used in genotoxicology to assess 
chromosomal damage caused by various genotoxic agents (Fenech et al., 
1999).  
We therefore used the CBMN assay for the first time to determine the effects of 
MYR B (10µМ) and MYR N (20µМ) in lymphocytes particularly from pre-
cancerous patients to confirm our results from the Comet assay. 
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As we used the two different particle sizes of myricetin (bulk and nano) and 
knowing that the toxicity of NPs is considered as a major concern when using 
them in genotoxicity studies, we therefore determined the cell viability and 
cytotoxicity of chemicals under test, using the trypan blue exclusion and MTT 
assay respectively, in lymphocytes from all the investigative groups including 
healthy individuals, pre-cancerous patients and multiple myeloma (MM) patients 
for 1, 24 and 48 hrs. Various concentrations of chemicals were considered. 
Analysis of results shows that cell viability did not drop below 80% in 
lymphocytes from healthy individuals and pre-cancerous patients at any 
considered concentration (chapter 3, figure 3.3). However, both forms of 
myricetin induced a time and dose dependent cytotoxicity in lymphocytes from 
MM patients when compared the healthy control only at higher concentrations. 
The cell survival decreased to 68% and 51% by MYR B (40µМ) and MYR N 
(40µМ) correspondingly after 48 hours of treatment (figure 6.1). Therefore, in 
the current study, only non-toxic concentrations with viability more than 80% 
(Henderson et al., 1998) were used to exclude any artefact effects due to 
toxicity. The genotoxic potential was also assessed employing the Comet assay 
where both forms of myricetin induced a concentration dependent genotoxicity 
only at higher concentrations. Indicated by the results only the optimal non-
genotoxic concentrations determined by both parameters of the Comet assay 
(10µМ for MYR B and 20µМ for MYR N) were chosen to be used throughout the 
current in vitro study involving lymphocytes from healthy individuals, pre-
cancerous blood patients and MM patients.  
The results from the Comet assay have shown that the optimal doses used for 
MYR B (10µМ) and MYR N (20µМ) were non-genotoxic exhibiting no 
statistically significant DNA damage, in lymphocytes from pre-cancerous 
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patients, MM patients and those from healthy individuals when compared to 
their respective negative control groups(figure 3.5, 3.6, 6.2, 6.3). High levels of 
basal DNA damage were observed throughout the in vitro study in lymphocytes 
from patient group. When lymphocytes from pre-cancerous patients and healthy 
individuals were exposed to 50 µМ H2O2, a known stress inducer, DNA damage 
was significantly increased which was substantially attenuated by MYR B and 
MYR N (p<0.001) addition (figure 4.4 A, B). However, MYR N has proven to be 
more effective against the damage. These results suggest genoprotective and 
anti-oxidant activities of MYR B and MYR N at lower non-genotoxic 
concentrations of 10µМ and 20µМ respectively, attributed by reduction in H2O2-
induced DNA damage. 
The effects of PhIP, in lymphocytes from pre-cancerous patients and healthy 
individuals were also investigated using the Comet assay. PhIP is an 
abundantly occurring HCA and a well-studied dietary mutagen/carcinogen and it 
has been shown to cause various types of DNA damage (Mimmler et al., 2016).  
PhIP treatment induced statistically significant DNA damage in lymphocytes 
from both groups (p<0.001)(figure 5.3 and 5.4). The patient group has shown 
increased sensitivity to PhIP may be due their compromised genome stability 
owing to the disease status (figure 5.4 a, b).  MYR B (10µМ) and MYR N 
(20µМ) addition however, could significantly decrease the PhIP-mediated DNA 
insult and MYR N (p<0.001) has shown a better genoprotective effect against 
the damage. Results show the anti-mutagenic property of myricetin against 
PhIP-induced mutagenicity and that myricetin could protect the lymphocytes 
(both healthy individuals and pre-cancerous patients) from the deleterious 
effects of PhIP, ultimately protecting the cells from carcinogenesis, enhancing 
their repair capacity and promote the survival of the cells.  
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In the current study the results from the CBMN assay revealed that the 
frequencies of all the assay parameters such as MNi, nuclear buds and bridges 
were higher in pre-cancerous patient group at basal level compared to the 
healthy control group. Consistent with our results from the Comet assay MYR B 
(10µМ) and MYR N (20µМ) treatment induced no significant damage to the 
cells at chromosomal level; neither had they induced any nuclear buds or 
bridges (Table 3.6).  Evaluation of the assay results shows that the incidence of 
MNi in BiNC from healthy volunteers and pre-cancerous patients declined when 
treated with myricetin bulk and the nanoparticle form but effect was not 
significant (Figure 3.8a). There were a few MNi seen in MoNC of healthy 
individuals which gives indication of little pre-existing damage due to lifestyle 
factors or any medical procedure undertaken. However, this number increased 
in the patient group pointing towards already present basal DNA damage. 
Myricetin nano (20µМ) significantly reduced the MNi formation in MoNC from 
pre-cancerous patients when compared to the untreated group exhibiting its 
potential to reduce the basal damage in lymphocytes from pre-cancerous 
patients. Untreated healthy individuals have shown lower levels of DNA and 
chromosomal damage than the untreated patient group observed throughout 
the study in agreement with various past studies (Blasiak et al., 2004; 
Kontogianni et al., 2007; Stoyanova et al., 2010). The effects of PhIP on 
genome stability of healthy individuals’ vs pre-cancerous patients was also 
investigated for the first time, to our knowledge, using the CBMN assay. Results 
demonstrated a significant increase in MNi formation in BiNC from both the 
investigated groups upon treatment with PhIP alone indicating the DNA damage 
was caused after the treatment (figure 5.3). Binucleated cellular division 
confirms the presence of a test chemical and DNA damage induced after 
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treatment (Doherty, 2012). However, MNi induction was inhibited to statistically 
significant levels when PhIP was combined with MYR B (10µМ) and MYR N 
(20µМ). MYR N was capable of causing better reduction in DNA damage, than 
MYR B.  These results suggest that PhIP is a clastogenic, genotoxic and 
mutagenic agent which could potentially contribute towards the carcinogenesis 
in healthy individuals as well as in pre-cancerous patients. However, myricetin 
shows the ability to attenuate the harmful effects of PhIP by decreasing the 
DNA damage in a genoprotective and anti-mutagenic manner. Also, that MYR N 
(20µМ) has shown better potential to bring these beneficial effects.  
Since myricetin exhibits strong anti-oxidant activities in various cell systems and 
cell types (Semwal et al., 2016) we considered its anti-oxidant property as the 
mode of causing protection against DNA damage by supressing ROS related 
oxidative stress in lymphocytes especially from pre-cancerous patients. 
Oxidative stress in already known as a major cell signalling regulator of various 
pathways involved in cellular injuries (Schins and Knaapen, 2007) presenting it 
as a strong determinant of the effects of myricetin. Therefore, we investigated 
for the first time the effects of MYR B (10µМ) and MYR N (20µМ) on the 
intracellular ROS present at the basal levels, as well as after induction with the 
stress inducer, TBHP in lymphocytes from healthy individuals and those from 
pre-cancerous patients. Treatment groups (MYR B and MYR N) were compared 
against the untreated controls whereas the combination groups of MYR B or 
MYR N with TBHP were compared against the positive control (TBHP alone).  
Evaluation of the results showed that myricetin in both forms significantly 
reduced the basal levels of ROS in lymphocytes from both the inspected groups 
(healthy and pre-cancerous), originally demonstrated in the current study (figure 
4.5 and 4.6). Though, MYR N has shown better protection. TBHP induced the 
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intracellular ROS to a substantial significant level i.e. 40% in both studied 
groups. However, a significant attenuation of ROS was observed when co-
treated with MYR B or MYR N. Again MYR N showed better capacity to protect 
the lymphocytes against TBHP-induced oxidative stress. These results were 
consistent with previous studies involving the protection of myricetin against 
TBHP-triggered cellular damage in various cell lines (Fraga et al., 1987; Pandey 
et al., 2009). Hence, the results suggest an overall anti-oxidant activity of MYR 
B (10µМ) and MYR N (20µМ) in lymphocytes from pre-cancerous patients and 
healthy individuals determined by a decrease in ROS levels upon treatment with 
myricetin particles alone and also against TBHP-induced effects.  
Since GSH is the main anti-oxidant defence system in our cells, we assessed 
and analysed the effects of MYR B (10µМ) and MYR N (20µМ) on the basal 
levels of the enzyme in lymphocytes from both studied groups (healthy 
individuals, pre-cancerous patients) and on H2O2 or PhIP-induced alterations in 
the enzyme levels. In-vitro treatment of lymphocytes from healthy individuals 
and patients with stress inducers H2O2 (50µM) or PhIP (100µМ) showed no 
significant effect on GSH levels or GSH/GSSG ratio. Co-supplementation of 
MYR B (10µM) and MYR N (20µM) also had no significant effect on the 
enzyme’s levels in lymphocytes from either of the investigative group (figure 4.7 
and 5.6). 
The accommodation of approximately 2m long DNAs in roughly 10µМ of nuclei 
of the human cells is made practical as a result of its organization into the 
chromatin by histone and non-histone proteins. This arrangement of DNA into 
compact chromatin is not only important for its functional effective activities but 
also for its regulation with other cellular processes (Kinner et al., 2008). 
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Alterations of chromatin have been widely studied with respect to transcriptional 
regulation but there is strong evidence now that chromatin structural 
modifications play a crucial role in the DNA repair mechanisms (Groth et al., 
2007). Human cells are prone to endogenous and exogenous damage at all the 
times. DNA lesions or damage is categorised into two types depending on the 
degree of their effects on genome integrity. The first type includes, base or 
nucleotide damage as well as some single sugar backbone interruptions; an 
error-free repair could be easily accommodated to repair these lesions with the 
help of a complimentary DNA strand as a template with minor restructuring of 
chromatin and  without much affecting the genome integrity. The other category, 
mainly includes DSBs, being lethal to cells are most deleterious types of DNA 
lesions which if left unrepaired could bring serious consequences for cellular 
survival and present a great threat to the genome integrity (Podhorecka et al., 
2010). The induction of DSBs always triggers the initiation of several factors 
including the phosphorylation of the histone H2AX, a variant of H2A family 
proteins forming γH2AX. H2AX is an element of the histone octamer in 
nucleosomes. H2AX protein is phosphorylated on the 139th serine residue in the 
presence of DNA damage (Rogakou et al., 1998) by ATM, ATR and DNA-PK 
kinases under varying circumstances in the PI3K pathway but ATM is the major 
protein that phosphorylate H2AX (Burma et al., 2001). Hence, γH2AX is the 
initial step towards the recruitment of the DNA repair proteins upon induction of 
DSBs. Gamma-H2AX foci form in a 1 to 1 manner in response to DSBs 
formation and used as a biomarker of damage (Kuo and Yang, 2008). γH2AX 
foci can be detected and visualised using a primary and secondary antibody 
immunocytochemically hence, gives the measure of DSBs formation.  Evidence 
suggests that γH2AX is a sensitive and initial biomarker of DSBs in vitro and in 
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vivo and it can detect low levels of DNA damage. The induction and repair of 
DSBs could be monitored. It could also be potentially used for monitoring and 
improving cancer therapies in future. Lymphocytes are the easiest and most 
commonly obtainable cells to detect γH2AX foci in vivo ((Ivashkevich et al,. 
2012). Under healthy conditions lymphocytes show very low levels of γH2AX 
foci, typically less than one per cell. However this frequency increases upon 
induction of DNA damage in the form of DSBs (Geisel et al., 2008). 
Therefore, we studied the effects of MYR B (10µМ) and MYR N (20µМ) on the 
basal levels of DSBs immunocytochemically using an antibody against γH2AX, 
in lymphocytes from pre-cancerous patients compared to those from healthy 
individuals. We also investigated the gene expression levels of ATM kinase in 
lymphocytes from the pre-cancerous patients after in vitro treatment with both 
forms of myricetin using real-time PCR. Our results show that both forms of 
myricetin did not significantly induce DSBs in healthy individuals when 
compared to the untreated group (figure 4.8). Doxorubicin, used as the positive 
control has caused significant induction of DSBs in lymphocytes from both the 
groups’ i.e. healthy individuals and pre-cancerous blood patients indicated by 
the number of γH2AX foci formed per cell. Results showed an increased 
number of foci formation in untreated lymphocytes of pre-cancerous patients but 
the exposure to MYR B and MYR N could reduce their frequency but levels 
were not significant. Results suggest that myricetin does not induce DSBs in 
lymphocytes from healthy individuals and those from pre-cancerous patients at 
basal levels.   
The results from real-time PCR show that there is no significant effect seen on 
the regulation of ATM kinase in lymphocytes from the pre-cancerous blood 
patients when treated with MYR B and MYR N (figure 3.9b). Research confirms 
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various crucial roles of ATM protein in cellular regulation including initiation of 
DDR, induction of apoptosis, triggering defence mechanisms against oxidative 
injuries and inhibition of ROS etc. (Semlitsch et al., 2011; Marinoglou, 2012). 
Studies also show that formation of DSBs leads to dimer dissociation and auto-
phosphorylation of ATM kinase at serine 1981 (Rogakou et al., 1998; Bakkenist 
and Kastan, 2003; Helt et al., 2005). Research evidence also suggests that 
γH2AX plays a significant part in recruitment of ATM to DSB location and 
consequent events leading to ATM-regulated cellular responses (Kobayashi et 
al., 2004).  Based on our results from the Comet assay, micronucleus assay 
and immunocytochemistry we show that MYR B (10µМ) and MYR N (20µМ) do 
not induce DNA damage, MNi or DSBs in lymphocytes from both healthy 
individuals and pre-cancerous patients at basal levels.  
ATR kinase plays an important role in phosphorylation of P53 and CHK1 in the 
presence of severe hypoxia and oxidative stressed induced DNA damage 
(Barzilai and Yamamoto, 2004). Therefore we investigated the effects of PhIP 
on ATR kinase regulation. PhIP has shown different effects on gene expression 
levels of ATR in lymphocytes from healthy individuals to those from pre-
cancerous patients. The ATR gene was significantly (p<0.001) up-regulated by 
PhIP in healthy lymphocytes and it was further enhanced by myricetin 
supplementation where MYR N has shown p<0.01 significance (figure 5.7A). 
However, PhIP has demonstrated reverse effects on ATR expression in 
lymphocytes from the patient group. It significantly down-regulated the ATR 
gene levels (p<0.01) which were insignificantly up-regulated by myricetin 
addition (figure 5.7B).  These results indicated that protective effects caused by 
myricetin on PhIP-induced damage might be dependent on the tumour-
suppression activity of the P53 gene. Results also suggest that PhIP may cause 
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oxidative stress in lymphocytes from pre-cancerous patients that may be 
attenuated by ATR Kinase phosphorylation upon treatment with MYR B (10µМ) 
and MYR N (20µМ) dependent on P53. Thus enhancing the cellular capacity to 
recruit repair mechanisms before entering replication and maintain genome 
integrity.   
 But the mechanisms involved in diverse ATR regulation by PhIP in 
lymphocytes from healthy individuals compared to those from pre-cancerous 
patients are not fully understood.  
The eukaryotic cell cycle is a highly organised and regulated process which 
allows cellular division and proliferation. It is mainly dependent on two decisive 
points also called checkpoints: one occurs in G1-phase where cells can 
undergo DNA synthesis after progression to S phase and the other comes at 
the G2/M boundary when cells are committed to DNA repair before entering 
mitosis (Huang et al., 2015). P53, a multifunctional tumour-suppressor protein is 
believed to play a crucial role in the regulation of transcription and the cell cycle 
(Darcy et al., 2008). The fate of the cells to experience cell cycle arrest at 
GI/arrest or apoptosis depends on the degree of DNA damage present in the 
cells. If damage is to a lesser content then the G1/arrest signal it is initiated by 
P53 to allow cells to undergo repair before committing to S-phase but if DNA 
shows dramatic damage then the death signal is triggered hence cells enter 
apoptosis. P53 is believed to trigger GI/arrest by transactivation and regulation 
of the expression of a cyclin dependent kinase inhibitor (CDKIs), p21 though 
controls the progression through the cell cycle (Haupt and Haupt, 2017). 
Although, P53 is well recognised as an effective transcription factor, it is also 
known to regulate some strong genes associated with the apoptotic pathway; 
the expression of Bcl-2, an anti-apoptotic protein can be repressed by P53 and 
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on the other hand, Bax being a promising candidate for its pro-apoptotic 
activities is characterised to be up-regulated by P53, triggering apoptosis (Kuo 
et al., 2006). The ability of P53 to differentially regulate specific proteins 
provides a complementary response to its transactivation activities.  
Uncontrolled cellular proliferation in most of the tumour cells is due to their 
ability to evade apoptosis and cell cycle checkpoints. As P53 plays a crucial role 
in the healthy progression of the cell cycle, its mutation or deletion could lead to 
uncontrolled cellular proliferation giving rise to tumorigenesis putting tumour 
suppression at serious threat. The integrity of cellular DNA can also be 
compromised due to P53 inactivation hence leading to high mutational rates. 
P53 is a commonly mutated gene in most of the tumours resulting in various 
deleterious effects (Kong et al., 2012). Hence reintroduction of wt-P53 in tumour 
cells may present a promising strategy to overcome the resistance to apoptosis 
and control tumour cell proliferation. Increased levels of P53 may also help 
damaged cells to enter repair pathways before progression to mitosis thus 
repressing mutations (Shaw, 1996).  
Therefore we further investigated the role of MYR B (10µМ) and MYR N (20µМ) 
on the expression levels of P53 protein at post-translational and mRNA levels in 
lymphocytes from pre-cancerous patients and MM patients compared to those 
from healthy individuals. We also investigated the effects on some of the P53 
regulated genes; Bcl-2 and Bax while evaluating their regulation in lymphocytes 
from MM patients and healthy individuals.  
Evaluation of the protein and gene expression was conducted using the 
Western blot analysis and the real-time PCR study respectively, in lymphocytes 
from patient groups’ v/s healthy individuals. Results show that the P53 protein 
was significantly increased in healthy lymphocytes with MYR B (10µМ) and 
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MYR N (20µМ) treatment whereas its up-regulation in lymphocytes from pre-
cancerous patients was less statistically significant at basal levels (figure 6.6 
and 6.7). MYR B has shown better results than MYR N exhibiting 2.3-fold 
increase in P53 protein levels in healthy individuals when compared to the 
untreated group. However, in lymphocytes from pre-cancerous patients MYR N 
has been proven more effective than its larger particles, up-regulating protein 
levels to 1.4-fold (figure 3.10), consistent with the results from PCR where the 
P53 gene was significantly increased (p<0.01) in lymphocytes from pre-
cancerous patients when exposed to MYR N treatment (figure 3.9a). In vitro 
treatment of lymphocytes from healthy individuals, with PhIP has shown 
significant down-regulation in the protein expression of P53 and Bcl-2. MYR B 
and MYR N addition, however, could attenuate this effect and increased both 
proteins to a significant level (figure 5.8). Consistent with our results from PCR 
where PhIP treatment significantly decreased the P53 gene expression, 
however, this was significantly up-regulated upon supplementation with MYR B 
and with MYR in healthy lymphocytes. In lymphocytes from the pre-cancerous 
patients the P53 gene was non-significantly down-regulated with PhIP treatment 
whereas significantly up-regulated upon MYR N addition (p<0.001) (figure 5.7).  
Apoptosis is a route of programmed cell death (PCD) which is known to happen 
in multicellular organisms and plays a crucial role in maintenance of the normal 
cellular homeostasis. It presents an effective way to get rid of cancer cells. It 
has been demonstrated that reduced susceptibility of cancer cells to apoptosis 
is closely associated with poor prognosis of cancer (Hall et al., 2008). Hence, 
inducing apoptosis in cancer cells by means of natural compounds could be a 
promising strategy to overcome the increasing number of cancers worldwide. 
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Based on our results from the Comet assay we showed that both forms of 
myricetin, MYR B and MYR N at lower concentrations of 10µМ and 20µМ 
respectively, have not exhibited a significant genotoxic or genoprotective effects 
in lymphocytes from MM patients, when compared to the healthy controls. Thus, 
we further looked into the potential molecular processes mediated by myricetin 
in lymphocytes from MM patients. Myricetin has been shown in past studies to 
exhibit anticancer  effects in various cancer cell lines possibly through its pro-
oxidant activity (Pérez-Cano and Castell 2016; Semwal et al., 2016). We 
therefore, hypothesized that myricetin could potentially activate the P53-
regulated apoptotic genes dependent on oxidative stress. Initiation of the 
intrinsic-apoptotic pathway mainly depends on the balance between the pro 
(e.g. Bax, Bad) and anti-apoptotic (e.g. bcl-2, bcl-xl) factors of the Bcl-2 family 
(Brunelle and Letai, 2009). Accumulating research has left no doubt that P53 
plays various important roles in the regulation of different cellular processes 
such as cell cycle arrest, apoptosis, DNA repair and angiogenesis etc. (Dary et 
al., 2008). Therefore, increasing the amount of P53 may be a new strategy for 
treating cancer as it regulates the intrinsic apoptosis pathway such as Bax (kuo 
et al., 2006). Therefore, we analysed some of the factors involved in this 
pathway i.e. tumour-suppressor, P53, anti-apoptotic Bcl-2 and pro-apoptotic 
Bax in lymphocytes from MM patients comparing them with the effects in those 
from healthy individuals at basal levels. We investigated at both the mRNA and 
protein levels of all these genes.  
In the current study myricetin bulk and nano forms were found to regulate the 
Bcl-2 family apoptosis-related proteins in lymphocytes from multiple myeloma 
patients but not in those from healthy individuals. Myricetin bulk and 
nanoparticles were observed to significantly increase the levels of P53 and Bax 
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while down-regulate the Bcl-2 expression in lymphocytes from myeloma 
patients at mRNA and protein levels (fig 6.5, 6.7). However, MYR B and MYR N 
regulate the expression levels of these genes differentially in lymphocytes from 
healthy individuals. P53 and Bcl-2 levels were significantly up-regulated while 
Bax was down-regulated at both protein and mRNA levels (Fig 6.4 & 6.6).  
This might be due to differential effects of myricetin on healthy and patient 
lymphocytes. The lymphocytes from MM patient are possibly more sensitive to 
myricetin than the ones from healthy individuals due to their genome integrity or 
disease status. Our results are in agreement with a previous study where 
myricetin induced apoptosis in colon cancer cells by increasing the ratio 
between Bax and Bcl-2 protein levels (Kim et al., 2014).  
In conclusion, both forms of myricetin (MYR B and MYR N) at lower non-
genotoxic concentrations of 10 and 20µМ respectively, have exhibited 
genoprotective, anti-oxidant and anti-cancer effects in lymphocytes from pre-
cancerous blood patients, MM patients and healthy individuals. It showed strong 
anti-oxidant potential against H2O2 and TBHP-induced oxidative stress. It has 
also shown modulating effects against PhIP-induced genotoxicity and 
mutagenicity in lymphocytes from healthy individuals and pre-cancerous 
patients.  Myricetin in both forms has exhibited anti-cancer and pro-oxidant 
potential in lymphocytes from MM patients by increasing the Bax/Bcl-2 ratio 
dependent on P53 and ROS, in the absence of cytotoxicity. In general, MYR N 
(20µМ) has shown better protective effects than its larger particle size i.e. MYR B 
(10µМ). This could be due to NPs seeming to be capable of passing through the 
biological membranes and inflowing the cell nucleus instead of the cytoplasm to a 
better extent compared to larger particles of the same material and afterwards NPs could 
gain access to the nucleus (Magdolenova et al., 2014) and becomes closer to the 
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DNA and consequently could be more effective (Chen et al., 2013). This could be 
checked in future using TEM analysis by studying the interaction of these particles with 
cells. The kinetics of their transport and communications with the cellular membranes 
are important factors affecting the function and biological effects of NPs (Manshian et 
al., 2017). The smaller size of NPs enhances their physio-chemical properties including, 
larger volume to surface area, reactivity in biological systems, solubility and stability 
etc. these properties could affect the activities of NPs by affecting their bioavailability 
in living systems (Franklin et al., 2007). The proficient effects of MYR N could 
also be possible due to its double concentration used than MYR B. 
Collectively data from the current study suggests that myricetin supplementation in our 
regular diet with its enhanced bioavailability could have potential health beneficial 
effects and it could possibly protect and defend against various diseases including 
cancer. Effective formulation of myricetin as a food supplement or as a chemoprotective 
agent is possible after considering its physiological range, bioavailability, genotoxicity 
at higher concentrations and other biological factors involved. 
7.2 Future work 
 
As elaborated in chapter 3, myricetin bulk and nano forms have shown in vitro 
protective effects in peripheral lymphocytes from pre-cancerous patients 
compared to those from healthy individuals by exhibiting reduction in DNA 
damage and triggering the induction of P53 and ATM kinase. This requires 
further investigation of various other molecular processes and factors that may 
involve in protective effects of myricetin including P21.  
 
There is in vitro evidence shown, of the strong anti-oxidant potential of myricetin 
bulk and nano forms in lymphocytes against H2O2 and TBHP-induced oxidative 
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stress as well as at basal levels. Therefore, further research on anti-oxidant 
defence mechanisms including the transcription factors, NF-kB and EpRE, and 
other intracellular anti-oxidant enzymes such as CAT would be useful to 
determine if myricetin also has an effect on the activity of these enzymes. Past 
study has shown positive effect of myricetin on regulation of these enzymes 
using various cell lines and in different disease conditions (Semwal, 2016).  
 
The effect on DSBs formation has been shown in chapter 4, however, requires 
additional investigation of other repair mechanisms that may implicate the 
effects of myricetin in lymphocytes from pre-cancerous patients and healthy 
individuals. The Comet repair can be implicated by assessing the DNA damage 
at different time periods. Oxidative stress can also be investigated using FPG 
technique in future. 
 
Myricetin has shown modulating effects against PhIP-triggered DNA damage by 
regulating P53, Bcl-2 and ATR kinase. This requires more research on the 
regulation of ATM pathway as a biomarker of DSBs formation. Research has 
shown that the ATM can be directly activated by DNA adducts and DSBs; 
hence, studying ATM will be usful to identify if PhIP induces DSBs in 
lymphocytes and whether myricetin has any protective effect against it (Choi et 
al., 2009; Kemp et al., 2011). 
 
Evidence from chapter 6 showed that myricetin in both forms increase Bax/Bcl-
2 ratio dependent on oxidative stress and P53 in lymphocytes from myeloma 
patients. Further study of the apoptotic cell numbers using TUNEL assay or flow 
cytometry systems would be beneficial to make a strong conclusion.  
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Appendix # 1 
 
 
 
Consent form  
Title of Project: Molecular mechanisms of myricetin bulk and nano forms 
mediating genoprotective and genotoxic effects in lymphocytes from pre-
cancerous and myeloma patients 
Reviewed by Leeds Central Ethics Committee (REC) (REC reference number: 
12/YH/0464) 
1. I confirm that I have read and understand the information sheet for the 
above study. I have had opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw any time without giving any reason, without my medical care or 
legal rights being affected. 
 
 
3. I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by the individuals from the 
NHS trust or the University of Bradford, where it is relevant to my taking 
part in this research. I give permission to these individuals to have 
access to my records. 
 
4. I agree that the sample I have given and the information gathered about 
me can be stored at the University of Bradford, as described in the 
attached information sheet. 
 
 
5. I agree to take part in the above study. 
 
Name of patient             Date                       Signature 
------------------------         ---------                      ----------------- 
 
Name of person 
Taking consent               Date                      Signature 
------------------------        ------------                   ---------------------- 
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When completed, 1 for patient; 1 for researcher site file; 1 original to be 
kept in medical notes. 
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Appendix # 2 
 
 
 
Participant information sheet for patients 
Title of Project: Molecular mechanisms of myricetin bulk and nano forms 
mediating genoprotective and genotoxic effects in lymphocytes from pre-
cancerous and myeloma patients 
Reviewed by Leeds Central Ethics Committee (REC) (REC reference number: 
12/YH/0464) 
Invitation to the research study 
We would like to invite you to take part in a research study. Before you decide 
to take part you need to understand the purpose of the study and how it would 
involve you. Please take time to read the following information carefully before 
considering.  
What is the purpose of the study? 
In this white blood cells (lymphocytes) will be isolated from the blood sample 
and treated with small chemicals particles to determine the potential effects of 
drug. A blood sample around 20mls will be taken. Samples will be stored for 
only the duration of study and used for studies with similar nature. The research 
is for PhD programme involving PhDs and post-doctoral fellows.  
Why have I been invited? 
You have been invited because you have disease states like and we would like 
to determine the possible effects of the chemicals used in your blood compared 
to the healthy individuals. 
Do I have to take part? 
It is entirely up to you to decide and sign the consent form to show that you 
agreed to take part. You can withdraw freely at any time without giving reason. 
What will happen to me if I take part? 
A small blood sample will be taken and you will need to attend the clinic again 
for this research study. Researchers will complete a brief questionnaire with 
you. We shall access your notes so that they can be linked in an anonymous 
way with your clinical notes. Each individual will be given a coded study 
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number. The data obtained will used by and kept with study team and will not 
be given back to you. Results will be compared on group basis. And data may 
be published in scientific papers. The work will benefit the medical and scientific 
community but will not benefit you as individuals. More information can be 
provided if required. 
 
People who cannot take part in the study 
People who are not well enough to take part will be excluded. If you have 
further questions you could contact the research team: Professor Diana 
Anderson, Established Chair in Biomedical Sciences, BSc, MSc, PhD, DipEd, 
FSB, FATS, FRC, Path, FIFST, FBTS, FRSM, FHEA, FRSC, University of 
Bradford, Richmond road, Bradford, BD7-2RR UK and Honorary Research 
Consultant to Bradford NHS Trust.  
Dr Mojgan Najefzadeh MD, PhD post-doctoral fellow. Division of Medical 
Sciences, University of Bradford, Richmond road, Bradford, BD7-2RR UK. 
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Appendix # 3 
 
 
 
Data collection form 
Title of study: Molecular mechanisms of myricetin bulk and nano forms 
mediating genoprotective and genotoxic effects in lymphocytes from pre-
cancerous and myeloma patients 
Reviewed by Leeds Central Ethics Committee (REC) (REC reference number: 
12/YH/0464) 
SAMPLE NUMBER                            DATE OF SAMPLE  
AGE 
SEX (PLEASE TICK)       M/F          CONSENT INFORMATION SHEET 
ETHNIC GROUP  
OCCUPATION                             
CURRENT SMOKER       Y/N            PAST SMOKER       Y/N 
HOW MANY CIGARETTES PER DAY  
CIGARETTES                     CIGARS                      PIPES 
ALCOHOL         Y/N             UNITS/WEEK  
VITAMINS/ANTIOXIDANTS  
PRESCRIBED DRUGS  
DIET   WESTERN    ASIAN   OMNIVORE      VEGAN           VEGETARIAN 
RECREATIONAL DRUG USE    Y/N 
IF YES PLEASE LIST 
MEDICAL  
CANCER/ INFLAMMATORY DISEASE 
EXTENT               SITE                 HISTOLOGY            SURGERY 
CANCER 
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INFLAMMATORY DISEASE 
PRE CANCEROUS STATE 
OTHER MEDICAL CONDITIONS 
FAMILY HISTORY OF CANCER AND INFLAMMATORY DISEASE 
CHEMOTHERAPY OR RADIOTHERAPY 
MOST RECENT MEASURES 
WEIGHT 
HEIGHT 
BMI 
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Appendix # 4 
 
Equipment 
Equipment and other materials Company/Resources 
Centrifuge Mistral 3000 MSE, Albertville, USA 
CCD camera Hitachi KPMI/EK Monochrome 
Centrifuge (Biofuge 28 RS) Heraeus, Sepatech, Germany 
Coplin jars  VWR, Lutterworth, UK 
Culture flasks VWR, Lutterworth, UK 
Cover slips VWR, Lutterworth, UK 
Electrophoresis tank (HU20) Scie-Plas, Renfrewchire, UK 
Dry incubator (370C) LKB BIOCHROM Leec Ltd, Nottingham, UK 
Freezer -200C Sanyo, Ultra low, Japan 
Freezer -800C Sanyo, Ultra low, Japan 
Falcon tubes BD, Swindon, UK 
Fluorescent microscope Leica, Weztler, Germany 
Fume hood ray air Maiche Aire, Bolton, UK 
Fume cupboard Milton, UK 
Ice maker(Scotsman AF 100) Namur, Belgium 
Komet 6 software Kinetic Imaging, Nottingham, UK 
Light microscope Nikon, Japan 
Incubator 370C with CO2 Andor Technology Ltd, Belfast 
Micro-centrifuge MSE GMI, Alberville, USA 
Microplate reader Dynex Technology, Sussex, UK 
Microscope (ortholux) Leitz, Sturttgart, Germany 
Pipettes Gilson, Middleton, WI, USA 
Mini protein gel electrophoresis Bio-Rad, Hertfordshire, UK 
 pH meter Dunmow, UK 
Power pack supply Pharmacia LKB, Uppsala, Sweden 
Water bath Grant Instruments, Cambridge, UK 
Super frost slides VWR, Lutterworth, UK 
Zeta sizer-nano Malvern instruments, UK 
Microplate reader Tecan, Switzerland 
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Appendix # 5 
 
Abstract titles presented for scientific conferences 
Shabana Akhtar,  Rajendran C. Gopalan,  Mojgan Najafzadeh, Mohammad 
Isreb and Diana Anderson. Effect of myricetin nano and bulk forms on 
lymphocytes from blood cancer and pre-cancerous patients compared to 
those from healthy individuals. Molecular Epidemiology Group, UK (MEGUK) 
Spring Meeting, Aberdeen, UK. March 2017 (Poster). 
Shabana Akhtar,  Rajendran C. Gopalan,  Mojgan Najafzadeh, Mohammad 
Isreb and Diana Anderson. Reactive oxygen species (ROS) induced 
oxidative damage in lymphocytes from healthy individuals and those from 
blood cancer patients: Protection by myricetin nano and bulk forms. 
UKEMS Annual Meeting, Leuven, Belgium. June 2017 (Poster).  
 
 
 
 
